

Logging in to Dialog

Trying 3106900061...Open

DIALOG INFORMATION SERVICES

PLEASE LOGON:

\*\*\*\*\*

ENTER PASSWORD:

□t840lcpq

\*\*\*\*\*

Welcome to DIALOG

Dialog leel 99.12.23D

Lat logoff: 04jan00 18:09:07

Logon file001 08jan00 15:58:44

ANNOUNCEMENT \*\*\*\* ANNOUNCEMENT \*\*\*\* ANNOUNCEMENT

NEW

\*\*\*Kompa Mexico (File 586)

\*\*\*Market Gide Compan Financial (File 100)

\*\*\*Frót & Sllian Market Engineering (File 767)

\*\*\*

RELOADED

\*\*\*CLAIMS(r)/U.S. Patent (File 340,341,942)

\*\*\*Gale Grop PROMT (File 16, 160)

\*\*\*Gale Grop F&S Index (File 18)

\*\*\*RAPRA (File 323)

\*\*\*Gale Grop New Prodct Annoncement (File 621)

REMOVED

\*\*\*The Colmb Dipatch (File 495)

\*\*\*A-V Online (File 46)

\*\*\*BNA Dail (File 655)

>>> Enter BEGIN HOMEBASE for Dialog Annoncement <<<

>>> of new databae, price change, etc. <<<

□dialog

\*\*\* ANNOUNCEMENT \*\*\*

Dialog Alerts for January 1, 2000 will be run on January 2  
to minimize delivery delays due to scheduled network and IT  
systems testing being performed by our customers on Jan 1.

\*\*\*\*

For news about price changes for Jan 1, 2000, enter  
HELP NEWRATES.

\*\*\*\*

\*\*\*

\*\*\*

File 1:ERIC 1966-1999/Oct

(c) format only 1999 The Dialog Corporation

\*File 1: File has been reloaded. See HELP NEWS 1.

Limits of /ED and /EJ currently not working.

Set Items Description

? b 410

>>>'IALOG' not recognized as set or accession number

? set hi ;set hi

08jan00 15:58: User233835 Session D354.1  
\$0.35 0.101 DialUnits File1  
\$0.35 Estimated cost File1  
\$0.05 TYMNET  
\$0.40 Estimated cost this search  
\$0.40 Estimated total session cost 0.101 DialUnits

File 410:Chronolog(R) 1981-1999 Nov/Dec  
(c) 1999 The Dialog Corporation plc

Set	Items	Description
-----	-------	-------------

?

HIGHLIGHT set on as ''

**HIGHLIGHT set on as ''**

? b 155, 5, 399, 357, 654

08jan00 15:59:08 User233835 Session D354.2  
\$0.00 0.049 DialUnits File410  
\$0.00 Estimated cost File410  
\$0.01 TYMNET  
\$0.01 Estimated cost this search  
\$0.41 Estimated total session cost 0.150 DialUnits

SYSTEM:OS - DIALOG OneSearch

File 155:MEDLINE(R) 1966-1999/Dec W4

(c) format only 1999 Dialog Corporation

File 5:BIOSIS PREVIEWS(R) 1969-1999/NOV W4

(c) 1999 BIOSIS

File 399:CA SEARCH(R) 1967-2000/UD=13202

(c) 2000 AMERICAN CHEMICAL SOCIETY

\*File 399: Use is subject to the terms of your user/customer agreement.

RANK charge added; see HELP RATES 399.

File 357:DERWENT BIOTECHNOLOGY ABS 1982-1999/DEC B2

(c) 1999 DERWENT PUBL LTD

\*File 357: Derwent changes DialUnit pricing from May 1, 1999. See  
HELP DERWENT for details.

File 654:US PAT.FULL. 1990-2000/JAN 04

(c) FORMAT ONLY 2000 THE DIALOG CORP.

\*File 654: Reassignment data current through 12/06/1999 recordings.  
Reexamination, extension, expiration, reinstatement updated weekly.

Set	Items	Description
-----	-------	-------------

? s oligonucleotide and (aspirin or ibuprofen or warfarin )

80069	OLIGONUCLEOTIDE
-------	-----------------

54476	ASPIRIN
-------	---------

14222	IBUPROFEN
-------	-----------

15321	WARFARIN
-------	----------

S1	240	OLIGONUCLEOTIDE AND (ASPIRIN OR IBUPROFEN OR WARFARIN )
----	-----	---

? rd

>>>Duplicate detection is not supported for File 654.

>>>Records from unsupported files will be retained in the RD set.

...examined 50 records (50)

...examined 50 records (100)

...examined 50 records (150)

...examined 50 records (200)

...completed examining records

S2	233	RD (unique items)
----	-----	-------------------

? t s2/6/1-50

2/6/1 (Item 1 from file: 155)  
09664924 98377781

Effect of **aspirin** on protein binding and tissue disposition of  
**oligonucleotide** phosphorothioate in rats.  
1998

2/6/2 (Item 2 from file: 155)  
09549655 98292170

Cyclooxygenase regulates angiogenesis induced by colon cancer cells  
[published erratum appears in Cell 1998 Jul 24;94(2):following 271]  
May 29 1998

2/6/3 (Item 3 from file: 155)  
09514418 98254304

Induction of the differentiation of HL-60 promyelocytic leukemia cells by  
nonsteroidal anti-inflammatory agents in combination with low levels of  
vitamin D3.  
Feb 1998

2/6/4 (Item 4 from file: 155)  
08625019 96025839

Insulin activates nuclear factor kappa B in mammalian cells through a  
Raf-1-mediated pathway.  
Oct 13 1995

2/6/5 (Item 5 from file: 155)  
08347817 95315191

Transcriptional regulation of human CYP2C genes: functional comparison of  
CYP2C9 and CYP2C18 promoter regions.  
Jun 27 1995

2/6/6 (Item 6 from file: 155)  
08194323 95058969

Functional cytochrome P4503A isoforms in human embryonic tissues:  
expression during organogenesis.  
Nov 1994

2/6/7 (Item 7 from file: 155)  
07591964 93328964

An analysis with sequence-specific **oligonucleotide** probes of the  
association between **aspirin** -induced asthma and antigens of the HLA  
system.  
Jul 1993

2/6/8 (Item 8 from file: 155)  
06603266 91056037

Tyrosine 385 of prostaglandin endoperoxide synthase is required for  
cyclooxygenase catalysis.  
Nov 25 1990

2/6/9 (Item 9 from file: 155)  
06590485 90203007

The **aspirin** and heme-binding sites of ovine and murine  
prostaglandin endoperoxide synthases.  
Mar 25 1990

2/6/10 (Item 10 from file: 155)  
05991398 88144447

Primary structure of prostaglandin G/H synthase from sheep vesicular gland determined from the complementary DNA sequence [published erratum appears in Proc Natl Acad Sci U S A 1988 Jul;85(14):5056]  
Mar 1988

2/6/11 (Item 11 from file: 155)  
05128261 88033058

Effect of propeptide mutations on post-translational processing of factor IX. Evidence that beta-hydroxylation and gamma-carboxylation are independent events.  
Nov 5 1987

2/6/12 (Item 1 from file: 654)  
03054946  
ANTISENSE MODULATION OF LFA-3  
FULL TEXT: 2984 lines

2/6/13 (Item 2 from file: 654)  
03054875  
SUPPORTS AND COMBINATORIAL CHEMICAL LIBRARIES THEREOF ENCODED BY NON-SEQUENCABLE TAGS  
FULL TEXT: 2832 lines

2/6/14 (Item 3 from file: 654)  
03051427  
HUMAN SELENOPROTEIN  
FULL TEXT: 1796 lines

2/6/15 (Item 4 from file: 654)  
03046904  
METHOD OF DIAGNOSING AN INCREASED RISK OF THROMBUS ASSOCIATED DISEASE BY DETECTING A CERTAIN T-PA POLYMORPHISM  
FULL TEXT: 865 lines

2/6/16 (Item 5 from file: 654)  
03042622  
AGENTS AFFECTING THROMBOSIS AND HEMOSTASIS  
FULL TEXT: 1795 lines

2/6/17 (Item 6 from file: 654)  
03042389  
ASSAYS TO IDENTIFY INDUCERS OF PLANT DEFENSE RESISTANCE  
FULL TEXT: 2597 lines

2/6/18 (Item 7 from file: 654)  
03038221  
ALTERED FORMS OF THE NIM1 GENE CONFERRING DISEASE RESISTANCE IN PLANTS  
FULL TEXT: 3839 lines

2/6/19 (Item 8 from file: 654)  
03033314  
AMINIMIDE-CONTAINING MOLECULES AND MATERIALS AS MOLECULAR RECOGNITION AGENTS



FULL TEXT: 2577 lines

2/6/20 (Item 9 from file: 654)  
03032013  
SCREENING OF SOLUBLE CHEMICAL COMPOUNDS FOR THEIR PHARMACOLOGICAL  
PROPERTIES UTILIZING TRANSPONDERS  
FULL TEXT: 815 lines

2/6/21 (Item 10 from file: 654)  
03032739  
MONOCLONAL ANTIBODIES REACTIVE WITH DEFINED REGIONS OF THE T CELL ANTIGEN  
RECEPTOR  
FULL TEXT: 3006 lines

2/6/22 (Item 11 from file: 654)  
03028678  
ANTIVIRAL PHOSPHONOMETHOXY NUCLEOTIDE ANALOGS HAVING INCREASED ORAL  
BIOAVAILABILITY  
FULL TEXT: 3211 lines

2/6/23 (Item 12 from file: 654)  
03028672  
METHOD FOR USING POLYNUCLEOTIDES, OLIGONUCLEOTIDES AND DERIVATIVES THEREOF  
TO TREAT VARIOUS DISEASE STATES  
FULL TEXT: 3008 lines

2/6/24 (Item 13 from file: 654)  
03028382  
METHODS OF TRANSCRIPTIONALLY MODULATING GENE EXPRESSION AND OF DISCOVERING  
CHEMICALS CAPABLE AS GENE EXPRESSION MODULATORS  
FULL TEXT: 3472 lines

2/6/25 (Item 14 from file: 654)  
03028123  
MONOCLONAL ANTIBODIES REACTIVE WITH DEFINED REGIONS OF THE T CELL ANTIGEN  
RECEPTOR  
FULL TEXT: 2877 lines

2/6/26 (Item 15 from file: 654)  
03024027  
TRYPTASE INHIBITOR  
FULL TEXT: 2095 lines

2/6/27 (Item 16 from file: 654)  
03024013  
CARBONIC ANHYDRASE VIII  
FULL TEXT: 2466 lines

2/6/28 (Item 17 from file: 654)  
03020177  
STABLE BIOCATALYSTS FOR ESTER HYDROLYSIS  
FULL TEXT: 3880 lines

2/6/29 (Item 18 from file: 654)  
03019953

AGENTS AFFECTING THROMBOLYSIS AND HEMOSTASIS  
FULL TEXT: 1711 lines

2/6/30 (Item 19 from file: 654)  
03019853  
UBIQUITIN CONJUGATING ENZYMES 8 AND 9  
FULL TEXT: 2051 lines

2/6/31 (Item 20 from file: 654)  
03019792  
METHODS FOR RECORDING THE REACTION HISTORY OF A SOLID SUPPORT  
FULL TEXT: 2851 lines

2/6/32 (Item 21 from file: 654)  
03019536  
RADIOLABELED ANNEXIN CONJUGATES WITH HEXOSE AND A CHELATOR  
FULL TEXT: 3355 lines

2/6/33 (Item 22 from file: 654)  
03016199  
HUMAN LYSOPHOSPHOLIPASE  
FULL TEXT: 2129 lines

2/6/34 (Item 23 from file: 654)  
03016188  
KOJIBIOSE PHOSPHORYLASE OBTAINABLE FROM THERMOANAEROBIUM BROCKII, ITS  
PREPARATION AND USES  
FULL TEXT: 2172 lines

2/6/35 (Item 24 from file: 654)  
03012569  
HUMAN RNA-BINDING PROTEIN  
FULL TEXT: 1888 lines

2/6/36 (Item 25 from file: 654)  
03005370  
THROMBIN RECEPTOR DEFICIENT TRANSGENIC MICE  
FULL TEXT: 1346 lines

2/6/37 (Item 26 from file: 654)  
03005170  
ANTISENSE MODULATION OF PECAM-1  
FULL TEXT: 4433 lines

2/6/38 (Item 27 from file: 654)  
03005147  
RSE RECEPTOR ACTIVATION  
FULL TEXT: 2994 lines

2/6/39 (Item 28 from file: 654)  
03005022  
NEMATODE-EXTRACTED SERINE PROTEASE INHIBITORS AND ANTICOAGULANT PROTEINS  
FULL TEXT: 10254 lines

2/6/40 (Item 29 from file: 654)  
03004994  
USE OF PLATELET POLYMORPHISM P1A2 TO DIAGNOSE RISK OF THROMBOTIC DISEASE  
FULL TEXT: 950 lines

2/6/41 (Item 30 from file: 654)  
02994150  
UBIQUITIN CONJUGATING ENZYMES 7, 8 AND 9  
FULL TEXT: 2054 lines

2/6/42 (Item 31 from file: 654)  
02994104  
NEMATODE-EXTRACTED ANTICOAGULANT PROTEIN  
FULL TEXT: 3846 lines

2/6/43 (Item 32 from file: 654)  
02987920  
METHODS AND KITS FOR STIMULATING PRODUCTION OF MEGAKARYOCYTES AND  
THROMBOCYTES  
FULL TEXT: 2613 lines

2/6/44 (Item 33 from file: 654)  
02984017  
USE OF UTEROGLOBIN EXPRESSION AS A MOLECULAR MARKER FOR PROSTATIC  
INTRAEPITHELIAL NEOPLASIA  
FULL TEXT: 2001 lines

2/6/45 (Item 34 from file: 654)  
02983712  
METHODS OF PREPARING GAS-FILLED LIPOSOMES  
FULL TEXT: 2102 lines

2/6/46 (Item 35 from file: 654)  
02973363  
CHEMICAL REACTION APPARATUS FOR PERFORMING MULTIPLE REACTION ON A SURFACE  
AND COLLECTING THE PRODUCT  
FULL TEXT: 1599 lines

2/6/47 (Item 36 from file: 654)  
02970140  
ANTIVIRAL PHOSPHONOMETHYOXY NUCLEOTIDE ANALOGS HAVING INCREASED ORAL  
BIOAVAILABILITY  
FULL TEXT: 9563 lines

2/6/48 (Item 37 from file: 654)  
02966750  
METHODS OF TREATING TNF.ALPHA.-MEDIATED DISEASE USING CHIMERIC ANTI-TNF  
ANTIBODIES  
FULL TEXT: 5413 lines

2/6/49 (Item 38 from file: 654)  
02960942  
ANTI-CD18 ANTIBODIES IN STROKE  
FULL TEXT: 1694 lines

2/6/50 (Item 39 from file: 654)  
02958579  
CLONING, EXPRESSION AND DIAGNOSIS OF HUMAN CYTOCHROME P450 2C19: THE  
PRINCIPAL DETERMINANT OF S-MEPHENYTOIN METABOLISM  
FULL TEXT: 4889 lines  
? t s2/7/1

2/7/1 (Item 1 from file: 155)  
DIALOG(R) File 155:MEDLINE(R)  
(c) format only 1999 Dialog Corporation. All rts. reserv.

09664924 98377781  
Effect of **aspirin** on protein binding and tissue disposition of  
**oligonucleotide** phosphorothioate in rats.  
Agrawal S; Zhang X; Cai Q; Kandimalla ER; Manning A; Jiang Z; Marcel T;  
Zhang R  
Hybridon, Inc., Cambridge, MA 02139, USA.  
J Drug Target (SWITZERLAND) 1998, 5 (4) p303-12, ISSN 1061-186X  
Journal Code: B3S  
Languages: ENGLISH  
Document type: JOURNAL ARTICLE  
Pharmacokinetic studies of phosphorothioate oligodeoxynucleotides  
(PS-oligonucleotides) in animals show that following intravenous  
administration, PS-**oligonucleotide** clears out rapidly from the plasma  
and is distributed to majority of the organs. PS-oligonucleotides are bound  
to plasma proteins extensively. This study was aimed to determine the  
effect of **aspirin**, a commonly used drug, on pharmacokinetics of  
PS-oligonucleotides. In the present study, PS-**oligonucleotide** was  
administered to rats that had received **aspirin** by gavage.  
Pharmacokinetic study shows that if PS-**oligonucleotide** was  
administered following **aspirin** administration in rats, a) plasma  
pharmacokinetic parameters (t1/2alpha?, t1/2beta, AUC, etc.) had lower  
values, b) tissue disposition was different, and c) rate and route of  
elimination was affected in animals compared to rats receiving PS-  
**oligonucleotide** alone. This finding suggests that pharmacokinetics of  
PS-oligonucleotides can be affected with certain class of drugs, which may  
have direct impact on biological activity and safety.  
? s oligonucleotide and albumin

80069 OLIGONUCLEOTIDE  
211722 ALBUMIN  
S3 6532 OLIGONUCLEOTIDE AND ALBUMIN  
? s s3 and ligand

6532 S3  
202209 LIGAND  
S4 2692 S3 AND LIGAND  
? ds

Set	Items	Description
S1	240	OLIGONUCLEOTIDE AND (ASPIRIN OR IBUPROFEN OR WARFARIN )
S2	233	RD (unique items)
S3	6532	OLIGONUCLEOTIDE AND ALBUMIN
S4	2692	S3 AND LIGAND

? s s1 and s3

240 S1  
6532 S3  
S5 150 S1 AND S3  
? t s5/6/1-15

5/6/1 (Item 1 from file: 654)

03054875  
SUPPORTS AND COMBINATORIAL CHEMICAL LIBRARIES THEREOF ENCODED BY  
NON-SEQUENCABLE TAGS  
FULL TEXT: 2832 lines

5/6/2 (Item 2 from file: 654)  
03051427  
HUMAN SELENOPROTEIN  
FULL TEXT: 1796 lines

5/6/3 (Item 3 from file: 654)  
03042622  
AGENTS AFFECTING THROMBOSIS AND HEMOSTASIS  
FULL TEXT: 1795 lines

5/6/4 (Item 4 from file: 654)  
03042389  
ASSAYS TO IDENTIFY INDUCERS OF PLANT DEFENSE RESISTANCE  
FULL TEXT: 2597 lines

5/6/5 (Item 5 from file: 654)  
03032739  
MONOCLONAL ANTIBODIES REACTIVE WITH DEFINED REGIONS OF THE T CELL ANTIGEN  
RECEPTOR  
FULL TEXT: 3006 lines

5/6/6 (Item 6 from file: 654)  
03028678  
ANTIVIRAL PHOSPHONOMETHOXY NUCLEOTIDE ANALOGS HAVING INCREASED ORAL  
BIOAVAILABILITY  
FULL TEXT: 3211 lines

5/6/7 (Item 7 from file: 654)  
03028672  
METHOD FOR USING POLYNUCLEOTIDES, OLIGONUCLEOTIDES AND DERIVATIVES THEREOF  
TO TREAT VARIOUS DISEASE STATES  
FULL TEXT: 3008 lines

5/6/8 (Item 8 from file: 654)  
03028382  
METHODS OF TRANSCRIPTIONALLY MODULATING GENE EXPRESSION AND OF DISCOVERING  
CHEMICALS CAPABLE AS GENE EXPRESSION MODULATORS  
FULL TEXT: 3472 lines

5/6/9 (Item 9 from file: 654)  
03028123  
MONOCLONAL ANTIBODIES REACTIVE WITH DEFINED REGIONS OF THE T CELL ANTIGEN  
RECEPTOR  
FULL TEXT: 2877 lines

5/6/10 (Item 10 from file: 654)  
03024027  
TRYPTASE INHIBITOR  
FULL TEXT: 2095 lines

5/6/11 (Item 11 from file: 654)  
03024013  
CARBONIC ANHYDRASE VIII  
FULL TEXT: 2466 lines

5/6/12 (Item 12 from file: 654)  
03020177  
STABLE BIOCATALYSTS FOR ESTER HYDROLYSIS  
FULL TEXT: 3880 lines

5/6/13 (Item 13 from file: 654)  
03019953  
AGENTS AFFECTING THROMBOSIS AND HEMOSTASIS  
FULL TEXT: 1717 lines

5/6/14 (Item 14 from file: 654)  
03019853  
UBIQUITIN CONJUGATING ENZYMES 8 AND 9  
FULL TEXT: 2051 lines

5/6/15 (Item 15 from file: 654)  
03019792  
METHODS FOR RECORDING THE REACTION HISTORY OF A SOLID SUPPORT  
FULL TEXT: 2851 lines  
? ds

Set	Items	Description
S1	240	OLIGONUCLEOTIDE AND (ASPIRIN OR IBUPROFEN OR WARFARIN )
S2	233	RD (unique items)
S3	6532	OLIGONUCLEOTIDE AND ALBUMIN
S4	2692	S3 AND LIGAND
S5	150	S1 AND S3
? s antisense and albumin		
	42038	ANTISENSE
	211722	ALBUMIN
S6	3037	ANTISENSE AND ALBUMIN
? t s6/6/1-10		

6/6/1 (Item 1 from file: 155)  
10078200 99379619  
Co-introduction of an **antisense** gene for an endogenous seed storage protein can increase expression of a transgene in *Arabidopsis thaliana* seeds.  
Jul 30 1999

6/6/2 (Item 2 from file: 155)  
10044746 99344071  
Cultivation and characterization of a new immortalized human hepatocyte cell line, HepZ, for use in an artificial liver support system.  
Jun 18 1999

6/6/3 (Item 3 from file: 155)  
10036745 99288704  
Induction of monocyte chemoattractant protein-1 by **albumin** is mediated by nuclear factor kappaB in proximal tubule cells.  
Jun 1999

6/6/4 (Item 4 from file: 155)  
09997949 99160618

Subtilisin-like proprotein convertases, PACE4 and PC8, as well as furin, are endogenous proalbumin convertases in HepG2 cells.  
Mar 1999

6/6/5 (Item 5 from file: 155)  
09969169 99264465

Calcium antagonists ameliorate ischemia-induced endothelial cell permeability by inhibiting protein kinase C.  
May 18 1999

6/6/6 (Item 6 from file: 155)  
09941008 99266651

Growth and differentiation of cultured fetal hepatocytes isolated various developmental stages.  
Feb 1999

6/6/7 (Item 7 from file: 155)  
09933232 99156720

Upstream region of rat serum **albumin** gene promoter contributes to promoter activity: presence of functional binding site for hepatocyte nuclear factor-3.  
Mar 1 1999

6/6/8 (Item 8 from file: 155)  
09841864 99083099

Advanced glycation endproducts inhibit prostacyclin production and induce plasminogen activator inhibitor-1 in human microvascular endothelial cells.  
Dec 1998

6/6/9 (Item 9 from file: 155)  
09825664 99011322

Differentiation and proliferation of primary rat hepatocytes cultured as spheroids.  
Nov 1998

6/6/10 (Item 10 from file: 155)  
09812609 99078097

The effect on IgG glycosylation of altering beta1, 4-galactosyltransferase-1 activity in B cells.  
Dec 1998  
? ds

Set	Items	Description
S1	240	OLIGONUCLEOTIDE AND (ASPIRIN OR IBUPROFEN OR WARFARIN )
S2	233	RD (unique items)
S3	6532	OLIGONUCLEOTIDE AND ALBUMIN
S4	2692	S3 AND LIGAND
S5	150	S1 AND S3
S6	3037	ANTISENSE AND ALBUMIN

? t s6/6/11-20

6/6/11 (Item 11 from file: 155)  
09656217 98435605

Autocrine self-elimination of cultured ovarian cancer cells by tumour  
necrosis factor alpha (TNF-alpha).  
Oct 1998

6/6/12 (Item 12 from file: 155)  
09637148 98404010  
Endothelial-cell permeability and protein kinase C in pre-eclampsia.  
Mar 28 1998

6/6/13 (Item 13 from file: 155)  
09622387 98379107  
Multidrug resistance and its reversal.  
Jul-Aug 1998

6/6/14 (Item 14 from file: 155)  
09521491 98245000  
Leukocyte-endothelial interaction is augmented by high glucose  
concentrations and hyperglycemia in a NF-kB-dependent fashion.  
May 1 1998

6/6/15 (Item 15 from file: 155)  
09497262 98232195  
Protein kinase C beta modulates thrombin-induced Ca<sup>2+</sup> signaling and  
endothelial permeability increase.  
Jun 1998

6/6/16 (Item 16 from file: 155)  
09317891 98027999  
Evaluation of the toxicity of ISIS 2302, a phosphorothioate  
oligonucleotide, in a 4-week study in CD-1 mice.  
Oct 1997

6/6/17 (Item 17 from file: 155)  
09289502 97477136  
Advanced glycation end product (AGE)-mediated induction of tissue factor  
in cultured endothelial cells is dependent on RAGE.  
Oct 7 1997

6/6/18 (Item 18 from file: 155)  
09271912 97351140  
A new peptide vector for efficient delivery of oligonucleotides into  
mammalian cells.  
Jul 15 1997

6/6/19 (Item 19 from file: 155)  
09227202 96189096  
The aromatic hydrocarbon receptor modulates the Hepa 1c1c7 cell cycle and  
differentiated state independently of dioxin.  
May 1996

6/6/20 (Item 20 from file: 155)  
09137809 97334390  
Expression and functional role of the Id HLH family in cultured  
astrocytes.  
Jun 1997  
? t s6/7/18



6/7/18 (Item 18 from file: 155)  
DIALOG(R) File 155:MEDLINE(R)  
(c) format only 1999 Dialog Corporation. All rts. reserv.

09271912 97351140

A new peptide vector for efficient delivery of oligonucleotides into mammalian cells.

Morris MC; Vidal P; Chaloin L; Heitz F; Divita G

Centre de Recherches de Biochimie Macromoléculaire, URS-155 CNRS, BP 5051, 1919 Route de Mende, 34033 Montpellier Cedex 1, France.

Nucleic Acids Res (ENGLAND) Jul 15 1997, 25 (14) p2730-6, ISSN 0305-1048 Journal Code: O8L

Languages: ENGLISH

Document type: JOURNAL ARTICLE

The development of **antisense** and gene therapy has focused mainly on improving methods for oligonucleotide and gene delivery into cells. In the present work, we describe a potent new strategy for oligonucleotide delivery based on the use of a short peptide vector, termed MPG (27 residues), which contains a hydrophobic domain derived from the fusion sequence of HIV gp41 and a hydrophilic domain derived from the nuclear localization sequence of SV40 T-antigen. The formation of peptide vector/oligonucleotide complexes was investigated by measuring changes in intrinsic tryptophan fluorescence of peptide and of mandsyl-labelled oligonucleotides. MPG exhibits relatively high affinity for both single- and double-stranded DNA in a nanomolar range. Based on both intrinsic and extrinsic fluorescence titrations, it appears that the main binding between MPG and oligonucleotides occurs through electrostatic interactions, which involve the basic-residues of the peptide vector. Further peptide/peptide interactions also occur, leading to a higher MPG/oligonucleotide ratio (in the region of 20/1), which suggests that oligonucleotides are most likely coated with several molecules of MPG. Premixed complexes of peptide vector with single or double stranded oligonucleotides are delivered into cultured mammalian cells in less than 1 h with relatively high efficiency (90%). This new strategy of oligonucleotide delivery into cultured cells based on a peptide vector offers several advantages compared to other commonly used approaches of delivery including efficiency, stability and absence of cytotoxicity. The interaction with MPG strongly increases both the stability of the oligonucleotide to nuclease and crossing of the plasma membrane. The mechanism of cell delivery of oligonucleotides by MPG does not follow the endosomal pathway, which explains the rapid and efficient delivery of oligonucleotides in the nucleus. As such, we propose this peptide vector as a powerful tool for potential development in gene and **antisense** therapy.

? t s6/6/21-30

6/6/21 (Item 21 from file: 155)  
09043183 97213191

Wholesale hepatocytic differentiation in the rat from ductular oval cells, the progeny of biliary stem cells.  
Feb 1997

6/6/22 (Item 22 from file: 155)  
09009361 97218081

Scavenger receptor-mediated delivery of **antisense** mini-exon phosphorothioate oligonucleotide to Leishmania-infected macrophages. Selective and efficient elimination of the parasite.  
Feb 7 1997

6/6/23 (Item 23 from file: 155)  
08967483 97190163

Involvement of mannose receptor in cytokine interleukin-1beta (IL-1beta), IL-6, and granulocyte macrophage colony-stimulating factor responses, but not in chemokine macrophage inflammatory protein 1beta (MIP-1beta), MIP-2, and KC responses, caused by attachment of *Candida albicans* to macrophages.  
Mar 1997

6/6/24 (Item 24 from file: 155)  
08965607 97072737

Uptake characteristics of oligonucleotides in the isolated rat liver perfusion system.  
Fall 1996

6/6/25 (Item 25 from file: 155)  
08961109 97172425

Comparison of the toxicity profiles of ISIS 1082 and ISIS 2105, phosphorothioate oligonucleotides, following subacute intradermal administration in Sprague-Dawley rats.  
Jan 15 1997

6/6/26 (Item 26 from file: 155)  
08848313 96436583

Interaction of diagnostic ultrasound with synthetic oligonucleotide-labeled perfluorocarbon-exposed sonicated dextrose **albumin** microbubbles.  
Aug 1996

6/6/27 (Item 27 from file: 155)  
08839485 96374928

Receptor-mediated delivery of hepatitis B virus DNA and **antisense** oligodeoxynucleotides to avian liver cells.  
Sep 1996

6/6/28 (Item 28 from file: 155)  
08807973 97012189

Disposition of oligonucleotides in isolated perfused rat kidney: involvement of scavenger receptors in their renal uptake.  
Oct 1996

6/6/29 (Item 29 from file: 155)  
08785863 96200030

Oligonucleotide targeting to alveolar macrophages by mannose receptor-mediated endocytosis.  
Mar 13 1996

6/6/30 (Item 30 from file: 155)  
08768921 96390840

Advanced glycosylation end products stimulate the growth but inhibit the prostacyclin-producing ability of endothelial cells through interactions with their receptors.  
Apr 8 1996  
? t s6/6/31-40

6/6/31 (Item 31 from file: 155)  
08702181 96244564

Advanced glycation endproducts-receptor interactions stimulate the growth of human pancreatic cancer cells through the induction of platelet-derived growth factor-B.

May 24 1996

6/6/32 (Item 32 from file: 155)  
08685287 96210093

Pharmacokinetic properties of several novel oligonucleotide analogs in mice.

May 1996

6/6/33 (Item 33 from file: 155)  
08599904 96356269

Renal disposition characteristics of oligonucleotides modified at terminal linkages in the perfused rat kidney.

Winter 1995

6/6/34 (Item 34 from file: 155)  
08574028 96359714

Direct solution hybridization of guanidine thiocyanate-solubilized cells for quantitation of mRNAs in hepatocytes.

Dec 10 1995

6/6/35 (Item 35 from file: 155)  
08563099 96113287

Bovine serum **albumin** is a major oligonucleotide-binding protein found on the surface of cultured cells.

Fall 1995

6/6/36 (Item 36 from file: 155)  
08538769 96172580

Inhibition of alpha-fetoprotein production in a hepatoma cell line by **antisense** oligonucleotide analogues.

May 1995

6/6/37 (Item 37 from file: 155)  
08434701 96029436

Oval cell differentiation into hepatocytes in the acetylaminofluorene-treated regenerating rat liver.

Oct 1995

6/6/38 (Item 38 from file: 155)  
08430963 96018670

Inhibition of hepatitis B viral gene expression and replication in vitro by targeted **antisense** oligonucleotides]

Jul 1995

6/6/39 (Item 39 from file: 155)  
08390459 95374535

Receptor-mediated toxicity to pericytes of advanced glycosylation end products: a possible mechanism of pericyte loss in diabetic microangiopathy.

Aug 15 1995

6/6/40 (Item 40 from file: 155)  
08277983 95197641

Purification and characterization of an estrogen-regulated Xenopus liver polysomal nuclease involved in the selective destabilization of **albumin** mRNA.

6/6/41 (Item 41 from file: 155)  
08165424 94266652

Light microscopical detection of inter-alpha-trypsin inhibitor and its different mRNAs in cultured hepatoma Hep G2 cells using immunocytochemical and in situ hybridization techniques.  
Mar 1994

6/6/42 (Item 42 from file: 155)  
08112305 95151809

Complete inactivation of target mRNA by biotinylated **antisense** oligodeoxynucleotide-avidin conjugates.  
Sep-Oct 1994

6/6/43 (Item 43 from file: 155)  
07950620 94300433

Protein restriction specifically decreases the abundance of serum **albumin** and transthyretin nuclear transcripts in rat liver.  
Jul 1994

6/6/44 (Item 44 from file: 155)  
07861184 94125197

**Antisense** DNA delivery in vivo: liver targeting by receptor-mediated uptake.  
Feb 1994

6/6/45 (Item 45 from file: 155)  
07842846 93391372

Polyunsaturated fatty acids inhibit S14 gene transcription in rat liver and cultured hepatocytes.  
Sep 15 1993

6/6/46 (Item 46 from file: 155)  
07635407 93236707

Phosphorothioate-phosphodiester oligonucleotide co-polymers: assessment for **antisense** application.  
Feb 1993

6/6/47 (Item 47 from file: 155)  
07443142 93003449

Uptake by macrophages of a biotinylated oligo-alpha-deoxythymidylate by using mannosylated streptavidin.  
Jul-Aug 1992

6/6/48 (Item 48 from file: 155)  
07369988 93015235

New hepatocellular carcinoma cell line SUHC-1 established from a patient with hepatitis C virus RNA in serum.  
Aug 1992

6/6/49 (Item 49 from file: 155)  
07340005 90183988

Accumulation of proto-oncogene c-erb-A related transcripts during *Xenopus* development: association with early acquisition of response to thyroid

Mar 1990

6/6/50 (Item 50 from file: 155)  
07174718 93027161

Drug targeting: synthesis and endocytosis of oligonucleotide-neoglycoprotein conjugates.

Sep 11 1992

? t s6/7/42,44,46

6/7/42 (Item 42 from file: 155)  
DIALOG(R)File 155:MEDLINE(R)

(c) format only 1999 Dialog Corporation. All rts. reserv.

08112305 95151809

Complete inactivation of target mRNA by biotinylated **antisense** oligodeoxynucleotide-avidin conjugates.

Boado RJ; Pardridge WM

Department of Medicine, UCLA School of Medicine 90024.

Bioconjug Chem (UNITED STATES) Sep-Oct 1994, 5 (5) p406-10, ISSN 1043-1802 Journal Code: ALT

Contract/Grant No.: R01-AI28760, AI, NIAID

Languages: ENGLISH

Document type: JOURNAL ARTICLE

Biotinylation of phosphodiester oligodeoxynucleotides (PO-ODN) allows for conjugation to avidin-based transcellular delivery systems. In addition, biotinylation of PO-ODN at the 3'-terminus provides complete protection against serum 3'-exonuclease degradation. The present study was undertaken to determine if **antisense** 3'-biotinylated PO-ODN-avidin constructs are able to recognize and inactivate the target mRNA through RNase H-mediated degradation. A 21-mer **antisense** PO-ODN complementary to the tat gene encompassing nucleotides 5402-5422 of the HIV-1 genome was synthesized with biotin conjugated to the 3'-terminus (bio-tat). Gel mobility assays using [5'-32P]-labeled bio-tat ODN and avidin showed that the bio-tat ODN was fully monobiotinylated. Aliquots of [32P]-labeled sense or **antisense** tat RNA (337 and 351 nucleotides, respectively) were prepared from transcription plasmids and were preincubated with an excess of bio-tat ODN with or without avidin constructs and digested with RNase H. Products were resolved with sequencing gel and analyzed by autoradiography. Complete conversion to predicted RNA fragments resulting from RNase H digestion of the RNA-ODN duplex (53 and 263 nucleotides) was observed when [32P]-tat sense RNA was incubated with **antisense** bio-tat ODN or conjugated to avidin or an avidin-cationized human serum **albumin** (chSA) complex. Conversely, no degradation of [32P]-tat-**antisense** RNA was observed after incubation with **antisense** bio-tat ODN and RNase H. In addition, the avidin-chSA complex significantly increased (84-fold) the uptake of [32P]-internally labeled bio-tat ODN and its stability against cellular nuclease degradation in peripheral blood lymphocytes. (ABSTRACT TRUNCATED AT 250 WORDS)

6/7/44 (Item 44 from file: 155)  
DIALOG(R)File 155:MEDLINE(R)

(c) format only 1999 Dialog Corporation. All rts. reserv.

07861184 94125197

**Antisense** DNA delivery in vivo: liver targeting by receptor-mediated uptake.

Lu XM; Fischman AJ; Jyawook SL; Hendricks K; Tompkins RG; Yarmush ML  
Surgical Services, Massachusetts General Hospital, Boston 02114.

J Nucl Med (UNITED STATES) Feb 1994, 35 (2) p269-75, ISSN 0161-5505  
Journal Code: JEC

Languages: ENGLISH

**Antisense** oligodeoxynucleotides coupled to asialoglycoprotein carrier molecules were evaluated in terms of their ability to accumulate preferentially in the liver and thus potentially serve as an important method to regulate liver gene expression. **METHODS:** Native and asialo-human alpha-1 acid glycoproteins were derivatized with low molecular weight poly(L)lysine and complexed with an **antisense** DNA (67 mer) complementary to the 5' end of rat serum **albumin** mRNA. The asialoglycoprotein **antisense** complex (conjugate) was characterized with respect to size, stability, and anti-sense loading, and the biodistribution of the conjugate was determined for normal rats at 5 min and 1, 6, and 24 hr after intravenous injection. In vivo stability of the anti-sense asialoglycoprotein complex was also evaluated using double-labeled (<sup>32</sup>P-**antisense** and <sup>3</sup>H-glycoprotein) preparations. **RESULTS:** The results of the conjugate characterization studies demonstrated that at least 30% of the anti-sense DNA dissociated from the carrier after 7 min under chromatographic conditions. When the conjugate was incubated with PBS, MEM or MEM plus 10% FBS for 1 hr at 37 degrees C, about 85% of the **antisense** DNA was dissociated from the carrier. The results of the biodistribution studies showed that the accumulation of the asialo-glycoprotein anti-sense complex in the liver was rapid and greatly exceeded the accumulation of the sialo-glycoprotein **antisense** analog or **antisense** alone. **CONCLUSION:** These findings have significant implications for the targeted delivery of therapeutic **antisense** molecules to the liver.

6/7/46 (Item 46 from file: 155)

DIALOG(R) File 155:MEDLINE(R)

(c) format only 1999 Dialog Corporation. All rts. reserv.

07635407 93236707

Phosphorothioate-phosphodiester oligonucleotide co-polymers: assessment for **antisense** application.

Ghosh MK; Ghosh K; Cohen JS

Pharmacology Department, Georgetown University Medical Center, Washington, DC 20007.

Anticancer Drug Des (ENGLAND) Feb 1993, 8 (1) p15-32, ISSN 0266-9536  
Journal Code: AC5

Languages: ENGLISH

Document type: JOURNAL ARTICLE

Efforts have been made to reduce the disadvantages associated with the natural oligonucleotides (all-PO) for **antisense** application by introducing phosphorothioate (PS) linkages into the molecule. A series of such oligodeoxynucleotide copolymers (17-mers) complementary to the coding region of the rabbit beta-globin mRNA, and containing different proportions and arrangements of PO and PS bonds, were synthesized and tested for their protein-binding properties, nuclease stability in vitro, hybridizing ability with the complementary DNA (cDNA), ability to form RNase H-sensitive substrates and **antisense** activity in cell-free systems. The melting temperatures (T<sub>m</sub>) of the co-polymers were reduced by up to 6 degrees C relative to the all-PO oligo, compared to 11 degrees C for the all-PS compound, indicating intermediate hybridizing abilities of the co-polymers. The protein-binding studies with human serum **albumin** exhibited a linear correlation with the percentage of PS linkage present in the molecule. Nuclease susceptibilities of the co-polymers were also improved, but the number and position of the PS linkages played a significant role in such improvement. Translation inhibition by these oligonucleotides was only found in wheat germ agglutinin (WGA) extract, but not in rabbit reticulocyte lysate (RRL) cell-free system, suggesting the involvement of RNase H in their **antisense** activities. Provided they have > or = 50% PS linkages, the co-polymers produced almost the same increased inhibition in the WGA system as that of the all-PS oligo. The translation arrest in WGA extract is in good agreement with the in vitro cleavage found for rabbit globin mRNA in the oligo:mRNA duplex by RNase H

alone. It is concluded that a copolymer of PO and PS might be preferable to either all-PO or all-PS for antisense applications.  
? s antisense and (aspirin or ibuprofen or warfarin )

42038 ANTISENSE  
54476 ASPIRIN  
14222 IBUPROFEN  
15321 WARFARIN

S7 169 ANTISENSE AND (ASPIRIN OR IBUPROFEN OR WARFARIN )  
? rd

>>>Duplicate detection is not supported for File 654.

>>>Records from unsupported files will be retained in the RD set.

...examined 50 records (50)  
...examined 50 records (100)  
...examined 50 records (150)  
...completed examining records  
S8 164 RD (unique items)  
? t s8/6/1-15

8/6/1 (Item 1 from file: 155)  
10140019 99413988

Selective targeting of cyclooxygenase-2 reveals its role in renal medullary interstitial cell survival.  
Sep 1999

8/6/2 (Item 2 from file: 155)  
10124953 99429297

Sodium salicylate and 17beta-estradiol attenuate nuclear transcription factor NF-kappaB translocation in cultured rat astroglial cultures following exposure to amyloid A beta(1-40) and lipopolysaccharides.  
Oct 1999

8/6/3 (Item 3 from file: 155)  
09856347 99149550

Non-steroidal anti-inflammatory drug-induced apoptosis in gastric cancer cells is blocked by protein kinase C activation through inhibition of c-myc.  
Feb 1999

8/6/4 (Item 4 from file: 155)  
09655467 98421095

[Physiopathology of myocardial infarction: the acute coronary occlusion]  
Physiopathologie de l'infarctus du myocarde: l'occlusion coronaire aigue.  
Apr 1998

8/6/5 (Item 5 from file: 155)  
09549655 98292170

Cyclooxygenase regulates angiogenesis induced by colon cancer cells [published erratum appears in Cell 1998 Jul 24;94(2):following 271]  
May 29 1998

8/6/6 (Item 6 from file: 155)  
09514418 98254304

Induction of the differentiation of HL-60 promyelocytic leukemia cells by nonsteroidal anti-inflammatory agents in combination with low levels of vitamin D3.  
Feb 1998

8/6/7 (Item 7 from file: 155)  
09088964 97313416

Cytotoxicity and apoptosis produced by arachidonic acid in Hep G2 cells overexpressing human cytochrome P4502E1.  
Jun 6 1997

8/6/8 (Item 8 from file: 155)  
08583560 95408275

Participation of a proton-cotransporter, MCT1, in the intestinal transport of monocarboxylic acids.  
Sep 14 1995

8/6/9 (Item 9 from file: 155)  
08551058 96112765

Inflammation, reproduction, cancer and all that.... The regulation and role of the inducible prostaglandin synthase.  
Dec 1995

8/6/10 (Item 10 from file: 155)  
08218315 94365203

Tissue factor controls the balance of angiogenic and antiangiogenic properties of tumor cells in mice.  
Sep 1994

8/6/11 (Item 11 from file: 155)  
07481360 93100312

Selective expression of mitogen-inducible cyclooxygenase in macrophages stimulated with lipopolysaccharide.  
Dec 25 1992

8/6/12 (Item 1 from file: 399)  
DIALOG(R)File 399:(c) 2000 AMERICAN CHEMICAL SOCIETY. All rts. reserv.

Effect of aspirin on protein binding and tissue disposition of oligonucleotide phosphorothioate in rats

8/6/13 (Item 1 from file: 357)  
0232538 DBA Accession No.: 99-02639

Human ubiquitin conjugating enzyme and related nucleic acid - vector-mediated gene transfer and expression in host cell, agonist and antagonist e.g. **antisense** sequence, used for virus infection or AIDS diagnosis, therapy or gene therapy, etc. 1998

8/6/14 (Item 1 from file: 654)  
03054946

**ANTISENSE** MODULATION OF LFA-3  
FULL TEXT: 2984 lines

8/6/15 (Item 2 from file: 654)  
03051427

HUMAN SELENOPROTEIN  
FULL TEXT: 1796 lines  
? t s8/7/12,13



8/7/12 (Item 1 from file: 399)

DIALOG(R) File 399:CA 399:CH(R)

(c) 2000 AMERICAN CHEMICAL SOCIETY. All rts. reserv.

129117425 CA: 129(10)117425r JOURNAL

Effect of aspirin on protein binding and tissue disposition of  
oligonucleotide phosphorothioate in rats

AUTHOR(S): Agrawal, Sudhir; Zhang, Xueshu; Cai, Qiuyin; Kandimalla,  
Ekambar R.; Manning, Adrienne; Jiang, Zhiwie; Marcel, Tony; Zhang, Ruiwen

LOCATION: Hybridon, Inc., Cambridge, MA, 02139, USA

JOURNAL: J. Drug Targeting DATE: 1998 VOLUME: 5 NUMBER: 4 PAGES:  
303-312 CODEN: JDTAEH ISSN: 1061-186X LANGUAGE: English PUBLISHER:  
Harwood Academic Publishers

SECTION:

CA201002 Pharmacology

IDENTIFIERS: phosphorothioate antisense oligonucleotide aspirin  
pharmacokinetics, drug interaction oligonucleotide aspirin pharmacokinetics

DESCRIPTORS:

Drug interactions... Oligonucleotides...

effect of aspirin on protein binding and tissue disposition of  
oligonucleotide phosphorothioate in rats

Phosphates, biological studies...

phosphorothioates; effect of aspirin on protein binding and tissue  
disposition of oligonucleotide phosphorothioate in rats

CAS REGISTRY NUMBERS:

50-78-2 effect of aspirin on protein binding and tissue disposition of  
oligonucleotide phosphorothioate in rats

8/7/13 (Item 1 from file: 357)

DIALOG(R) File 357:DERWENT BIOTECHNOLOGY ABS

(c) 1999 DERWENT PUBL LTD. All rts. reserv.

0232538 DBA Accession No.: 99-02639 PATENT

Human ubiquitin conjugating enzyme and related nucleic acid -  
vector-mediated gene transfer and expression in host cell, agonist and  
antagonist e.g. **antisense** sequence, used for virus infection or  
AIDS diagnosis, therapy or gene therapy, etc.

AUTHOR: Ni J; Gentz R; Adams M D

CORPORATE SOURCE: Gaithersburg, MA, USA.

PATENT ASSIGNEE: Hum.Genome-Sci. 1998

PATENT NUMBER: US 5849286 PATENT DATE: 981215 WPI ACCESSION NO.:

99-069655 (9906)

PRIORITY APPLIC. NO.: US 464604 APPLIC. DATE: 950605

NATIONAL APPLIC. NO.: US 464604 APPLIC. DATE: 950605

LANGUAGE: English

ABSTRACT: A new human ubiquitin conjugating enzyme is encoded by a  
specified DNA sequence that encodes amino acids 2-154 of a specified  
154 amino acid protein sequence as encoded by cDNA in ATCC 95976 or  
ATCC 95878. The proteins may be produced recombinantly and used to  
treat malignant transformation (where associated with c-Mos and v-Jum  
proto-oncoproteins, since these undergo ubiquitin-dependent  
degradation) or immunological disorders (e.g. hypersensitivity to  
wasp/bee stings or **aspirin**-sensitive asthma), to mark  
virus-infected cells for apoptosis, or to screen for agonists or  
antagonists that interact with the protein. The protein is especially  
used for therapy of virus infection and AIDS or to raise antibodies for  
diagnosis. Antagonists (e.g. **antisense** nucleic acid) may be used  
to treat atrophy of skeletal muscle, cervix cancer, endemic pemphigus  
foliaceus and African-pig-fever virus infection. Mutations in genes  
encoding the enzyme may be used for disease diagnosis, fragments of the  
DNA may be used as DNA probes or DNA primers for isolation of related  
sequences, and the DNA may also be used for gene therapy. (34pp)

? s antisense and antidiabetic

42038 ANTI-USE  
19313 ANTI-ABETIC  
S9 61 ANTISENSE AND ANTIDIABETIC  
? rd

>>>Duplicate detection is not supported for File 654.

>>>Records from unsupported files will be retained in the RD set.  
...examined 50 records (50)  
...completed examining records  
S10 61 RD (unique items)  
? t s10/6/1-10

10/6/1 (Item 1 from file: 5)  
11790216 BIOSIS NO.: 199900036325  
Contribution of Na/Ca exchange to Ca<sup>2+</sup> outflow and entry in the rat  
pancreatic beta-cell. Studies with **antisense** oligonucleotides.  
1998

10/6/2 (Item 2 from file: 5)  
10216014 BIOSIS NO.: 199698670932  
Rat amylin **antisense** cDNA transfer into primary cultured rat  
pancreatic islets mediated by adenovirus.  
1995

10/6/3 (Item 1 from file: 399)  
DIALOG(R)File 399:(c) 2000 AMERICAN CHEMICAL SOCIETY. All rts. reserv.

Genes for apobec-1 and assocd. proteins as treatment target for  
atherosclerosis, obesity, and Type II diabetes

10/6/4 (Item 2 from file: 399)  
DIALOG(R)File 399:(c) 2000 AMERICAN CHEMICAL SOCIETY. All rts. reserv.

Antibody gene-based method for inhibiting antibody-mediated rejection of  
xenogeneic tissues

10/6/5 (Item 3 from file: 399)  
DIALOG(R)File 399:(c) 2000 AMERICAN CHEMICAL SOCIETY. All rts. reserv.

Methods for treating diabetes by inhibiting GDF-8

10/6/6 (Item 4 from file: 399)  
DIALOG(R)File 399:(c) 2000 AMERICAN CHEMICAL SOCIETY. All rts. reserv.

Methods using a modulator of a MAPK/ERK, JNK, or p38 signal transduction  
pathway for treating and preventing insulin resistance and related  
disorders

10/6/7 (Item 5 from file: 399)  
DIALOG(R)File 399:(c) 2000 AMERICAN CHEMICAL SOCIETY. All rts. reserv.

Identification, cloning, sequence, and therapeutic use, of weight control  
pathway Tub interactor genes and proteins of human and mice

10/6/8 (Item 6 from file: 399)  
DIALOG(R)File 399:(c) 2000 AMERICAN CHEMICAL SOCIETY. All rts. reserv.

Mesangial cell lines as models for the study and treatment of diabetic tissue complications

10/6/9 (Item 7 from file: 399)  
DIALOG(R) File 399:(c) 2000 AMERICAN CHEMICAL SOCIETY. All rts. reserv.

Agent for gene therapy of tumors and neurodegenerative, cardiovascular, and autoimmune diseases

10/6/10 (Item 8 from file: 399)  
DIALOG(R) File 399:(c) 2000 AMERICAN CHEMICAL SOCIETY. All rts. reserv.

Construction of modified SV40 viral vectors for gene delivery  
? t s10/6/11-20

10/6/11 (Item 9 from file: 399)  
DIALOG(R) File 399:(c) 2000 AMERICAN CHEMICAL SOCIETY. All rts. reserv.

Cloning and cDNA sequence for human facilitative glucose transport protein GLUT8

10/6/12 (Item 10 from file: 399)  
DIALOG(R) File 399:(c) 2000 AMERICAN CHEMICAL SOCIETY. All rts. reserv.

Antisense oligodeoxynucleotides (ODN) against protein kinase C (PKC) isoforms for treatment of endothelial barrier dysfunction

10/6/13 (Item 11 from file: 399)  
DIALOG(R) File 399:(c) 2000 AMERICAN CHEMICAL SOCIETY. All rts. reserv.

Lipoproteins as nucleic acid vectors for gene therapy

10/6/14 (Item 12 from file: 399)  
DIALOG(R) File 399:(c) 2000 AMERICAN CHEMICAL SOCIETY. All rts. reserv.

Respiration-uncoupling protein 2 for treatment of obesity, diabetes, syndrome X, or hypothermia

10/6/15 (Item 13 from file: 399)  
DIALOG(R) File 399:(c) 2000 AMERICAN CHEMICAL SOCIETY. All rts. reserv.

Methods for diagnosing and treating diabetes and for identifying therapeutic agents using hepatocyte nuclear factor 4 and its gene

10/6/16 (Item 14 from file: 399)  
DIALOG(R) File 399:(c) 2000 AMERICAN CHEMICAL SOCIETY. All rts. reserv.

Diabetes-mediating proteins and their therapeutic uses

10/6/17 (Item 15 from file: 399)  
DIALOG(R) File 399:(c) 2000 AMERICAN CHEMICAL SOCIETY. All rts. reserv.

Therapeutic compositions and methods and diagnostic assays for type II diabetes involving hepatic nuclear factor-1 (HNF-1)

10/6/18 (Item 16 from file: 399)  
DIALOG(R)File 399:(c) 2000 AMERICAN CHEMICAL SOCIETY. All rts. reserv.

Guanyldhydrazones useful for treating diseases associated with T-cell activation

10/6/19 (Item 17 from file: 399)  
DIALOG(R)File 399:(c) 2000 AMERICAN CHEMICAL SOCIETY. All rts. reserv.

Compositions and methods for treating type II diabetes involving hepatic nuclear factor-4 (HNF-4)

10/6/20 (Item 18 from file: 399)  
DIALOG(R)File 399:(c) 2000 AMERICAN CHEMICAL SOCIETY. All rts. reserv.

SPARC-deficient transgenic mice  
? t s10/6/21-30

10/6/21 (Item 19 from file: 399)  
DIALOG(R)File 399:(c) 2000 AMERICAN CHEMICAL SOCIETY. All rts. reserv.

Cloning and sequences of rat and human cDNA encoding galanin GALR3 receptors and their pharmacological profiles and therapeutic uses

10/6/22 (Item 20 from file: 399)  
DIALOG(R)File 399:(c) 2000 AMERICAN CHEMICAL SOCIETY. All rts. reserv.

Method and phosphopeptides for treatment of insulin resistance based on the assocn. of protein tyrosine phosphatase 1B with the activated insulin receptor

10/6/23 (Item 21 from file: 399)  
DIALOG(R)File 399:(c) 2000 AMERICAN CHEMICAL SOCIETY. All rts. reserv.

Methods and compositions for inhibiting hexokinase in mammalian cells and their use for treating diabetes

10/6/24 (Item 22 from file: 399)  
DIALOG(R)File 399:(c) 2000 AMERICAN CHEMICAL SOCIETY. All rts. reserv.

A Leflunomide-induced RNA helicase-like ATP- and nucleic acid-binding protein

10/6/25 (Item 1 from file: 357)  
0212929 DBA Accession No.: 97-08050  
New DNA encoding the neuropeptide Y-Y5 receptor - human, mouse or rat gene expression in CHO, Spodoptera frugiperda Sf9 or 293 cell culture, for use in drug screening 1997

10/6/26 (Item 2 from file: 357)  
0176533 DBA Accession No.: 95-03354  
Gene-introduced mammalian animal - transgenic animal for use as a diabetes disease animal model and for use in drug testing 1994

10/6/27 (Item 3 from file: 357)

0172633 DBA Accession No.: 94-15184

New human transaldolase polypeptide - recombinant protein, diagnostic DNA probe, monoclonal antibody, **antisense** DNA and gene therapy 1994

10/6/28 (Item 4 from file: 357)

0149971 DBA Accession No.: 93-08023

New cytokine CD40-L as CD40-agonist and CD40-antagonist - human recombinant soluble CD40-L production; may be used as antiallergic, antirheumatic, **antidiabetic**, in lupus and graft-versus-host disease therapy, and as a recombinant vaccine adjuvant 1993

10/6/29 (Item 1 from file: 654)

03037986

DEVICES FOR ADMINISTRATION OF NAKED POLYNUCLEOTIDES WHICH ENCODE BIOLOGICALLY ACTIVE PEPTIDES  
FULL TEXT: 1986 lines

10/6/30 (Item 2 from file: 654)

02998034

BIFLAVANOIDS AND DERIVATIVES THEREOF AS ANTIVIRAL AGENTS  
FULL TEXT: 2684 lines  
? t s10/3,ab/29

10/3,AB/29 (Item 1 from file: 654)

DIALOG(R)File 654:US PAT.FULL.

(c) FORMAT ONLY 2000 THE DIALOG CORP. All rts. reserv.

03037986

Utility

DEVICES FOR ADMINISTRATION OF NAKED POLYNUCLEOTIDES WHICH ENCODE BIOLOGICALLY ACTIVE PEPTIDES

PATENT NO.: 5,985,847

ISSUED: November 16, 1999 (19991116)

INVENTOR(s): Carson, Dennis A., Del Mar, CA (California), US (United States of America)  
Raz, Eyal, San Diego, CA (California), US (United States of America)

ASSIGNEE(s): The Regents of the University of California, (A U.S. Company or Corporation), Oakland, CA (California), US (United States of America)  
[Assignee Code(s): 13234]

APPL. NO.: 8-928,412

FILED: September 12, 1997 (19970912)

PRIORITY: PCT-US94-09661, WO (World Intellectual Property Org), August 25, 1994 (19940825)

#### RELATED U.S. PATENT APPLICATIONS

This is a continuation of application Ser. No. 08-464,879, filed Jun. 7, 1995, now abandoned, which is a continuation-in-part of U.S. Ser. No. 08-112,440, filed in the United States Patent and Trademark Office on Aug. 26, 1993 now abandoned.

#### STATEMENT OF GOVERNMENT RIGHTS

This invention may have been made with Government support under Grant Nos. AR07567 and AR25443, awarded by the National Institutes of Health. The Government may have certain rights in this invention.

## ABSTRACT

This invention relates to apparatus and compositions for administering antigens and immunostimulatory peptides to a mammalian host by the introduction of one or more naked polynucleotides to operatively encode for the antigens and immunostimulatory peptides, preferably by non-invasive means.

? ds

Set	Items	Description
S1	240	OLIGONUCLEOTIDE AND (ASPIRIN OR IBUPROFEN OR WARFARIN )
S2	233	RD (unique items)
S3	6532	OLIGONUCLEOTIDE AND ALBUMIN
S4	2692	S3 AND LIGAND
S5	150	S1 AND S3
S6	3037	ANTISENSE AND ALBUMIN
S7	169	ANTISENSE AND (ASPIRIN OR IBUPROFEN OR WARFARIN )
S8	164	RD (unique items)
S9	61	ANTISENSE AND ANTIDIABETIC
S10	61	RD (unique items)

? s antisense and conjugated and drug and ligand

	42038	ANTISENSE
	91354	CONJUGATED
	3794096	DRUG
	202209	LIGAND
S11	964	ANTISENSE AND CONJUGATED AND DRUG AND LIGAND

? t s11/6/1-15

11/6/1 (Item 1 from file: 399)  
DIALOG(R)File 399:(c) 2000 AMERICAN CHEMICAL SOCIETY. All rts. reserv.

Property-affecting and/or property-exhibiting compositions for therapeutic and diagnostic uses

11/6/2 (Item 1 from file: 654)  
03065296  
CALCIUM RECEPTOR-ACTIVE MOLECULES  
FULL TEXT: 8512 lines

11/6/3 (Item 2 from file: 654)  
03065248  
NUCLEIC ACID **LIGAND** COMPLEXES  
FULL TEXT: 2200 lines

11/6/4 (Item 3 from file: 654)  
03065077  
SEQUENCE-DIRECTED DNA BINDING MOLECULES COMPOSITIONS AND METHODS  
FULL TEXT: 14120 lines

11/6/5 (Item 4 from file: 654)  
03062266  
GROWTH DIFFERENTIATION FACTOR-11 TRANSGENIC MICE  
FULL TEXT: 1877 lines

11/6/6 (Item 5 from file: 654)  
03062176

**ANTISENSE** MODULATION OF PHOSPHOLIPASE A2 GROUP IV EXPRESSION  
FULL TEXT: 2916 lines

11/6/7 (Item 6 from file: 654)  
03062171

NUCLEIC ACIDS ENCODING A NEURAL TISSUE AFFECTING FACTOR  
FULL TEXT: 832 lines

11/6/8 (Item 7 from file: 654)  
03062168

COMPACTED NUCLEIC ACIDS AND THEIR DELIVERY TO CELLS  
FULL TEXT: 3488 lines

11/6/9 (Item 8 from file: 654)  
03062154

STANNIOCALCIN-2  
FULL TEXT: 2125 lines

11/6/10 (Item 9 from file: 654)  
03062032

IMMUNOMODULATORY OLIGONUCLEOTIDES  
FULL TEXT: 1665 lines

11/6/11 (Item 10 from file: 654)  
03061853

BRAIN-ASSOCIATED INHIBITOR OF TISSUE-TYPE PLASMINOGEN ACTIVATOR  
FULL TEXT: 3466 lines

11/6/12 (Item 11 from file: 654)  
03061847

METHOD OF MAKING LIPID METABOLIC PATHWAY COMPOSITIONS  
FULL TEXT: 3838 lines

11/6/13 (Item 12 from file: 654)  
03061824

**ANTISENSE** OLIGONUCLEOTIDES FOR MITOGEN-ACTIVATED PROTEIN KINASES AS  
THERAPY FOR CANCER  
FULL TEXT: 1338 lines

11/6/14 (Item 13 from file: 654)  
03061818

MACROMOLECULE DELIVERY METHOD AND COMPOSITION  
FULL TEXT: 1351 lines

11/6/15 (Item 14 from file: 654)  
03058405

PROTEIN SEQUENCES OF SERRATE GENE PRODUCTS  
FULL TEXT: 6631 lines  
? t s11/3,ab/3,8

11/3,AB/3 (Item 2 from file: 654)  
DIALOG(R)File 654:US PAT.FULL.







03065248

Utility

NUCLEIC ACID **LIGAND** COMPLEXES

PATENT NO.: 6,011,020  
ISSUED: January 04, 2000 (20000104)  
INVENTOR(s): Gold, Larry, Boulder, CO (Colorado), US (United States of America)  
Schmidt, Paul G., San Marino, CA (California), US (United States of America)  
Janjic, Nebojsa, Boulder, CO (Colorado), US (United States of America)  
ASSIGNEE(s): NeXstar Pharmaceuticals, Inc , (A U.S. Company or Corporation), Boulder, CO (Colorado), US (United States of America)  
APPL. NO.: 8-434,465  
FILED: May 04, 1995 (19950504)

RELATED APPLICATIONS

This application is a Continuation-in-Part of U.S. patent application Ser. No. 07-714,131, filed Jun. 10, 1991, entitled Nucleic Acid Ligands, now U.S. Pat. No. 5,475,096 which was filed as a Continuation-in-Part of U.S. patent application Ser. No. 07-536,428, filed Jun. 11, 1990, entitled Systematic Evolution of Ligands by Exponential Enrichment, now abandoned. This application is also a Continuation-in-Part of U.S. patent application Ser. No. 08-234,997, filed Apr. 28, 1994, entitled "Systematic Evolution of Ligands by Exponential Enrichment: Blended SELEX," now U.S. Pat. No. 5,683,867.

FULL TEXT: 2200 lines

ABSTRACT

This invention discloses a method for preparing a therapeutic or diagnostic complex comprised of a nucleic acid **ligand** and a lipophilic compound or non-immunogenic, high molecular weight compound by identifying a nucleic acid **ligand** by SELEX methodology and associating the nucleic acid **ligand** with a lipophilic compound or a non-immunogenic, high molecular weight compound. The invention further discloses complexes comprising one or more nucleic acid ligands in association with a lipophilic compound or non-immunogenic, high molecular weight compound.

11/3,AB/8 (Item 7 from file: 654)  
DIALOG(R) File 654:US PAT.FULL.  
(c) FORMAT ONLY 2000 THE DIALOG CORP. All rts. reserv.

03062168

Utility

COMPACTED NUCLEIC ACIDS AND THEIR DELIVERY TO CELLS

PATENT NO.: 6,008,336  
ISSUED: December 28, 1999 (19991228)  
INVENTOR(s): Hanson, Richard W., Cleveland Heights, OH (Ohio), US (United States of America)  
Perales, Jose C., Cleveland Heights, OH (Ohio), US (United States of America)  
Ferkol, Thomas W., Euclid, OH (Ohio), US (United States of America)  
ASSIGNEE(s): Case Western Reserve University, (A U.S. Company or Corporation), Cleveland, OH (Ohio), US (United States of America)





Ohio University, (A U.S. Company or Corporation), Athens, OH  
(Ohio), (United States of America)  
[Assignee Code(s): 14316; 14635]

APPL. NO.: 9-54,453

FILED: April 03, 1998 (19980403)

This application is a continuation of U.S. Ser. No. 08-716,415, 102(e) date Feb. 12, 1997, now U.S. Pat. No. 5,877,302, which is a 371 of PCT-US95-03677, filed Mar. 23, 1995, and a continuation-in-part of U.S. Ser. No. 08-216,534, filed Mar. 23, 1994, abandoned.

This invention was made with government support under DK21859, DK25541, and HL53672 awarded by the National Institute of Health. The government has certain rights in the invention.

FULL TEXT: 3488 lines

#### ABSTRACT

Nucleic acids are compacted, substantially without aggregation, to facilitate their uptake by target cells of an organism to which the compacted material is administered. The nucleic acids may achieve a clinical effect as a result of gene expression, hybridization to endogenous nucleic acids whose expression is undesired, or site-specific integration so that a target gene is replaced, modified or deleted. The targeting may be enhanced by means of a target cell-binding moiety. The nucleic acid is preferably compacted to a condensed state.

? s oligonucleotide and conjugated and drug and ligand

80069 OLIGONUCLEOTIDE

91354 CONJUGATED

3794096 DRUG

202209 LIGAND

S12 1575 OLIGONUCLEOTIDE AND CONJUGATED AND DRUG AND LIGAND

? t s12/6/1-15

12/6/1 (Item 1 from file: 155)

09179007 97356472

Delivery of oligoribonucleotides to human hepatoma cells using cationic lipid particles **conjugated** to ferric protoporphyrin IX (heme).  
Jun 1997

12/6/2 (Item 2 from file: 155)

09179006 97356471

Identification of a phosphodiester hexanucleotide that inhibits HIV-1 infection in vitro on covalent linkage of its 5'-end with a dimethoxytrityl residue.  
Jun 1997

12/6/3 (Item 1 from file: 5)

11027707 BIOSIS NO.: 199799648852

Delivery of oligoribonucleotides to human hepatoma cells using cationic lipid particles **conjugated** to ferric protoporphyrin IX (heme).  
1997

12/6/4 (Item 2 from file: 5)

11019715 BIOSIS NO.: 199799640860

Identification of a phosphodiester hexanucleotide that inhibits HIV-1 infection in vitro on covalent linkage of its 5'-end with a

12/6/5 (Item 1 from file: 654)  
03065365  
IDENTIFICATION AND ISOLATION OF NOVEL POLYPEPTIDES HAVING WW DOMAINS AND  
METHODS OF USING SAME  
FULL TEXT: 4957 lines

12/6/6 (Item 2 from file: 654)  
03065296  
CALCIUM RECEPTOR-ACTIVE MOLECULES  
FULL TEXT: 8512 lines

12/6/7 (Item 3 from file: 654)  
03065248  
NUCLEIC ACID **LIGAND** COMPLEXES  
FULL TEXT: 2200 lines

12/6/8 (Item 4 from file: 654)  
03065228  
COMPOSITIONS FOR THE TREATMENT OF BLOOD DISORDERS  
FULL TEXT: 2136 lines

12/6/9 (Item 5 from file: 654)  
03065077  
SEQUENCE-DIRECTED DNA BINDING MOLECULES COMPOSITIONS AND METHODS  
FULL TEXT: 14120 lines

12/6/10 (Item 6 from file: 654)  
03062266  
GROWTH DIFFERENTIATION FACTOR-11 TRANSGENIC MICE  
FULL TEXT: 1877 lines

12/6/11 (Item 7 from file: 654)  
03062176  
ANTISENSE MODULATION OF PHOSPHOLIPASE A2 GROUP IV EXPRESSION  
FULL TEXT: 2916 lines

12/6/12 (Item 8 from file: 654)  
03062171  
NUCLEIC ACIDS ENCODING A NEURAL TISSUE AFFECTING FACTOR  
FULL TEXT: 832 lines

12/6/13 (Item 9 from file: 654)  
03062168  
COMPACTED NUCLEIC ACIDS AND THEIR DELIVERY TO CELLS  
FULL TEXT: 3488 lines

12/6/14 (Item 10 from file: 654)  
03062154  
STANNIOCALCIN-2  
FULL TEXT: 2125 lines

12/6/15 (Item 11 from file: 654)  
03062032  
IMMUNOMODULATORY OLIGONUCLEOTIDES  
FULL TEXT: 1665 lines  
? t s12/7/1,2

12/7/1 (Item 1 from file: 155)  
DIALOG(R) File 155:MEDLINE(R)  
(c) format only 1999 Dialog Corporation. All rts. reserv.

09179007 97356472

Delivery of oligoribonucleotides to human hepatoma cells using cationic lipid particles **conjugated** to ferric protoporphyrin IX (heme).

Takle GB; Thierry AR; Flynn SM; Peng B; White L; Devonish W; Galbraith RA; Goldberg AR; George ST

Innovir Laboratories, Inc., New York, NY 10021, USA.

Antisense Nucleic Acid Drug Dev (UNITED STATES) Jun 1997, 7 (3)  
p177-85, ISSN 1087-2906 Journal Code: CJY

Languages: ENGLISH

Document type: JOURNAL ARTICLE

The receptor-**ligand** interaction between hepatocyte heme receptors and heme was evaluated as a basis for developing a targeted cationic lipid delivery reagent for nucleic acids. Heme (ferric protoporphyrin IX) was **conjugated** to the aminolipid dioleoyl phosphatidylethanolamine (DOPE) and used to form cationic lipid particles with dioleoyl trimethylammonium propane (DOTAP). These lipid particles (DDH) protect oligoribonucleotides from degradation in human serum and increase oligoribonucleotide uptake into 2.2.15 human hepatoma cells (to a level of 50-60 ng oligo/10<sup>4</sup> cells) when compared with the same lipid particles (DD) prepared identically without heme. The DDH heme level that was optimal for oligoribonucleotide delivery was also optimal for maximum expression of plasmid-encoded luciferase. The enhancing effect of heme was evident only at net particle negative charge. Fluorescence microscopy showed that DDH delivered oligoribonucleotides into both the 2.2.15 cell cytoplasm and nucleus. DDH may thus be a potentially useful delivery vehicle for **oligonucleotide**-based therapeutics and transgenes, appropriate for use in such liver diseases as viral hepatitis, hepatoma, and hypercholesterolemia.

12/7/2 (Item 2 from file: 155)  
DIALOG(R) File 155:MEDLINE(R)  
(c) format only 1999 Dialog Corporation. All rts. reserv.

09179006 97356471

Identification of a phosphodiester hexanucleotide that inhibits HIV-1 infection in vitro on covalent linkage of its 5'-end with a dimethoxytrityl residue.

Furukawa H; Momota K; Agatsuma T; Yamamoto I; Kimura S; Shimada K

Biological Research Laboratories, Sankyo Co. Ltd, Tokyo, Japan.

Antisense Nucleic Acid Drug Dev (UNITED STATES) Jun 1997, 7 (3)  
p167-75, ISSN 1087-2906 Journal Code: CJY

Languages: ENGLISH

Document type: JOURNAL ARTICLE

It has been shown in previous reports that a guanine-rich phosphodiester **oligonucleotide** bearing a dimethoxytrityl (DmTr) residue on its 5'-terminal. DmTr-TGGGAGGTGGGTCTG (SA-1042), is an inhibitor of HIV-1 infection in vitro. SA-1042 interfered with the attachment of gp120 to the CD4 receptor and the subsequent entry stage of viral infection. We investigated the structure-activity relationship of the DmTr-**conjugated** oligomer by using 15-mer oligonucleotides with various nucleotide sequences. Results show that location of guanine nucleosides at the 5'-terminal and modification of the 5'-terminal with DmTr are essential for anti-HIV-1 activity. First, substitution of the guanine nucleoside close to the 5'-terminal of SA-1042 with another nucleotide prevented

antiviral activity. Second, the existence of at least three consecutive guanine nucleosides adjacent to the 5'-terminal is required for the activity. Finally, modification of the 5'-terminal was essential for the activity. Based on these findings, the hexanucleotide, DmTr-TGGGAG, was identified as a potent inhibitor of HIV-1 infection. The hexamer was found to be capable of inhibiting the binding of gp120 to its receptor CD4 molecule, and it was also capable of inhibiting accessibility of anti-V3 monoclonal antibody to its **ligand** V3 peptide.  
? t sl2/3,ab/8

12/3,AB/8 (Item 4 from file: 654)  
DIALOG(R)File 654:US PAT.FULL.  
(c) FORMAT ONLY 2000 THE DIALOG CORP. All rts. reserv.

03065228

Utility  
COMPOSITIONS FOR THE TREATMENT OF BLOOD DISORDERS

PATENT NO.: 6,011,000  
ISSUED: January 04, 2000 (20000104)  
INVENTOR(s): Perrine, Susan P., 27 Harding Ave., Braintree, MA  
(Massachusetts), US (United States of America), 02184  
Faller, Douglas V., 27 Harding Ave., Braintree, MA  
(Massachusetts), US (United States of America), 02184  
APPL. NO.: 8-470,831  
FILED: June 06, 1995 (19950606)

This application is a continuation application of prior application Ser. No. 08-398,588, filed Mar. 3, 1995.

#### RIGHT IN THE INVENTION

This invention was made with support from the United States government under grant numbers HL-37118, HL-45940, HL-20895 and HL-15157, awarded by the National Institutes of Health, and grant number 000831, awarded by the United States Food & **Drug** Administration, and the United States government has certain rights in the invention.

FULL TEXT: 2136 lines

#### ABSTRACT

The invention relates to compositions containing chemical compounds and compositions containing steel factor which stimulate the expression of hemoglobin or globin protein such as embryonic or fetal globin, or the proliferation of hemoglobin expressing and other cells. These compositions can be used to treat or prevent the symptoms associated with anemia, sickle cell diseases, thalassemia and other blood disorders. The invention also relates to methods for administering these compositions to patients and to medical aids for the treatment and prevention of blood and other disorders.  
? logoff

08jan00 16:53:20 User233835 Session D354.3  
\$2.19 0.684 DialUnits File155  
\$0.00 74 Type(s) in Format 6  
\$1.40 7 Type(s) in Format 7  
\$1.40 81 Types  
\$3.59 Estimated cost File155  
\$2.29 0.410 DialUnits File5  
\$0.00 4 Type(s) in Format 6  
\$0.00 4 Types  
\$2.29 Estimated cost File5



\$9.20 0.83 DialUnits File399  
\$12.00 1 Type(s) in Format 6  
\$2.60 1 Type(s) in Format 7  
\$14.60 25 Types  
\$23.80 Estimated cost File399  
\$2.05 0.173 DialUnits File357  
\$0.00 5 Type(s) in Format 6  
\$2.20 1 Type(s) in Format 7  
\$2.20 6 Types  
\$4.25 Estimated cost File357  
\$4.82 0.816 DialUnits File654  
\$0.00 83 Type(s) in Format 6  
\$3.80 4 Type(s) in Format 4 (UDF)  
\$3.80 87 Types  
\$8.62 Estimated cost File654  
OneSearch, 5 files, 2.816 DialUnits FileOS  
\$2.75 TYMNET  
\$45.30 Estimated cost this search  
\$45.71 Estimated total session cost 2.965 DialUnits  
Logoff: level 99.12.23 D 16:53:20

Logging in to Dialog

Trying 3106900061...Open

DIALOG INFORMATION SERVICES  
PLEASE LOGON:

\*\*\*\*\*

ENTER PASSWORD:

□t840lcpq

\*\*\*\*\*

Welcome to DIALOG

Dialog leel 99.12.23D

Lat logoff: 11jan00 10:46:33

Logon file001 12jan00 10:15:53

ANNOUNCEMENT \*\*\*\* ANNOUNCEMENT \*\*\*\* ANNOUNCEMENT

NEW

\*\*\*Kompa Mexico (File 586)

\*\*\*Market Gide Compan Financial (File 100)

\*\*\*Frot & Sllian Market Engineering (File 767)

\*\*\*

RELOADED

\*\*\*CLAIMS(r)/U.S. Patent (File 340,341,942)

\*\*\*Gale Grop PROMT (File 16, 160)

\*\*\*Gale Grop F&S Index (File 18)

\*\*\*RAPRA (File 323)

\*\*\*Gale Grop New Prodct Annoncement (File 621)

REMOVED

\*\*\*The Colmb Dipatch (File 495)

\*\*\*A-V Online (File 46)

\*\*\*BNA Dail (File 655)

>>> Enter BEGIN HOMEBASE for Dialog Annoncement <<<

>>> of new databae, price change, etc. <<<

□dialog

\*\*\* ANNOUNCEMENT \*\*\*

Dialog Alerts for January 1, 2000 will be run on January 2  
to minimize delivery delays due to scheduled network and IT  
systems testing being performed by our customers on Jan 1.

\*\*\*\*

For news about price changes for Jan 1, 2000, enter  
HELP NEWRATES.

\*\*\*\*

\*\*\*

\*\*\*

File 1:ERIC 1966-1999/Oct

(c) format only 1999 The Dialog Corporation

\*File 1: File has been reloaded. See HELP NEWS 1.

Limits of /ED and /EJ currently not working.

Set Items Description

--- ----

? b 410

>>>'IALOG' not recognized as set or accession number

? set hi ;set hi

12jan00 10:15:50 User233835 Session D357.1  
\$0.36 0.102 DialUnits File1  
\$0.36 Estimated cost File1  
\$0.05 TYMNET  
\$0.41 Estimated cost this search  
\$0.41 Estimated total session cost 0.102 DialUnits

File 410:Chronolog(R) 1981-1999 Nov/Dec  
(c) 1999 The Dialog Corporation plc

Set	Items	Description
-----	-------	-------------

?

HIGHLIGHT set on as ''

HIGHLIGHT set on as ''

? b a55, 5, 399, 357, 654

>>>"A55" is not a valid category or service name

<-----User Break----->

u!

? b 155, 5, 399, 357, 654

12jan00 10:16:38 User233835 Session D357.3  
\$0.08 0.015 DialUnits File5  
\$0.08 Estimated cost File5  
\$0.19 0.015 DialUnits File399  
\$0.19 Estimated cost File399  
\$0.18 0.015 DialUnits File357  
\$0.18 Estimated cost File357  
\$0.09 0.015 DialUnits File654  
\$0.09 Estimated cost File654  
OneSearch, 4 files, 0.060 DialUnits FileOS  
\$0.01 TYMNET  
\$0.55 Estimated cost this search  
\$0.98 Estimated total session cost 0.209 DialUnits

SYSTEM:OS - DIALOG OneSearch

File 155:MEDLINE(R) 1966-1999/Dec W4

(c) format only 1999 Dialog Corporation

File 5:BIOSIS PREVIEWS(R) 1969-1999/NOV W4

(c) 1999 BIOSIS

File 399:CA SEARCH(R) 1967-2000/UD=13202

(c) 2000 AMERICAN CHEMICAL SOCIETY

\*File 399: Use is subject to the terms of your user/customer agreement.  
RANK charge added; see HELP RATES 399.

File 357:DERWENT BIOTECHNOLOGY ABS 1982-1999/DEC B2

(c) 1999 DERWENT PUBL LTD

\*File 357: Derwent changes DialUnit pricing from May 1, 1999. See  
HELP DERWENT for details.

File 654:US PAT.FULL. 1990-2000/JAN 04

(c) FORMAT ONLY 2000 THE DIALOG CORP.

\*File 654: Reassignment data current through 12/06/1999 recordings.  
Reexamination, extension, expiration, reinstatement updated weekly.

Set	Items	Description
-----	-------	-------------

? s oligonucleotide and ligand and (coumarins or isocoumarins or  
anilinocoumarin or ketoprofen or carprofen or etodolac)

80069	OLIGONUCLEOTIDE
202209	LIGAND
13743	COUMARINS

555 ISOCUMARINS  
 15 ANILINOCUMARIN  
 4865 KETOPROFEN  
 829 CARPROFEN  
 1024 ETODOLAC  
 S1 71 OLIGONUCLEOTIDE AND LIGAND AND (COUMARINS OR ISOCUMARINS  
 OR ANILINOCUMARIN OR KETOPROFEN OR CARPROFEN OR  
 ETODOLAC)

? s oligonucleotide and ligand and (coumarins or isocoumarins or  
 anilinocoumarin or ketoprofen or carprofen or etodolac or suprofen or  
 indoprofen or fenbufen)

80069 OLIGONUCLEOTIDE  
 202209 LIGAND  
 13743 COUMARINS  
 555 ISOCUMARINS  
 15 ANILINOCUMARIN  
 4865 KETOPROFEN  
 829 CARPROFEN  
 1024 ETODOLAC  
 1068 SUPROFEN  
 823 INDOPROFEN  
 1013 FENBUFEN  
 S2 71 OLIGONUCLEOTIDE AND LIGAND AND (COUMARINS OR ISOCUMARINS  
 OR ANILINOCUMARIN OR KETOPROFEN OR CARPROFEN OR ETODOLAC  
 OR SUPROFEN OR INDOPROFEN OR FENBUFEN)

? rd

>>>Duplicate detection is not supported for File 654.

>>>Records from unsupported files will be retained in the RD set.

...examined 50 records (50)  
 ...completed examining records  
 S3 71 RD (unique items)  
 ? t s3/6/1-71

3/6/1 (Item 1 from file: 654)  
 03058289  
 PROMISCUOUS G-PROTEIN COMPOSITIONS AND THEIR USE  
 FULL TEXT: 1938 lines

3/6/2 (Item 2 from file: 654)  
 03057994  
 AUTOMATIC DEVICE FOR NUCLEIC ACID SEQUENCE DETECTION EMPLOYING  
 AMPLIFICATION PROBES  
 FULL TEXT: 3059 lines

3/6/3 (Item 3 from file: 654)  
 03055295  
 CHEMILUMINESCENT COMPOUNDS AND METHODS OF USE  
 FULL TEXT: 1802 lines

3/6/4 (Item 4 from file: 654)  
 03054946  
 ANTISENSE MODULATION OF LFA-3  
 FULL TEXT: 2984 lines

3/6/5 (Item 5 from file: 654)  
 03051659  
 4'-DESMETHYL NUCLEOSIDE ANALOGS, AND OLIGOMERS THEREOF

FULL TEXT: 1898 lines

3/6/6 (Item 6 from file: 654)  
03051191  
ENERGY TRANSFER HYBRIDIZATION ASSAY USING INTERCALATORS AND LANTHANIDE METALS  
FULL TEXT: 791 lines

3/6/7 (Item 7 from file: 654)  
03042622  
AGENTS AFFECTING THROMBOSIS AND HEMOSTASIS  
FULL TEXT: 1795 lines

3/6/8 (Item 8 from file: 654)  
03038215  
PHOTOCLEAVABLE AGENTS AND CONJUGATES FOR THE DETECTION AND ISOLATION OF BIOMOLECULES  
FULL TEXT: 3733 lines

3/6/9 (Item 9 from file: 654)  
03033314  
AMINIMIDE-CONTAINING MOLECULES AND MATERIALS AS MOLECULAR RECOGNITION AGENTS  
FULL TEXT: 2577 lines

3/6/10 (Item 10 from file: 654)  
03023966  
ATP-DEPENDENT PROTEASE AND USE OF INHIBITORS FOR SAME IN THE TREATMENT OF CACHEXIA AND MUSCLE WASTING  
FULL TEXT: 2818 lines

3/6/11 (Item 11 from file: 654)  
03019953  
AGENTS AFFECTING THROMBOSIS AND HEMOSTASIS  
FULL TEXT: 1717 lines

3/6/12 (Item 12 from file: 654)  
03005329  
SUBSTRATES FOR .BETA.-LACTAMASE AND USES THEREOF  
FULL TEXT: 2318 lines

3/6/13 (Item 13 from file: 654)  
03005170  
ANTISENSE MODULATION OF PECAM-1  
FULL TEXT: 4433 lines

3/6/14 (Item 14 from file: 654)  
02997742  
METHODS FOR THE DETECTION AND ISOLATION OF BIOMOLECULES  
FULL TEXT: 3701 lines

3/6/15 (Item 15 from file: 654)  
02997352  
COMPOSITIONS, METHODS AND APPARATUS FOR ULTRAFAST ELECTROSEPARATION ANALYSIS

FULL TEXT: 1747 lines

3/6/16 (Item 16 from file: 654)  
02984223  
CHEMILUMINESCENT COMPOUNDS AND METHODS OF USE  
FULL TEXT: 1838 lines

3/6/17 (Item 17 from file: 654)  
02976679  
METHODS AND COMPOSITIONS FOR SENSITIVE AND RAPID, FUNCTIONAL IDENTIFICATION  
OF GENOMIC POLYNUCLEOTIDES AND SECONDARY SCREENING CAPABILITIES  
FULL TEXT: 2688 lines

3/6/18 (Item 18 from file: 654)  
02956485  
LOW BACKGROUND MULTI-WELL PLATES WITH GREATER THAN 864 WELLS FOR  
FLUORESCENCE MEASUREMENTS OF BIOLOGICAL AND BIOCHEMICAL SAMPLES  
FULL TEXT: 1732 lines

3/6/19 (Item 19 from file: 654)  
02928728  
PHOSPHATE LINKED OLIGOMERS  
FULL TEXT: 3407 lines

3/6/20 (Item 20 from file: 654)  
02928389  
ENGINEERING ORAL TISSUES  
[ Growing viable oral tissue cells on a synthetic matrix in vitro under  
conditions effective and for a period of time sufficient to allow  
proliferation of viable oral tissue cells]  
FULL TEXT: 7476 lines

3/6/21 (Item 21 from file: 654)  
02916066  
FACTOR VIIA INHIBITORS  
[ Administering pharmaceutical composition comprising excipient and fusion  
protein of Factor VIIa active site inhibitor domain, peptide linker domain,  
and tissue factor domain to inhibit procoagulant activity; cardiovascular  
disorders]  
FULL TEXT: 2327 lines

3/6/22 (Item 22 from file: 654)  
02893128  
CHEMICAL PROMOTION OF NUCLEIC ACID HYBRIDIZATION  
FULL TEXT: 864 lines

3/6/23 (Item 23 from file: 654)  
02874949  
AGENTS AFFECTING THROMBOSIS AND HEMOSTASIS  
[Blood coagulation factor for hemophilia]  
FULL TEXT: 1889 lines

3/6/24 (Item 24 from file: 654)  
02867575  
DERIVATIVES OF 6,8-DIFLUORO-7-HYDROXYCOUMARIN  
FULL TEXT: 2161 lines

3/6/25 (Item 25 from file: 654)  
02849991  
COMPOUNDS WITH PTH ACTIVITY  
[Parathyroid hormone peptide with amino acid sequences]  
FULL TEXT: 4675 lines

3/6/26 (Item 26 from file: 654)  
02842634  
FLUORESCENT OXYGEN CHANNELING IMMUNOASSAYS  
[Photosensitizer; generating free radicals; measuring light]  
FULL TEXT: 2529 lines

3/6/27 (Item 27 from file: 654)  
02835442  
DIOXETANE-PRECURSOR-LABELED PROBES AND DETECTION ASSAYS EMPLOYING THE SAME  
FULL TEXT: 829 lines

3/6/28 (Item 28 from file: 654)  
02832437  
REACTIVE DERIVATIVES OF SULFORHODAMINE 101 WITH ENHANCED HYDROLYTIC  
STABILITY  
[ Detecting complementary member of specific binding pair using fluorescent  
conjugate]  
FULL TEXT: 1461 lines

3/6/29 (Item 29 from file: 654)  
02819684  
ATP-DEPENDENT PROTEASE AND USE OF INHIBITORS FOR SAME IN THE TREATMENT OF  
CACHEXIA AND MUSCLE WASTING  
[Muscular disorders]  
FULL TEXT: 2782 lines

3/6/30 (Item 30 from file: 654)  
02819578  
MICROSPHERES WITH FLUORESCENT SPHERICAL ZONES  
[Polymeric microsphere displaying distinct fluorescent ring concentric with  
and within said sphere; labels, calibrating microscopes]  
FULL TEXT: 1274 lines

3/6/31 (Item 31 from file: 654)  
02806606  
PRO DRUGS FOR SELECTIVE DRUG DELIVERY  
[ Comprises a chemiluminescent moiety, a photochromic moiety and a  
biologically active agent capable of being released]  
FULL TEXT: 3217 lines

3/6/32 (Item 32 from file: 654)  
02800042  
OLIGONUCLEOTIDES CONTAINING BASE-FREE LINKING GROUPS WITH PHOTOACTIVATABLE  
SIDE CHAINS  
[FOR DETECTING Nucleic acid sequences by using a pair of probes]  
FULL TEXT: 1667 lines

3/6/33 (Item 33 from file: 654)  
02799360

APPARATUS AND METHOD FOR MULTIPLE SIMULTANEOUS SYNTHESIS  
[ SUITABLE ENVIRONMENT FOR SIMULTANEOUS SYNTHESIS OF ORGANIC COMPOUNDS,  
INORGANIC COMPOUNDS AND ORGANOMETALLIC COMPOUNDS]  
FULL TEXT: 2946 lines

3/6/34 (Item 34 from file: 654)  
02785787  
ADENOSINE DIPHOSPHORIBOSE POLYMERASE BINDING NITROSO AROMATIC COMPOUNDS  
USEFUL AS RETROVIRAL INACTIVATING AGENTS, ANTI-RETROVIRAL AGENTS,  
ANTI-RETROVIRAL AGENTS AND ANTI-TUMOR AGENTS  
[Administering enzyme inhibitors as anticancer agents]  
FULL TEXT: 1589 lines

3/6/35 (Item 35 from file: 654)  
02767444  
FACTOR VIIA INHIBITORS  
[ A fusion protein comprising a Factor VIIa active site inhibitor domain, a  
linker domain and a tissue factor domain]  
FULL TEXT: 2344 lines

3/6/36 (Item 36 from file: 654)  
02745793  
PHOSPHORAMIDATE AND PHOSPHOROTHIOMIDATE OLIGOMERIC COMPOUNDS  
[Complexing with proteins, nucleic acids, lipids]  
FULL TEXT: 2416 lines

3/6/37 (Item 37 from file: 654)  
02743013  
PYRROLIDINE-CONTAINING MONOMERS AND OLIGOMERS  
[**Oligonucleotide** having receptor binding sites; enzyme inhibitors,  
antiinflammatory agents, medical diagnosis]  
FULL TEXT: 2505 lines

3/6/38 (Item 38 from file: 654)  
02742550  
SYSTEM FOR MULTIPLE SIMULTANEOUS SYNTHESIS  
[ Reservoir racks with reaction wells; gas dispersion tubes containing  
filters; holder block with apertures; manifold]  
FULL TEXT: 3563 lines

3/6/39 (Item 39 from file: 654)  
02732734  
AMINIMIDE-CONTAINING MOLECULES AND MATERIALS AS MOLECULAR RECOGNITION  
AGENTS  
[Peptide mimetic]  
FULL TEXT: 2129 lines

3/6/40 (Item 40 from file: 654)  
02729512  
APPARATUS AND METHOD FOR MULTIPLE SIMULTANEOUS SYNTHESIS  
[ Reaction tube comprising gas dispersion tube having ground glass joint  
section]  
FULL TEXT: 2828 lines

3/6/41 (Item 41 from file: 654)  
02722003  
SULFONATED DERIVATIVES OF 7-AMINOCOUMARIN



[Complexing; using a fluorescent detector]  
FULL TEXT: 1611 lines

3/6/42 (Item 42 from file: 654)  
02713910  
METHODS OF MAKING CONJUGATED 4' DESMETHYL NUCLEOSIDE ANALOG COMPOUNDS  
FULL TEXT: 1636 lines

3/6/43 (Item 43 from file: 654)  
02710963  
TEMPLATE-DIRECTED LIGATION AND AMPLIFICATION ASSAY  
[Detecting polynucleotide sequences; hybridization]  
FULL TEXT: 1782 lines

3/6/44 (Item 44 from file: 654)  
02701056  
HETEROATOMIC OLIGONUCLEOSIDE LINKAGES  
[Macromolecules; regulating Rna expression; therapy]  
FULL TEXT: 2669 lines

3/6/45 (Item 45 from file: 654)  
02695553  
METHODS OF USE FOR AND KITS CONTAINING CHEMILUMINESCENT COMPOUNDS  
[Mixing sample, chemiluminescent compound and activator, then detecting and measuring luminescence which indicates amount of analyte in sample]  
FULL TEXT: 1905 lines

3/6/46 (Item 46 from file: 654)  
02685102  
ENGINEERED HUMAN-DERIVED KUNITZ DOMAINS THAT INHIBIT HUMAN NEUTROPHIL ELASTASE  
[Protein which binds and inhibits elastase]  
FULL TEXT: 10485 lines

3/6/47 (Item 47 from file: 654)  
02663176  
METHODS FOR THE DETECTION AND ISOLATION OF PROTEINS  
[Marking proteins and detection, incubation]  
FULL TEXT: 2046 lines

3/6/48 (Item 48 from file: 654)  
02656419  
PHOSPHORAMIDATE AND PHOSPHOROTHIOAMIDATE OLIGOMERIC COMPOUNDS  
[Binding proteins, nucleic acids, lipids; phospholipase inhibitor]  
FULL TEXT: 1619 lines

3/6/49 (Item 49 from file: 654)  
02649245  
COMPOSITIONS, METHODS AND APPARATUS FOR ULTRAFAST ELECTROSEPARATION ANALYSIS  
[Mixing binding partners (one labeled and one charged) with with possible analyte to form three-membered complex, then capillary electrophoresis]  
FULL TEXT: 1715 lines

3/6/50 (Item 50 from file: 654)  
02634382

PHOTOACTIVE INDICATOR COMPOUNDS  
FULL TEXT: 2287 lines

3/6/51 (Item 51 from file: 654)  
02629527  
APPARATUS AND METHOD FOR MULTIPLE SIMULTANEOUS SYNTHESIS  
[Synthesis of compounds]  
FULL TEXT: 3053 lines

3/6/52 (Item 52 from file: 654)  
02625348  
CONJUGATED 4'-DESMETHYL NUCLEOSIDE ANALOG COMPOUNDS  
FULL TEXT: 1647 lines

3/6/53 (Item 53 from file: 654)  
02610182  
APPARATUS FOR MULTIPLE SIMULTANEOUS SYNTHESIS  
[Containment of solid support within a gas dispersion tube]  
FULL TEXT: 2863 lines

3/6/54 (Item 54 from file: 654)  
02598488  
APPARATUS FOR MULTIPLE SIMULTANEOUS SYNTHESIS  
[ Having plurality of reaction tubes with filters on lower ends, reservoir  
with means for receiving filters, holder for supporting tubes, manifold  
enclosing upper ends, fasteners holding together holder and manifold,  
holder and reservoir]  
FULL TEXT: 2900 lines

3/6/55 (Item 55 from file: 654)  
02581613  
APPARATUS FOR MULTIPLE SIMULTANEOUS SYNTHESIS  
[Multicompartment chemical reactors]  
FULL TEXT: 2887 lines

3/6/56 (Item 56 from file: 654)  
02579360  
ATP-DEPENDENT PROTEASE AND USE OF INHIBITORS FOR SAME IN THE TREATMENT OF  
CACHEXIA AND MUSCLE WASTING  
[Reducing the muscle protein loss by reducing proteolysis]  
FULL TEXT: 2785 lines

3/6/57 (Item 57 from file: 654)  
02579185  
APPARATUS AND METHOD FOR MULTIPLE SIMULTANEOUS SYNTHESIS  
[Used for solid-phase synthesis]  
FULL TEXT: 2937 lines

3/6/58 (Item 58 from file: 654)  
02557954  
CHEMILUMINESCENT COMPOUNDS AND METHODS OF USE  
[Used as labels for immunoassay and nucleic acid probe assays]  
FULL TEXT: 1823 lines

3/6/59 (Item 59 from file: 654)  
02528660

PYRROLIDINE-CONTAINING MONOMERS AND OLIGOMERS  
[ANTIINFLAMMATORY AGENTS]  
FULL TEXT: 1716 lines

3/6/60 (Item 60 from file: 654)  
02521360  
SINGLE STEP SIGNAL GROUP-IMIDAZOLE LABELING OF ORGANIC PHOSPHATE GROUPS  
UNDER AQUEOUS CONDITIONS  
[Covalently linking labelling compound via imidazole moiety, in presence of  
an aqueous carbodiimide reagent, to free phosphate moiety of  
deoxynucleotides]  
FULL TEXT: 484 lines

3/6/61 (Item 61 from file: 654)  
02451512  
TEMPLATE-DIRECTED PHOTOLIGATION  
[Polynucleotides]  
FULL TEXT: 1823 lines

3/6/62 (Item 62 from file: 654)  
02427576  
PRODRUGS FOR SELECTIVE DRUG DELIVERY  
[Luminides; chemiluminescence; redox system, releasing free drug]  
FULL TEXT: 2597 lines

3/6/63 (Item 63 from file: 654)  
02427199  
MODIFICATION OF POLYMER SURFACES AND MOLECULAR IMMOBILIZATION BY  
PHOTOREACTION  
[Irradiating a solid polymer and a compound such as substituted indoles,  
benzofurans, angelicins, **coumarins** etc; heterogeneous immunoassays;  
fixing; surface treatment]  
FULL TEXT: 1270 lines

3/6/64 (Item 64 from file: 654)  
02330430  
ATP-DEPENDENT PROTEASE AND USE OF INHIBITORS FOR SAME IN THE TREATMENT OF  
CACHEXIA AND MUSCLE WASTING  
[Multipain and multipain-proteasome complex which cleave ubiquitinated and  
non-ubiquitinated proteins]  
FULL TEXT: 2733 lines

3/6/65 (Item 65 from file: 654)  
02330411  
ASSAY METHOD UTILIZING PHOTOACTIVATED CHEMILUMINESCENT LABEL  
FULL TEXT: 2686 lines

3/6/66 (Item 66 from file: 654)  
02312511  
APPARATUS FOR MULTIPLE SIMULTANEOUS SYNTHESIS  
FULL TEXT: 2964 lines

3/6/67 (Item 67 from file: 654)  
02243525  
REAGENTS FOR THE PREPARATION OF 5'-TAGGED OLIGONUCLEOTIDES  
[Fluorescent reagents]  
FULL TEXT: 691 lines

3/6/68 (Item 68 from file: 654)

02193548

TEMPLATE-DIRECTED PHOTOLIGATION

[ Polynucleotide probes bound to a target; having photoreactive functional groups which bind to each other upon activation]

FULL TEXT: 1828 lines

3/6/69 (Item 69 from file: 654)

02118538

DERIVATIVES OF TETRAHYDRO-2,3,6,7,1H,5H,11H-(1)BENZOPYRANO(6,7,8,I,J)QUINOLIZINONE-11 USABLE AS MARKERS FOR ORGANIC COMPOUNDS, PARTICULARLY BIOLOGICAL COMPOUNDS WITH A VIEW TO THEIR DETECTION BY CHEMILUMINESCENCE OR FLUORESCENCE

[Fluorescent marking compounds]

FULL TEXT: 739 lines

3/6/70 (Item 70 from file: 654)

02118528

ALKYNYLAMINO-NUCLEOTIDES

[DNA sequences]

FULL TEXT: 2672 lines

3/6/71 (Item 71 from file: 654)

01951826

FLUORESCENT REAGENTS FOR THE PREPARATION OF 5'-TAGGED OLIGONUCLEOTIDES

[DNA sequencing]

FULL TEXT: 693 lines

?

PLEASE ENTER A COMMAND OR BE LOGGED OFF IN 5 MINUTES

? t s3/3,ab/41, 17, 31, 36, 37, 41, 59

3/3,AB/41 (Item 41 from file: 654)

DIALOG(R)File 654:US PAT.FULL.

(c) FORMAT ONLY 2000 THE DIALOG CORP. All rts. reserv.

02722003

Utility

SULFONATED DERIVATIVES OF 7-AMINOCOUMARIN

[Complexing; using a fluorescent detector]

PATENT NO.: 5,696,157

ISSUED: December 09, 1997 (19971209)

INVENTOR(s): Wang, Hui-Ying, Eugene, OR (Oregon), US (United States of America)

Leung, Wai-Yee, Eugene, OR (Oregon), US (United States of America)

Mao, Fei, Eugene, OR (Oregon), US (United States of America)

ASSIGNEE(s): Molecular Probes, Inc , (A U.S. Company or Corporation), Eugene, OR (Oregon), US (United States of America)

[Assignee Code(s): 19082]

APPL. NO.: 8-749,753

FILED: November 15, 1996 (19961115)

FULL TEXT: 1611 lines

ABSTRACT

The present invention describes 7-aminocoumarin dyes that are substituted

one or more times at 3-, 6- and/or 8-positions by sulfonic acid or a salt of a sulfonic acid, said dyes being useful as fluorescent probes or in the preparation of enzyme substrates, caged probes, or adducts with reducing sugars. The dyes of the invention optionally possess a reactive group useful for preparing fluorescent conjugates, which conjugates and methods for their preparation are described herein.

3/3,AB/17 (Item 17 from file: 654)  
DIALOG(R) File 654:US PAT.FULL.  
(c) FORMAT ONLY 2000 THE DIALOG CORP. All rts. reserv.

02976679

Utility  
METHODS AND COMPOSITIONS FOR SENSITIVE AND RAPID, FUNCTIONAL IDENTIFICATION  
OF GENOMIC POLYNUCLEOTIDES AND SECONDARY SCREENING CAPABILITIES

PATENT NO.: 5,928,888  
ISSUED: July 27, 1999 (19990727)  
INVENTOR(s): Whitney, Michael A., La Jolla, CA (California), US (United States of America)  
ASSIGNEE(s): Aurora Biosciences Corporation, (A U.S. Company or Corporation), San Diego, CA (California), US (United States of America)  
[Assignee Code(s): 49627]  
APPL. NO.: 8-719,697  
FILED: September 26, 1996 (19960926)

FULL TEXT: 2688 lines

#### ABSTRACT

The invention provides for a methods and compositions for identifying proteins or compounds that directly or indirectly modulate a genomic polynucleotide and methods for identifying active genomic polynucleotides. Generally, the method comprises inserting a BL (beta-lactamase) expression construct into an eukaryotic genome, usually non-yeast, contained in at least one living cell, contacting the cell with a predetermined concentration of a modulator, and detecting BL activity in the cell.

3/3,AB/31 (Item 31 from file: 654)  
DIALOG(R) File 654:US PAT.FULL.  
(c) FORMAT ONLY 2000 THE DIALOG CORP. All rts. reserv.

02806606

Utility  
PRO DRUGS FOR SELECTIVE DRUG DELIVERY  
[ Comprises a chemiluminescent moiety, a photochromic moiety and a biologically active agent capable of being released]

PATENT NO.: 5,773,592  
ISSUED: June 30, 1998 (19980630)  
INVENTOR(s): Mills, Randell Lee, R.D. #2, Cochranville, PA (Pennsylvania), US (United States of America), 19330  
[Assignee Code(s): 68000]  
APPL. NO.: 8-450,672  
FILED: May 30, 1995 (19950530)

This application is a continuation of application Ser. No. 07-446,439 filed on Dec. 4, 1989, now U.S. Pat. No. 5,428,163, which in turn is a continuation-in-part of application Ser. No. 06-948,326 filed on Dec. 31, 1986, now abandoned and application Ser. No. 07-175,970 filed Mar. 31, 1998, now abandoned. The contents of all of the aforementioned applications are expressly incorporated by reference.

## ABSTRACT

A broad class of pharmaceutical agents which react directly with electron carriers or with reactive species produced by electron transport to release a pharmacologically active molecule to effect a therapeutic functional change in the organism by a receptor or nonreceptor mediated action.

3/3,AB/36 (Item 36 from file: 654)  
DIALOG(R) File 654:US PAT.FULL.  
(c) FORMAT ONLY 2000 THE DIALOG CORP. All rts. reserv.

02745793

## Utility

PHOSPHORAMIDATE AND PHOSPHOROTHIOMIDATE OLIGOMERIC COMPOUNDS  
[Complexing with proteins, nucleic acids, lipids]

PATENT NO.: 5,717,083  
ISSUED: February 10, 1998 (19980210)  
INVENTOR(s): Cook, Phillip Dan, Vista, CA (California), US (United States of America)  
Acevedo, Oscar, San Diego, CA (California), US (United States of America)  
Hebert, Normand, Cardiff, CA (California), US (United States of America)  
ASSIGNEE(s): ISIS Pharmaceuticals, Inc , (A U.S. Company or Corporation), Carlsbad, CA (California), US (United States of America)  
[Assignee Code(s): 28846]  
APPL. NO.: 8-693,112  
FILED: August 19, 1996 (19960819)  
PCT: PCT-US95-02267 (WO 95US2267)  
Section 371 Date: August 19, 1996 (19960819)  
Section 102(e) Date: August 19, 1996 (19960819)  
Filing Date: February 23, 1995 (19950223)  
Publication Number: WO95-23160 (WO 9523160)  
Publication Date: August 31, 1995 (19950831)

## CROSS REFERENCE TO RELATED APPLICATIONS

This application is a 371 application of PCT-US95-02267, filed Feb. 23, 1995 and is a continuation-in-part of U.S. application Ser. No. 08-200,638, filed Feb. 23, 1994, now U.S. Pat. No. 5,637,684. The contents of the foregoing patent application are incorporated herein by reference.

FULL TEXT: 2416 lines

## ABSTRACT

Compounds are provided having structure (I), wherein the L groups are backbone segments, the Y and T groups are functional groups for interacting with target molecules of interest, the X groups are oxygen or sulfur and the E groups are H, conjugate groups or intermediate groups used during the synthesis of the compounds and wherein the compounds are prepared using H phosphonate type chemistry wherein the functional groups are added during an oxidation step or during a coupling step. [See structure in original document]

3/3,AB/37 (Item 37 from file: 654)

02743013

Utility

PYRROLIDINE-CONTAINING MONOMERS AND OLIGOMERS

[**Oligonucleotide** having receptor binding sites; enzyme inhibitors, antiinflammatory agents, medical diagnosis]

PATENT NO.: 5,714,606  
ISSUED: February 03, 1998 (19980203)  
INVENTOR(s): Acevedo, Oscar L., San Diego, CA (California), US (United States of America)  
Hebert, Normand, Cardiff, CA (California), US (United States of America)  
ASSIGNEE(s): ISIS Pharmaceuticals, Inc , (A U.S. Company or Corporation), Carlsbad, CA (California), US (United States of America)  
[Assignee Code(s): 28846]  
APPL. NO.: 8-669,505  
FILED: August 15, 1996 (19960815)  
PCT: PCT-US95-00356 (WO 95US356)  
Section 371 Date: August 15, 1996 (19960815)  
Section 102(e) Date: August 15, 1996 (19960815)  
Filing Date: January 11, 1995 (19950111)  
Publication Number: WO95-18792 (WO 9518792)  
Publication Date: July 13, 1995 (19950713)

CROSS REFERENCE TO RELATED APPLICATIONS

This application is a 371 of PCT-US95-00356 filed Jan. 11, 1995 and a continuation-in-part of U.S. application Ser. No. 08-180,134, filed Jan. 11, 1994 now U.S. Pat. No. 5,519,134.

The contents of the foregoing patent application are incorporated herein by reference.

FULL TEXT: 2505 lines

ABSTRACT

The invention relates to pyrrolidine monomeric units and to oligomers which are joined via phosphate linkages, including phosphorothioate, phosphodiester and phosphoramidate linkages.

3/3,AB/41 (Item 41 from file: 654)  
DIALOG(R)File 654:US PAT.FULL.  
(c) FORMAT ONLY 2000 THE DIALOG CORP. All rts. reserv.

02722003

Utility

SULFONATED DERIVATIVES OF 7-AMINOCOUMARIN

[Complexing; using a fluorescent detector]

PATENT NO.: 5,696,157  
ISSUED: December 09, 1997 (19971209)  
INVENTOR(s): Wang, Hui-Ying, Eugene, OR (Oregon), US (United States of America)  
Leung, Wai-Yee, Eugene, OR (Oregon), US (United States of America)  
Mao, Fei, Eugene, OR (Oregon), US (United States of America)  
ASSIGNEE(s): Molecular Probes, Inc , (A U.S. Company or Corporation), Eugene, OR (Oregon), US (United States of America)

[Assignee Code(s): 19082]  
APPL. NO.: 8-749,753  
FILED: November 15, 1996 (19961115)

FULL TEXT: 1611 lines

#### ABSTRACT

The present invention describes 7-aminocoumarin dyes that are substituted one or more times at the 3-, 6- and/or 8-positions by a sulfonic acid or a salt of a sulfonic acid, said dyes being useful as fluorescent probes or in the preparation of enzyme substrates, caged probes, or adducts with reducing sugars. The dyes of the invention optionally possess a reactive group useful for preparing fluorescent conjugates, which conjugates and methods for their preparation are described herein.

3/3,AB/59 (Item 59 from file: 654)  
DIALOG(R)File 654:US PAT.FULL.  
(c) FORMAT ONLY 2000 THE DIALOG CORP. All rts. reserv.

02528660

Utility  
PYRROLIDINE-CONTAINING MONOMERS AND OLIGOMERS  
[ANTIINFLAMMATORY AGENTS]

PATENT NO.: 5,519,134  
ISSUED: May 21, 1996 (19960521)  
INVENTOR(s): Acevedo, Oscar L., San Diego, CA (California), US (United States of America)  
Hebert, Normand, San Marcos, CA (California), US (United States of America)  
ASSIGNEE(s): Isis Pharmaceuticals, Inc, (A U.S. Company or Corporation), Carlsbad, CA (California), US (United States of America)  
[Assignee Code(s): 28846]  
APPL. NO.: 8-180,134  
FILED: January 11, 1994 (19940111)

FULL TEXT: 1716 lines

#### ABSTRACT

Novel pyrrolidine monomers bearing various functional groups are used to prepare oligomeric structures. The pyrrolidine monomers can be joined via standard phosphate linkages including phosphodiester and phosphorothioate linkages. Useful functional groups include nucleobases as well as polar groups, hydrophobic groups, ionic groups, aromatic groups and/or groups that participate in hydrogen-bonding.

?

PLEASE ENTER A COMMAND OR BE LOGGED OFF IN 5 MINUTES

? s oligonucleotide and ligand and (arylproprionic or arylalkonic or fluoropropionic or glibenclamid or acetohexamide or arylalkanoic or tobutamide or gliclazide or metformin or curcumin or digitoxin or digoxin or diazepam)

80069 OLIGONUCLEOTIDE  
202209 LIGAND  
5 ARYLPROPRIONIC  
0 ARYLALKONIC  
0 FLUOROPROPIONIC  
119 GLIBENCLAMID  
624 ACETOHEXAMIDE  
309 ARYLALKANOIC  
7 TOBUTAMIDE



1064 GLICLONIDE  
 2894 METFORMIN  
 1903 CURCUMIN  
 4634 DIGITOXIN  
 22133 DIGOXIN  
 40891 DIAZEPAM  
 S4 217 OLIGONUCLEOTIDE AND LIGAND AND (ARYLPROPRIONIC OR  
 ARYLALKANONIC OR FLUOROPROPIONIC OR GLIBENCLAMID OR  
 ACETOHEXAMIDE OR ARYLALKANOIC OR TOBUTAMIDE OR GLICLAZIDE  
 OR METFORMIN OR CURCUMIN OR DIGITOXIN OR DIGOXIN OR  
 DIAZEPAM)

? rd

>>>Duplicate detection is not supported for File 654.

>>>Records from unsupported files will be retained in the RD set.

...examined 50 records (50)  
 ...examined 50 records (100)  
 ...examined 50 records (150)  
 ...examined 50 records (200)  
 ...completed examining records  
 S5 216 RD (unique items)  
 ? t s3/6/1

3/6/1 (Item 1 from file: 654)  
 03058289  
 PROMISCUOUS G-PROTEIN COMPOSITIONS AND THEIR USE  
 FULL TEXT: 1938 lines  
 ? s s4 not s3

217 S4  
 71 S3  
 S6 199 S4 NOT S3  
 ? t s5/6/1

5/6/1 (Item 1 from file: 155)  
 09908384 99156208  
 Ontogeny of **diazepam** binding inhibitor/acyl-CoA binding protein  
 mRNA and peripheral benzodiazepine receptor mRNA expression in the rat.  
 Feb 1999  
 ? t s5/6/1-10

5/6/1 (Item 1 from file: 155)  
 09908384 99156208  
 Ontogeny of **diazepam** binding inhibitor/acyl-CoA binding protein  
 mRNA and peripheral benzodiazepine receptor mRNA expression in the rat.  
 Feb 1999

5/6/2 (Item 2 from file: 155)  
 06171995 87161236  
 Bovine and human cDNA sequences encoding a putative benzodiazepine  
 receptor **ligand**.  
 Feb 1987

5/6/3 (Item 1 from file: 654)  
 03065112  
 RECOMBINANT BINDING PROTEINS AND PEPTIDES  
 FULL TEXT: 2433 lines

5/6/4 (Item 2 from file: 654)

03065089

TARGET SPECIFIC SCREENS AND THEIR USE FOR DISCOVERING SMALL ORGANIC  
MOLECULAR PHARMACOPHORES

FULL TEXT: 4776 lines

5/6/5 (Item 3 from file: 654)

03065085

DETECTION OF CERVICAL CHLAMYDIA TRACHOMATIS INFECTION

FULL TEXT: 1465 lines

5/6/6 (Item 4 from file: 654)

03061827

MULTIPARAMETRIC FLUORESCENCE IN SITU HYBRIDIZATION

FULL TEXT: 3282 lines

5/6/7 (Item 5 from file: 654)

03055295

CHEMILUMINESCENT COMPOUNDS AND METHODS OF USE

FULL TEXT: 1802 lines

5/6/8 (Item 6 from file: 654)

03054917

INTEGRIN-LINKED KINASE AND ITS USE

FULL TEXT: 2947 lines

5/6/9 (Item 7 from file: 654)

03054875

SUPPORTS AND COMBINATORIAL CHEMICAL LIBRARIES THEREOF ENCODED BY  
NON-SEQUENCABLE TAGS

FULL TEXT: 2832 lines

5/6/10 (Item 8 from file: 654)

03047342

LABELLING AND SELECTION OF MOLECULES

FULL TEXT: 3299 lines

? t s5/7/1, 2

5/7/1 (Item 1 from file: 155)

DIALOG(R) File 155: MEDLINE(R)

(c) format only 1999 Dialog Corporation. All rts. reserv.

09908384 99156208

Ontogeny of **diazepam** binding inhibitor/acyl-CoA binding protein  
mRNA and peripheral benzodiazepine receptor mRNA expression in the rat.

Burgi B; Lichtensteiger W; Lauber ME; Schlumpf M

Institute of Pharmacology, University of Zurich, Switzerland.

J Neuroendocrinol (ENGLAND) Feb 1999, 11 (2) p85-100, ISSN 0953-8194

Journal Code: BRL

Languages: ENGLISH

Document type: JOURNAL ARTICLE

The **Diazepam** Binding Inhibitor/Acyl-CoA Binding Protein (DBI/ACBP)  
has been implicated in different functions, as acyl-CoA transporter and as  
an endogenous **ligand** at the GABA(A) receptor and the peripheral  
benzodiazepine receptor (PBR). The latter is thought to be involved in  
control of steroidogenesis. We studied the ontogeny of DBI/ACBP and PBR  
mRNA expression in embryos and offspring of time-pregnant Long Evans rats  
by in-situ hybridization with 33P-endlabelled oligonucleotides. Both mRNAs

were present in embryo and placenta at gestational day 11, the earliest stage studied. DBI/ACBP mRNA was strongly expressed from embryonic through mid-foetal stages in central nervous system (maximum in neuroepithelium), cranial and sympathetic ganglia, anterior pituitary, adrenal cortex, thyroid, thymus, liver and (late foetal) brown adipose tissue, moderately in testis, heart, lung and kidney. In brain, a late foetal decrease of DBI/ACBP mRNA was followed by an increase at postnatal day 6. Peripheral benzodiazepine receptor mRNA expression started very low and increased to moderate levels in adrenal cortex and medulla, testis, thyroid, brown adipose tissue, liver, heart, lung, salivary gland at mid- to late-foetal stages. Data suggest a significant role of DBI/ACBP at early developmental stages. Both proteins may be involved in the control of foetal steroidogenesis. However, differences in developmental patterns indicate that additional functions may be equally important during ontogeny, such as the involvement in lipid metabolism in the case of DBI/ACBP.

5/7/2 (Item 2 from file: 155)  
 DIALOG(R)File 155:MEDLINE(R)  
 (c) format only 1999 Dialog Corporation. All rts. reserv.

06171995 87161236

Bovine and human cDNA sequences encoding a putative benzodiazepine receptor **ligand**.

Webb NR; Rose TM; Malik N; Marquardt H; Shoyab M; Todaro GJ; Lee DC

DNA (UNITED STATES) Feb 1987, 6 (1) p71-9, ISSN 0198-0238

Journal Code: EAW

Languages: ENGLISH

Document type: JOURNAL ARTICLE

cDNAs containing the entire coding sequence of endozepine, a putative **ligand** of the benzodiazepine receptor, were isolated from bovine and human cDNA libraries. These libraries were constructed using a novel **oligonucleotide** adapter molecule that allowed us to combine the use of G/C tailing with the preservation of the unique Eco RI site in the vector, lambda gt10. The amino acid sequences derived from these cDNA clones are identical to those previously determined for the purified proteins and are homologous to a related rat protein termed **diazepam**-binding inhibitor. The endozepine proteins are highly conserved, as illustrated by the finding that the nucleotide sequences of the coding regions are 93% conserved between the bovine and human forms. Analysis of these sequences indicates that endozepine is not, as expected, derived from a precursor molecule containing a transient signal peptide. Moreover, Northern analyses using the cloned cDNAs as hybridization probes indicate that the 650-nucleotide endozepine mRNA is expressed in a number of peripheral tissues in addition to brain. These observations may be consistent with a recent report describing the presence in peripheral tissues of benzodiazepine receptors on the outer mitochondrial membrane (Anholt et al., 1986). In addition to the endozepine cDNAs, we also isolated a bovine cDNA clone which encodes a larger protein, a portion of which is homologous to endozepine. This related protein may be synthesized in a precursor form containing putative signal peptide and membrane-spanning domains.

? ds

Set	Items	Description
S1	71	OLIGONUCLEOTIDE AND LIGAND AND (COUMARINS OR ISOCOUMARINS - OR ANILINOCOUMARIN OR KETOPROFEN OR CARPROFEN OR ETODOLAC)
S2	71	OLIGONUCLEOTIDE AND LIGAND AND (COUMARINS OR ISOCOUMARINS - OR ANILINOCOUMARIN OR KETOPROFEN OR CARPROFEN OR ETODOLAC OR - SUPROFEN OR INDOPROFEN OR FENBUFEN)
S3	71	RD (unique items)
S4	217	OLIGONUCLEOTIDE AND LIGAND AND (ARYLPROPRIONIC OR ARYLALKO- NIC OR FLUOROPROPIONIC OR GLIBENCLAMID OR ACETOHEXAMIDE OR A- RYLALKANOIC OR TOBUTAMIDE OR GLICLAZIDE OR METFORMIN OR CURCU-

MIN OR DIGITOXIN OR DIGOXIN OR DIAZEPAM)  
S5 216 RD (unfiled items)  
S6 199 S4 NOT S3  
? t s6/6/1-100

6/6/1 (Item 1 from file: 155)  
09908384 99156208

Ontogeny of **diazepam** binding inhibitor/acyl-CoA binding protein  
mRNA and peripheral benzodiazepine receptor mRNA expression in the rat.  
Feb 1999

6/6/2 (Item 2 from file: 155)  
06171995 87161236

Bovine and human cDNA sequences encoding a putative benzodiazepine  
receptor **ligand**.  
Feb 1987

6/6/3 (Item 1 from file: 5)  
05666376 BIOSIS NO.: 000084014781

BOVINE AND HUMAN COMPLEMENTARY DNA SEQUENCES ENCODING A PUTATIVE  
BENZODIAZEPINE RECEPTOR **LIGAND**  
1987

6/6/4 (Item 1 from file: 654)  
03065112  
RECOMBINANT BINDING PROTEINS AND PEPTIDES  
FULL TEXT: 2433 lines

6/6/5 (Item 2 from file: 654)  
03065089  
TARGET SPECIFIC SCREENS AND THEIR USE FOR DISCOVERING SMALL ORGANIC  
MOLECULAR PHARMACOPHORES  
FULL TEXT: 4776 lines

6/6/6 (Item 3 from file: 654)  
03065085  
DETECTION OF CERVICAL CHLAMYDIA TRACHOMATIS INFECTION  
FULL TEXT: 1465 lines

6/6/7 (Item 4 from file: 654)  
03061827  
MULTIPARAMETRIC FLUORESCENCE IN SITU HYBRIDIZATION  
FULL TEXT: 3282 lines

6/6/8 (Item 5 from file: 654)  
03054917  
INTEGRIN-LINKED KINASE AND ITS USE  
FULL TEXT: 2947 lines

6/6/9 (Item 6 from file: 654)  
03054875  
SUPPORTS AND COMBINATORIAL CHEMICAL LIBRARIES THEREOF ENCODED BY  
NON-SEQUENCABLE TAGS  
FULL TEXT: 2832 lines

6/6/10 (Item 7 from file: 654)  
03047342  
LABELLING AND SELECTION OF MOLECULES  
FULL TEXT: 3299 lines

6/6/11 (Item 8 from file: 654)  
03046900  
METHODS OF ASSAYING DIFFERENTIAL EXPRESSION  
FULL TEXT: 21651 lines

6/6/12 (Item 9 from file: 654)  
03046889  
METHODS FOR PREPARING SOLID SUPPORTS FOR HYBRIDIZATION AND REDUCING  
NON-SPECIFIC BACKGROUND  
FULL TEXT: 1189 lines

6/6/13 (Item 10 from file: 654)  
03042816  
LINKER AND LINKED FUSION POLYPEPTIDES  
FULL TEXT: 2365 lines

6/6/14 (Item 11 from file: 654)  
03042374  
HAPTEN ASSAY BY A COMPETITION-BASED METHOD  
FULL TEXT: 667 lines

6/6/15 (Item 12 from file: 654)  
03042356  
DETECTION OF AMPLIFIED NUCLEIC ACID SEQUENCES USING BIFUNCTIONAL  
HAPTENIZATION AND DYED MICROPARTICLES  
FULL TEXT: 962 lines

6/6/16 (Item 13 from file: 654)  
03037706  
PLATINUM-CONTAINING COMPOUNDS, METHODS FOR THEIR PREPARATION AND  
APPLICATIONS THEREOF  
FULL TEXT: 1421 lines

6/6/17 (Item 14 from file: 654)  
03033027  
MULTIPLEXED ANALYSIS OF CLINICAL SPECIMENS APPARATUS AND METHODS  
FULL TEXT: 1586 lines

6/6/18 (Item 15 from file: 654)  
03028910  
HIGH AFFINITY HUMAN ANTIBODIES TO TUMOR ANTIGENS  
FULL TEXT: 6509 lines

6/6/19 (Item 16 from file: 654)  
03028907  
SPECIFIC BINDING MEMBERS FOR ESTRADIOL; MATERIALS AND METHODS  
FULL TEXT: 1495 lines

6/6/20 (Item 17 from file: 654)  
03024009

GLUCOSE TRANSPORTER VESICLE AMINOPEPTIDASE  
FULL TEXT: 2531 lines

6/6/21 (Item 18 from file: 654)  
03023960  
HOMOGENEOUS IMMUNOASSAYS USING ENZYME INHIBITORS  
FULL TEXT: 1411 lines

6/6/22 (Item 19 from file: 654)  
03019820  
GLUCOSE TRANSPORTER VESICLE AMINOPEPTIDASE  
FULL TEXT: 1293 lines

6/6/23 (Item 20 from file: 654)  
03019804  
ANTISENSE **OLIGONUCLEOTIDE** MODULATION OF HUMAN HER-2 EXPRESSION  
FULL TEXT: 1637 lines

6/6/24 (Item 21 from file: 654)  
03019792  
METHODS FOR RECORDING THE REACTION HISTORY OF A SOLID SUPPORT  
FULL TEXT: 2851 lines

6/6/25 (Item 22 from file: 654)  
03019570  
ERBB3 ANTIBODIES  
FULL TEXT: 2068 lines

6/6/26 (Item 23 from file: 654)  
03016147  
METHOD OF INTRACELLULAR BINDING OF TARGET MOLECULES  
FULL TEXT: 3162 lines

6/6/27 (Item 24 from file: 654)  
03012819  
SCREENING METHODS FOR CYTOKINE INHIBITORS  
FULL TEXT: 4604 lines

6/6/28 (Item 25 from file: 654)  
03012561  
METHODS AND APPARATUS FOR IMPROVED LUMINESCENCE ASSAYS  
FULL TEXT: 2484 lines

6/6/29 (Item 26 from file: 654)  
03005083  
CHROMOSOME 18 MARKER  
FULL TEXT: 2846 lines

6/6/30 (Item 27 from file: 654)  
03005079  
SELF-CONTAINED DEVICE INTEGRATING NUCLEIC ACID EXTRACTION AMPLIFICATION AND  
DETECTION  
FULL TEXT: 954 lines

6/6/31 (Item 28 from file: 654)  
02997765  
NUCLEIC ACIDS ENCODING ANTIGEN-BINDING SITES SPECIFIC FOR CANCER ANTIGENS  
FULL TEXT: 2338 lines

6/6/32 (Item 29 from file: 654)  
02987711  
G-COUPLED RECEPTORS ASSOCIATED WITH MACROPHAGE-TROPHIC HIV, AND DIAGNOSTIC  
AND THERAPEUTIC USES THEREOF  
FULL TEXT: 1882 lines

6/6/33 (Item 30 from file: 654)  
02987707  
CHROMOSOME 18 MARKER  
FULL TEXT: 2690 lines

6/6/34 (Item 31 from file: 654)  
02983937  
METHODS FOR IMPROVED PARTICLE ELECTROCHEMILUMINESCENCE ASSAY  
FULL TEXT: 2165 lines

6/6/35 (Item 32 from file: 654)  
02980207  
THERAPEUTIC AND DIAGNOSTIC IMAGING COMPOSITIONS AND METHODS  
FULL TEXT: 927 lines

6/6/36 (Item 33 from file: 654)  
02976840  
POLYSACCHARIDE CONJUGATES OF BIOMOLECULES  
[ Compound formed by modifying polysaccharide such as dextran and reacting  
with polypeptide such as avidin, protein A, protein G]  
FULL TEXT: 1400 lines

6/6/37 (Item 34 from file: 654)  
02976662  
CDNA COLLECTIONS ENCODING PROTEINS REGULATED DURING PROGRAMMED CELL DEATH,  
AND METHOD OF USE THEREOF  
FULL TEXT: 2529 lines

6/6/38 (Item 35 from file: 654)  
02973363  
CHEMICAL REACTION APPARATUS FOR PERFORMING MULTIPLE REACTION ON A SURFACE  
AND COLLECTING THE PRODUCT  
FULL TEXT: 1599 lines

6/6/39 (Item 36 from file: 654)  
02970062  
RAPID SCREENING ASSAY METHODS AND DEVICES  
FULL TEXT: 992 lines

6/6/40 (Item 37 from file: 654)  
02966938  
HOMOGENEOUS IMMUNOASSAYS USING ENZYME INHIBITORS  
FULL TEXT: 1369 lines

6/6/41 (Item 38 from file: 654)  
02961223  
METHODS AND COMPOSITIONS FOR THE DIAGNOSIS AND TREATMENT OF  
NEUROPSYCHIATRIC DISORDERS  
FULL TEXT: 2666 lines

6/6/42 (Item 39 from file: 654)  
02961066  
KINASE RECEPTOR ACTIVATION ASSAY  
FULL TEXT: 3452 lines

6/6/43 (Item 40 from file: 654)  
02961060  
HOMOGENEOUS AMPLIFICATION AND DETECTION OF NUCLEIC ACIDS  
[Amplifying target nucleotide sequence, hybridizing **oligonucleotide**  
probes to amplified single strands forming termolecular complex, detecting  
complex; at least one probe has two sequences which are non-contiguous]  
FULL TEXT: 2931 lines

6/6/44 (Item 41 from file: 654)  
02935200  
MULTIVALENT SINGLE CHAIN ANTIBODIES  
FULL TEXT: 1207 lines

6/6/45 (Item 42 from file: 654)  
02935199  
PRODUCTION OF A SINGLE-GENE-ENCODED IMMUNOGLOBULIN  
FULL TEXT: 923 lines

6/6/46 (Item 43 from file: 654)  
02934856  
MAMMALIAN TUMOR SUSCEPTIBILITY GENES AND THEIR USES  
FULL TEXT: 1668 lines

6/6/47 (Item 44 from file: 654)  
02934838  
KINASE RECEPTOR ACTIVATION ASSAY  
FULL TEXT: 3461 lines

6/6/48 (Item 45 from file: 654)  
02931634  
METHOD OF PRODUCING SINGLE-CHAIN FV MOLECULES  
FULL TEXT: 1400 lines

6/6/49 (Item 46 from file: 654)  
02931625  
PEPTIDES SPECIFIC FOR THE FIRST CRK-SH3 DOMAIN  
FULL TEXT: 3865 lines

6/6/50 (Item 47 from file: 654)  
02931591  
HAPTEN DERIVATIZED CAPTURE MEMBRANE AND DIAGNOSTIC ASSAYS USING SUCH  
MEMBRANE  
FULL TEXT: 861 lines



6/6/51 (Item 48 from file: 654)  
02928391  
NUCLEAR LOCALIZATION FACTOR ASSOCIATED WITH CIRCADIAN RHYTHMS  
FULL TEXT: 4191 lines

6/6/52 (Item 49 from file: 654)  
02922406  
POLYOXYHYDROCARBYL RELATED PRODUCTS AND METHODS FOR FLUORESCENCE ASSAYS  
FULL TEXT: 1021 lines

6/6/53 (Item 50 from file: 654)  
02922389  
AMINOXY-CONTAINING LINKER COMPOUNDS FOR FORMATION OF STABLY-LINKED  
CONJUGATES AND METHODS RELATED THERETO  
FULL TEXT: 1208 lines

6/6/54 (Item 51 from file: 654)  
02919188  
MULTIVALENT SINGLE CHAIN ANTIBODIES  
FULL TEXT: 1922 lines

6/6/55 (Item 52 from file: 654)  
02913347  
METHODS FOR SCREENING FOR ANTIMYCOTICS  
FULL TEXT: 3277 lines

6/6/56 (Item 53 from file: 654)  
02910720  
MODIFIED ANTIBODY VARIABLE DOMAINS  
[ Humanized protein having altered moderate risk sites in the heavy and  
light chain variable regions, having reduced immunogenicity, capable of  
binding CD5 antigen; for treatment of arthritis, lupus, psoriasis, diabetes  
and autoimmune]  
FULL TEXT: 4008 lines

6/6/57 (Item 54 from file: 654)  
02907141  
ANTIBODY SELECTION METHODS USING CELL SURFACE EXPRESSED LIBRARIES  
[Competitive immunoassays for analyte detection.]  
FULL TEXT: 2030 lines

6/6/58 (Item 55 from file: 654)  
02898471  
BIO-OLIGOMER LIBRARIES AND A METHOD OF USE THEREOF  
[Screening randomly synthesized oligopeptide- or **oligonucleotide**  
-solid phase libraries with acceptor molecules (e.g. antibodies), isolating  
solid phase support/oligomer bound to molecule, sequencing oligomer]  
FULL TEXT: 2660 lines

6/6/59 (Item 56 from file: 654)  
02893186  
TRANSMEMBRANE TYROSINE PHOSPHATASE AND METHODS OF USE THEREOF  
FULL TEXT: 2835 lines

6/6/60 (Item 57 from file: 654)  
02893168

PROCESS FOR IMPROVING STABILITY OF ANTIBODIES  
FULL TEXT: 2925 lines

6/6/61 (Item 58 from file: 654)  
02890631  
METHOD OF INTRACELLULAR BINDING OF TARGET MOLECULES  
FULL TEXT: 3589 lines

6/6/62 (Item 59 from file: 654)  
02890582  
ANALYTE ASSAY USING A TRIFUNCTIONAL CONJUGATE  
FULL TEXT: 2345 lines

6/6/63 (Item 60 from file: 654)  
02890343  
THERAPEUTIC DELIVERY USING COMPOUNDS SELF-ASSEMBLED INTO HIGH AXIAL RATIO  
MICROSTRUCTURES  
FULL TEXT: 1604 lines

6/6/64 (Item 61 from file: 654)  
02888346  
ANTIGEN-BINDING SITES OF ANTIBODY MOLECULES SPECIFIC FOR CANCER ANTIGENS  
FULL TEXT: 2206 lines

6/6/65 (Item 62 from file: 654)  
02888076  
METHOD FOR MAKING A PRECONJUGATE  
FULL TEXT: 1158 lines

6/6/66 (Item 63 from file: 654)  
02887968  
PROCESS AND DEVICE FOR ASSAYING A HAPTEN  
FULL TEXT: 966 lines

6/6/67 (Item 64 from file: 654)  
02884969  
OLIGONUCLEOTIDES SPECIFIC FOR THE MOMP GENE SEQUENCE AND METHODS FOR THE  
DETECTION OF CHLAMYDIA TRACHOMATIS  
FULL TEXT: 1476 lines

6/6/68 (Item 65 from file: 654)  
02884931  
POLYPHOSHOINOSITIDE BINDING PEPTIDES FOR INTRACELLULAR DRUG DELIVERY  
FULL TEXT: 2083 lines

6/6/69 (Item 66 from file: 654)  
02881962  
TARGET BINDING POLYPEPTIDE  
FULL TEXT: 1710 lines

6/6/70 (Item 67 from file: 654)  
02881522  
GENETICALLY ENGINEERED ENZYMES AND THEIR CONJUGATES FOR DIAGNOSTIC ASSAYS  
FULL TEXT: 3011 lines

6/6/71 (Item 68 from file: 654)

02878078

TOPOLOGICALLY SEGREGATED, ENCODED SOLID PHASE LIBRARIES

[Synthetic test compounds attached to separate phase synthesis supports that also contain coding molecules that encode the structure of the synthetic test compound]

FULL TEXT: 4685 lines

6/6/72 (Item 69 from file: 654)

02875081

PYK2 RELATED POLYPEPTIDE PRODUCTS

[Amino acid sequences with phosphorylation activity]

FULL TEXT: 4208 lines

6/6/73 (Item 70 from file: 654)

02874811

PATCHED GENES AND THEIR USE

[Binds to hedgehog polypeptide; hybridization; genetic engineering and expression]

FULL TEXT: 2183 lines

6/6/74 (Item 71 from file: 654)

02874798

PYK2 RELATED POLYNUCLEOTIDE PRODUCTS

[Diagnosis and treatment of Alzheimer\*s and Parkinson\*s diseases, migraine, schizophrenia, and epilepsy; genetic engineering]

FULL TEXT: 3410 lines

6/6/75 (Item 72 from file: 654)

02874765

POLYNUCLEOTIDES ENCODING GELONIN SEQUENCES

[Treatment of autoimmune diseases, cancer, graft-versus-host disease]

FULL TEXT: 7510 lines

6/6/76 (Item 73 from file: 654)

02874729

PROCESS FOR THE MANUFACTURE OF WHOLLY MICROFABRICATED BIOSENSORS

FULL TEXT: 4105 lines

6/6/77 (Item 74 from file: 654)

02874721

PROCESS FOR THE MANUFACTURE OF WHOLLY MICROFABRICATED BIOSENSORS

[Permeable layers superimposed on detectors and bilayers superimposed on permeable layers]

FULL TEXT: 4428 lines

6/6/78 (Item 75 from file: 654)

02874523

MULTIVALENT AND MULTISPECIFIC BINDING PROTEINS, THEIR MANUFACTURE AND USE

[Polypeptides]

FULL TEXT: 5798 lines

6/6/79 (Item 76 from file: 654)

02874476

APPARATUS FOR MEASURING CHEMILUMINESCENCE OF MULTIPLE SAMPLES ON A CONTINUOUS MATRIX

[Test sample deposited on matrix; detection of light]  
FULL TEXT: 504 lines

6/6/80 (Item 77 from file: 654)  
02871538  
CHIMERIC VIRAL RECEPTOR POLYPEPTIDES  
[For target cell specific delivery of drugs or diagnostic agents]  
FULL TEXT: 3973 lines

6/6/81 (Item 78 from file: 654)  
02867026  
ELECTRODES AND METALLO ISOINDOLE RINGED COMPOUNDS  
[Redox system catalyzed by enzyme]  
FULL TEXT: 1523 lines

6/6/82 (Item 79 from file: 654)  
02857192  
CDNA COLLECTIONS ENCODING PROTEINS REGULATED DURING PROGRAMMED CELL DEATH,  
METHODS OF PREPARATION THEREOF AND METHODS OF USE THEREOF  
FULL TEXT: 2254 lines

6/6/83 (Item 80 from file: 654)  
02857177  
IMMUNOGLOBULIN VARIANTS  
[ Humanized antibody polypeptides which are less antigenic in humans than  
non-human antibodies but have desired antigen binding properties]  
FULL TEXT: 5323 lines

6/6/84 (Item 81 from file: 654)  
02856969  
MODIFIED ANTIBODY VARIABLE DOMAINS  
FULL TEXT: 3259 lines

6/6/85 (Item 82 from file: 654)  
02856699  
METHOD FOR TARGETING A DIAGNOSTIC AGENT TO CELLS  
[Administering a diagnostic agent complexed with a targeting **ligand**  
of folates or receptor-binding derivatives; for transporting exogenous  
molecules into cells with folate receptors; drug delivery]  
FULL TEXT: 901 lines

6/6/86 (Item 83 from file: 654)  
02846454  
ISOLATED NUCLEIC ACID MOLECULES ENCODING ANTIGEN BINDING SITES OF ANTIBODY  
MOLECULES SPECIFIC FOR CANCER ANTIGENS  
[For drug or toxin targeting, imaging, therapy]  
FULL TEXT: 2212 lines

6/6/87 (Item 84 from file: 654)  
02846424  
ELECTROCHEMILUMINESCENT RHENIUM MOIETIES AND METHODS FOR THEIR USE  
[Quantitative, qualitative analysis]  
FULL TEXT: 3352 lines

6/6/88 (Item 85 from file: 654)  
02842937

MAMMALIAN TUMOR SUSCEPTIBILITY GENES AND THEIR USES  
[Diagnosis and treatment of cancer]  
FULL TEXT: 1695 lines

6/6/89 (Item 86 from file: 654)  
02842630  
METHOD OF SCREENING FOR GENETIC PREDISPOSITION TO ANTICHOLINESTERASE  
THERAPY  
FULL TEXT: 2596 lines

6/6/90 (Item 87 from file: 654)  
02838896  
MODIFIED ANTIBODIES WITH HUMAN MILK FAT GLOBULE SPECIFICITY  
FULL TEXT: 6772 lines

6/6/91 (Item 88 from file: 654)  
02829355  
ELECTRODES AND METALLO ISOINDOLE RINGED COMPOUNDS  
[Hydrogen peroxide production]  
FULL TEXT: 1440 lines

6/6/92 (Item 89 from file: 654)  
02826492  
POLYNUCLEOTIDES ENCODING MODIFIED ANTIBODIES WITH HUMAN MILK FAT GLOBULE  
SPECIFICITY  
FULL TEXT: 6674 lines

6/6/93 (Item 90 from file: 654)  
02826257  
METHOD FOR CONDUCTING MULTIPARAMETRIC FLUORESCENCE IN SITU HYBRIDIZATION  
[Using set of combinatorially labeled oligonucleotide probes]  
FULL TEXT: 1777 lines

6/6/94 (Item 91 from file: 654)  
02826254  
METHOD AND KITS FOR AMPLIFYING TARGET NUCLEIC ACIDS APPLICABLE TO BOTH  
POLYMERASE AND LIGASE CHAIN REACTIONS  
[ Specific hybridization of probe/primer end so that the probability of the  
probe/primer contributing to spurious signal development is greatly reduced  
]  
FULL TEXT: 1706 lines

6/6/95 (Item 92 from file: 654)  
02826108  
MODIFIED GLYCOPROTEIN HORMONES HAVING A CTP AT THE AMINO TERMINUS  
[ Hormone subunit having an inserted carboxy terminal peptide (CTP) for  
improved clearance properties; muteins, side effect reduction]  
FULL TEXT: 1025 lines

6/6/96 (Item 93 from file: 654)  
02822673  
METHODS OF DETERMINING THE STRUCTURE OF A COMPOUND ENCODED BY IDENTIFIERS  
HAVING TAGS  
FULL TEXT: 2818 lines

6/6/97 (Item 94 from file: 654)

02816901  
POLYPHOSPHOINSITIDE BINDING PEPTIDES FOR INTRACELLULAR DRUG DELIVERY  
FULL TEXT: 1845 lines

6/6/98 (Item 95 from file: 654)  
02813442  
INTRON-MEDIATED RECOMBINANT TECHNIQUES AND REAGENTS  
FULL TEXT: 3156 lines

6/6/99 (Item 96 from file: 654)  
02813161  
APPARATUS FOR IMPROVED LUMINESCENCE ASSAYS  
[Measuring electrochemiluminescence; detection and quantitative analysis of  
biological and biochemical substances]  
FULL TEXT: 2039 lines

6/6/100 (Item 97 from file: 654)  
02809832  
MARKING OF PRODUCTS TO ESTABLISH IDENTITY AND SOURCE  
[Using low molecular weight hapten bound to a polymer]  
FULL TEXT: 1760 lines  
? ds

Set	Items	Description
S1	71	OLIGONUCLEOTIDE AND LIGAND AND (COUMARINS OR ISOCOUMARINS - OR ANILINOCOUMARIN OR KETOPROFEN OR CARPROFEN OR ETODOLAC)
S2	71	OLIGONUCLEOTIDE AND LIGAND AND (COUMARINS OR ISOCOUMARINS - OR ANILINOCOUMARIN OR KETOPROFEN OR CARPROFEN OR ETODOLAC OR - SUPROFEN OR INDOPROFEN OR FENBUFEN)
S3	71	RD (unique items)
S4	217	OLIGONUCLEOTIDE AND LIGAND AND (ARYLPROPRIONIC OR ARYLALKO- NIC OR FLUOROPROPRIONIC OR GLIBENCLAMID OR ACETOHEXAMIDE OR A- RYLALKANOIC OR TOBUTAMIDE OR GLICLAZIDE OR METFORMIN OR CURCU- MIN OR DIGITOXIN OR DIGOXIN OR DIAZEPAM)
S5	216	RD (unique items)
S6	199	S4 NOT S3

? t s6/6/100-199

6/6/100 (Item 97 from file: 654)  
02809832  
MARKING OF PRODUCTS TO ESTABLISH IDENTITY AND SOURCE  
[Using low molecular weight hapten bound to a polymer]  
FULL TEXT: 1760 lines

6/6/101 (Item 98 from file: 654)  
02803504  
PREVENTION AND TREATMENT OF CARDIOVASCULAR PATHOLOGIES  
[ Administering tamoxifen derivatives to inhibit smooth muscle cell  
proliferation associated with vascular trauma from surgery or  
transplantation of organs or medical devices]  
FULL TEXT: 4052 lines

6/6/102 (Item 99 from file: 654)  
02803462  
SENSORY AND MOTOR NEURON DERIVED FACTOR (SMDF)  
FULL TEXT: 3622 lines

6/6/103 (Item 100 from file: 654)  
02803110  
MODIFIED ANTIBODY VARIABLE DOMAINS AND THERAPEUTIC USES THEREOF  
FULL TEXT: 3997 lines

6/6/104 (Item 101 from file: 654)  
02800027  
AFAMIN: A HUMAN SERUM ALBUMIN-LIKE PROTEIN  
[ A complex of human afamin and apolipoprotein A1; a monoclonal antibody  
specific for human afamin]  
FULL TEXT: 2112 lines

6/6/105 (Item 102 from file: 654)  
02799700  
CYTOPLASMIC BACTERIOPHAGE DISPLAY SYSTEM  
[ VECTOR COMPRISING DNA ENCODING A PROTEIN FROM A BACERIOPHAGE JOINED TO A  
PROTEIN OR PEPTIDE]  
FULL TEXT: 1829 lines

6/6/106 (Item 103 from file: 654)  
02799681  
MODIFIED ANTIBODY VARIABLE DOMAINS  
[ Changing amino acid residues without diminishing the native affinity of  
the domain for antigen]  
FULL TEXT: 3277 lines

6/6/107 (Item 104 from file: 654)  
02799658  
KINASE RECEPTOR ACTIVATION ASSAY  
[Measuring autophosphorylation of tyrosine kinase receptor]  
FULL TEXT: 3482 lines

6/6/108 (Item 105 from file: 654)  
02795873  
SENSORY AND MOTOR NEURON DERIVED FACTOR (SMDF)  
FULL TEXT: 3668 lines

6/6/109 (Item 106 from file: 654)  
02792301  
MUTANT HUMAN HEDGEHOG GENE  
FULL TEXT: 1344 lines

6/6/110 (Item 107 from file: 654)  
02792271  
MULTIPARAMETRIC FLUORESCENCE IN SITU HYBRIDIZATION  
[Labeled **oligonucleotide** probes; diagnosing chromosome defects]  
FULL TEXT: 1855 lines

6/6/111 (Item 108 from file: 654)  
02788989  
IMMUNOTOXINS COMPRISING RIBOSOME-INACTIVATING PROTEINS  
[Have a cysteine available for disulfide bonding to targeting molecules]  
FULL TEXT: 7272 lines

6/6/112 (Item 109 from file: 654)  
02788750

6/6/113 (Item 110 from file: 654)  
02788593  
OLIGONUCLEOTIDES AND METHODS FOR THE DETECTION OF CHLAMYDIA TRACHOMATIS  
[Using ligase chain reaction]  
FULL TEXT: 1445 lines

6/6/114 (Item 111 from file: 654)  
02788591  
NUCLEOTIDE-DIRECTED ASSEMBLY OF BIMOLECULAR AND MULTIMOLECULAR DRUGS AND  
DEVICES  
[Synthesizing single-stranded nucleic acid molecule having first and second  
defined sequence segments, each of which binds different non-  
**oligonucleotide** molecule]  
FULL TEXT: 1542 lines

6/6/115 (Item 112 from file: 654)  
02782296  
METHODS OF DETECTING NUCLEIC ACIDS WITH NUCLEOTIDE PROBES CONTAINING  
4'-SUBSTITUTED NUCLEOTIDES AND KITS THEREFOR  
FULL TEXT: 1353 lines

6/6/116 (Item 113 from file: 654)  
02776184  
IMMUNOTOXINS COMPRISING RIBOSOME-INACTIVATING PROTEINS  
[Fusion protein]  
FULL TEXT: 7109 lines

6/6/117 (Item 114 from file: 654)  
02770562  
NUCLEOTIDE-DIRECTED ASSEMBLY OF BIMOLECULAR AND MULTIMOLECULAR DRUGS AND  
DEVICES  
[ For controlled placement of two or more selected molecules in appropriate  
spatial proximity to produce cooperative molecular assemblies]  
FULL TEXT: 1481 lines

6/6/118 (Item 115 from file: 654)  
02767415  
NUCLEOTIDE SEQUENCES AND PROCESS FOR AMPLIFYING AND DETECTION OF HEPATITIS  
B VIRAL DNA  
[Amplification by Dna hybridization]  
FULL TEXT: 1993 lines

6/6/119 (Item 116 from file: 654)  
02764924  
HUMAN DBI/ACBP-LIKE PROTEIN  
[Purified polynucleotide sequence which codes for a **diazepam** binding  
inhibitor protein(or polypeptide) or an acyl-coenzyme A binding protein(or  
polypeptide)]  
FULL TEXT: 1751 lines

6/6/120 (Item 117 from file: 654)  
02764643  
PROTEIN PRODUCTION AND DELIVERY  
[Patent not granted per O.G. errata of 4-28-98]



FULL TEXT:

1887 lines

6/6/121 (Item 118 from file: 654)  
02753212  
METHOD OF PURIFYING CARDIAC HYPERTROPHY FACTOR  
FULL TEXT: 4168 lines

6/6/122 (Item 119 from file: 654)  
02750444  
COMPLEX COMBINATORIAL CHEMICAL LIBRARIES ENCODED WITH TAGS  
FULL TEXT: 3036 lines

6/6/123 (Item 120 from file: 654)  
02745503  
METHOD OF CALIBRATION OF AN ELECTROCHEMILUMINESCENT ASSAY SYSTEM  
[Forming a solution containing an analyte comprising first chemiluminescent complex and an internal standard containing osmium bipyridyl complex, independently measuring electroluminescence emitted by analyte and standard]  
FULL TEXT: 2814 lines

6/6/124 (Item 121 from file: 654)  
02742798  
CY7-ALLOPHYCOCYANIN CONJUGATES FOR USE IN MULTIPLEX FLUORESCENCE DETECTION ASSAYS  
[Immunoassay; multiplex assays; kits; easily detectable emission spectra]  
FULL TEXT: 498 lines

6/6/125 (Item 122 from file: 654)  
02742744  
PLATINUM-CONTAINING COMPOUNDS, METHODS FOR THEIR PREPARATION AND APPLICATIONS THEREOF  
[Platinum containing detectable probe compound having marker moiety, stabilizing substituents, biomolecule]  
FULL TEXT: 1398 lines

6/6/126 (Item 123 from file: 654)  
02737784  
PHOTOACTIVATABLE CHEMILUMINESCENT MATRICES  
[Photosensitizer, singlet oxygen generation]  
FULL TEXT: 3083 lines

6/6/127 (Item 124 from file: 654)  
02735078  
PYRIDINE COMPLEXING AGENTS AND TARGETING IMMUNOREAGENTS USEFUL IN THERAPEUTIC AND DIAGNOSTIC COMPOSITIONS  
[Useful in therapeutic and diagnostic imaging]  
FULL TEXT: 2124 lines

6/6/128 (Item 125 from file: 654)  
02732555  
METHOD AND APPARATUS FOR MAGNETIC MICROPARTICULATE BASED LUMINESCENCE ASSAY INCLUDING PLURALITY OF MAGNETS  
[Complexing]  
FULL TEXT: 1500 lines

6/6/129 (Item 126 from file: 654)  
02732495  
REDUCTION OF BACKGROUND IN NONCOMPETITIVE BINDING ASSAYS  
FULL TEXT: 821 lines

6/6/130 (Item 127 from file: 654)  
02729873  
PROTECTION AGAINST LIVER DAMAGE BY HGF  
[Hepatocyte growth factor]  
FULL TEXT: 1879 lines

6/6/131 (Item 128 from file: 654)  
02722085  
MACROCYCLIC COMPLEXES OF YTTRIUM, THE LANTHANIDES AND THE ACTINIDES HAVING  
PERIPHERAL COUPLING FUNCTIONALITIES  
FULL TEXT: 2173 lines

6/6/132 (Item 129 from file: 654)  
02719012  
TRANSMEMBRANE TYROSINE PHOSPHATASE, NUCLEIC ACIDS ENCODING THE SAME, AND  
METHODS OF USE THEREOF  
FULL TEXT: 2936 lines

6/6/133 (Item 130 from file: 654)  
02713469  
COMPOSITION AND METHOD FOR TUMOR IMAGING  
[Enhancing cellular uptake of a diagnostic agent using a **ligand**  
complex]  
FULL TEXT: 1754 lines

6/6/134 (Item 131 from file: 654)  
02710992  
AMPLIFICATION OF RNA SEQUENCES USING THE LIGASE CHAIN REACTION  
FULL TEXT: 1931 lines

6/6/135 (Item 132 from file: 654)  
02703432  
GENE ENCODING CARDIAC HYPERTROPHY FACTOR  
[Therapy for heart failure, arrhythmic, inotropic and neurological  
disorders]  
FULL TEXT: 4187 lines

6/6/136 (Item 133 from file: 654)  
02690503  
METHODS FOR PRODUCING ANTIBODY LIBRARIES USING UNIVERSAL OR RANDOMIZED  
IMMUNOGLOBULIN LIGHT CHAINS  
[Gene expression and genes with antibodies and antigens]  
FULL TEXT: 3222 lines

6/6/137 (Item 134 from file: 654)  
02690301  
ANTIBODIES TO SMDF  
[Sensory and motor neuron derived factor and binding]  
FULL TEXT: 3585 lines

6/6/138 (Item 135 from file: 654)

02682692  
TRIFUNCTIONAL CONJUGATE  
[Useful in immunoassays and for targeted labeling of proteins]  
FULL TEXT: 2275 lines

6/6/139 (Item 136 from file: 654)  
02680183  
DNA ENCODING RAT TAURINE TRANSPORTER AND USES THEREOF  
[Isolated nucleic acid]  
FULL TEXT: 4604 lines

6/6/140 (Item 137 from file: 654)  
02680160  
DNA MOLECULES, EXPRESSION VECTORS AND HOST CELLS EXPRESSING ANTIGENIZED  
ANTIBODIES  
[DNA-expressed immunoglobulins containing heterologous antigenic epitope;  
vaccines]  
FULL TEXT: 689 lines

6/6/141 (Item 138 from file: 654)  
02677860  
NUCLEOTIDE-DIRECTED ASSEMBLY OF BIMOLECULAR AND MULTIMOLECULAR DRUGS AND  
DEVICES  
[Macromolecular complexes]  
FULL TEXT: 1575 lines

6/6/142 (Item 139 from file: 654)  
02675258  
PROTECTION AGAINST LIVER DAMAGE BY HGF  
[Molecule comprising first domain comprising hepatocyte growth factor,  
second domain comprising activin antagonist or transforming growth  
factor-beta antagonist]  
FULL TEXT: 2120 lines

6/6/143 (Item 140 from file: 654)  
02672923  
AFAMIN: A HUMAN SERUM ALBUMIN-LIKE GENE  
[Polynucleotide; genetic engineering]  
FULL TEXT: 2123 lines

6/6/144 (Item 141 from file: 654)  
02670776  
RANDOM BIO-OLIGOMER LIBRARY, A METHOD OF SYNTHESIS THEREOF, AND A METHOD OF  
USE THEREOF  
[Solid phase synthesis of peptides, random sequences, combinatorial  
chemistry]  
FULL TEXT: 2659 lines

6/6/145 (Item 142 from file: 654)  
02668261  
EXPRESSION OF FUNCTIONAL ANTIBODY FRAGMENTS  
FULL TEXT: 1589 lines

6/6/146 (Item 143 from file: 654)  
02663188  
METHODS FOR PROTEIN BINDING ENZYME COMPLEMENTATION ASSAYS  
[Kits for qualitative and quantitative analysis]

6/6/147 (Item 144 from file: 654)  
02660767

## METHODS FOR SCREENING FOR ANTIMYCOTICS

[Measuring expression level of reporter gene when mycotic cells are treated with potential translation(genetic) inhibitors]

FULL TEXT: 3210 lines

6/6/148 (Item 145 from file: 654)  
02653979

## METHOD FOR ENHANCING TRANSMEMBRANE TRANSPORT OF EXOGENOUS MOLECULES

[Contacting a membrane of a living cell with a complex formed between exogenous molecules and thiamin; useful for efficient delivery of peptides, nucleic acids into living cells]

FULL TEXT: 906 lines

6/6/149 (Item 146 from file: 654)  
02645104

## HYBRIDOMAS PRODUCING ANTIBODIES TO CARDIAC HYPERTROPHY FACTOR

FULL TEXT: 4191 lines

6/6/150 (Item 147 from file: 654)  
02645083

## METHODS FOR THE PRODUCTION OF PROTEINS WITH A DESIRED FUNCTION

FULL TEXT: 1588 lines

6/6/151 (Item 148 from file: 654)  
02642755

## ANTIBODIES TO CARDIAC HYPERTROPHY FACTOR AND USES THEREOF

[DNA codes and antagonist, antagonism]

FULL TEXT: 4176 lines

6/6/152 (Item 149 from file: 654)  
02636467

## METHOD OF CALIBRATION WITH PHOTOACTIVATABLE CHEMILUMINESCENT MATRICES

[Combining in a medium a chemiluminescent capable of emitting light upon irradiation and a solid matrix having a photosensitizer which upon activation generates a singlet oxygen, which activates luminescent, comparing decay time]

FULL TEXT: 2867 lines

6/6/153 (Item 150 from file: 654)  
02629559

## SUPER-GLOBULING FOR IN VIVO EXTENDED LIFETIMES

[Drug delivery]

FULL TEXT: 639 lines

6/6/154 (Item 151 from file: 654)  
02624996

## COMPOSITIONS AND METHODS FOR ENHANCED DRUG DELIVERY

[Iontophoresis]

FULL TEXT: 5232 lines

6/6/155 (Item 152 from file: 654)  
02623031

METHOD FOR PREVENTING AMPLIFICATION OF NUCLEIC ACID CONTAMINANTS IN  
AMPLIFICATION MIXTURES USING NUCLEASE-RECEPTOR CONJUGATES  
[Reducing side reaction by complexing with enzyme which degrades copies]  
FULL TEXT: 1871 lines

6/6/156 (Item 153 from file: 654)  
02621256  
METHODS FOR PROTEIN BINDING ENZYME COMPLEMENTATION  
[Enzyme donor polypeptide having specified amino acid sequence; qualitative  
and quantitative analysis]  
FULL TEXT: 2749 lines

6/6/157 (Item 154 from file: 654)  
02619007  
OLIGONUCLEOTIDES AND METHODS FOR THE DETECTION OF CHLAMYDIA TRACHOMATIS  
[ Probes which can hybridize with denatured DNA, then labeling and/or  
amplification, measurement, kits]  
FULL TEXT: 1482 lines

6/6/158 (Item 155 from file: 654)  
02612396  
METHOD FOR IDENTIFYING AN AGENT WHICH INCREASES TGF-BETA LEVELS  
[Transforming growth factor-beta activators]  
FULL TEXT: 3830 lines

6/6/159 (Item 156 from file: 654)  
02608001  
ELECTROCHEMILUMINESCENT RHENIUM MOIETIES AND METHODS FOR THEIR USE  
FULL TEXT: 2746 lines

6/6/160 (Item 157 from file: 654)  
02588750  
DETECTING AND AMPLIFYING TARGET NUCLEIC ACIDS USING EXONUCLEOLYTIC ACTIVITY  
FULL TEXT: 1914 lines

6/6/161 (Item 158 from file: 654)  
02586535  
CARDIAC HYPERTROPHY FACTOR  
FULL TEXT: 4044 lines

6/6/162 (Item 159 from file: 654)  
02586326  
HOMOGENEOUS IMMUNOASSAYS AND ENZYME BASED ASSAYS OF ANALYTES USING  
CAPILLARY ELECTROPHORESIS  
[Fluorescence, enzymes, proteins, digoxigenin, quantitative analysis]  
FULL TEXT: 1604 lines

6/6/163 (Item 160 from file: 654)  
02586321  
DETECTION AND AMPLIFICATION OF CANDIOTROPHIN-1 (CARDIAC HYPERTROPHY FACTOR)  
[ Hybridizing selected nucleic acid to sample nucleic acid, determine  
presence by hybrid molecule]  
FULL TEXT: 4197 lines

6/6/164 (Item 161 from file: 654)  
02579341

PRODUCTION OF CHIMERIC ANTIBODIES - A COMBINATORIAL APPROACH  
[Making antibody polypeptide dimers specific for antigens of interest]  
FULL TEXT: 4556 lines

6/6/165 (Item 162 from file: 654)  
02579333  
COMPLEX COMBINATORIAL CHEMICAL LIBRARIES ENCODED WITH TAGS  
[For identification of non-oligomeric compound, using solid support]  
FULL TEXT: 2865 lines

6/6/166 (Item 163 from file: 654)  
02554863  
THERAPEUTIC DELIVERY SYSTEMS RELATED APPLICATIONS  
[Apparatus for making therapeutic containing gas-filled liposomes]  
FULL TEXT: 3936 lines

6/6/167 (Item 164 from file: 654)  
02545681  
METHOD OF HETEROGENOUS PURIFICATION USING A BIDENTATE CONJUGATE  
[ Liquid phase and solid phase bidentate ligands, separation by elution, immobilization and regeneration]  
FULL TEXT: 1651 lines

6/6/168 (Item 165 from file: 654)  
02545676  
CARDIAC HYPERTROPHY FACTOR AND USES THEREFOR  
[Treatment of heart failure and neurological disorders]  
FULL TEXT: 3820 lines

6/6/169 (Item 166 from file: 654)  
02535663  
SERINE-RICH PEPTIDE LINKERS  
[ Imported solubility in physiological media, and improved resistance to proteolysis]  
FULL TEXT: 1119 lines

6/6/170 (Item 167 from file: 654)  
02528641  
REVERSE ANTIMICROBIAL PEPTIDES  
[Bactericides or fungicides]  
FULL TEXT: 4633 lines

6/6/171 (Item 168 from file: 654)  
02525979  
LIGASE CHAIN REACTION WITH ENDONUCLEASE IV CORRECTION AND CONTAMINATION CONTROL  
[ Hybridization the modified probe to the target sequences, ligation of a probe, correction of modified target with endonuclease then dissociation of product from target]  
FULL TEXT: 2759 lines

6/6/172 (Item 169 from file: 654)  
02505888  
INTRON-MEDIATED RECOMBINANT TECHNIQUES AND REAGENTS  
FULL TEXT: 2712 lines

6/6/173 (Item 170 from file: 654)

02501749

MONOMERIC PHTHALOCYANINE REAGENTS

[Covalently conjugated with physiological analyte; Detectable markers fluorescent dyes or chromogens; ELISA]

FULL TEXT: 1792 lines

6/6/174 (Item 171 from file: 654)

02488529

POLYPEPTIDE LINKERS FOR PRODUCTION OF BIOSYNTHETIC PROTEINS

[DNA in cells for codes of polypeptides and sequences]

FULL TEXT: 1697 lines

6/6/175 (Item 172 from file: 654)

02472680

DEVICES FOR DETECTION OF AN ANALYTE BASED UPON LIGHT INTERFERENCE

FULL TEXT: 4293 lines

6/6/176 (Item 173 from file: 654)

02457559

IMMUNOTHERAPY USING SINGLE CHAIN POLYPEPTIDE BINDING MOLECULES

FULL TEXT: 2306 lines

6/6/177 (Item 174 from file: 654)

02447587

OLIGONUCLEOTIDES CONTAINING 4'-SUBSTITUTED NUCLEOTIDES

[Substituent selected from linking group containing modifiers such as biotin, reactive groups, nucleic acids, catalysts, DNA intercalators, minor groove binders, cleavage agents, and detectable labels]

FULL TEXT: 1307 lines

6/6/178 (Item 175 from file: 654)

02447387

METHOD FOR NON-COMPETITIVE BINDING ASSAYS

[Complexing analyte with labeled binder, then reacting it with insoluble material joined to analyte derivative and solid phase carrying a binder, then separation and measurement of label bound to solid phase]

FULL TEXT: 673 lines

6/6/179 (Item 176 from file: 654)

02438658

BRAIN DERIVED NEUROTROPHIC FACTOR

[Non denatured proteins; treats parkinson's and alzheimer's diseases]

FULL TEXT: 4695 lines

6/6/180 (Item 177 from file: 654)

02438522

HETEROGENEOUS BINDING ASSAYS

[Complexing analyte with first binding partner, incubation, then binding to second partner which has been coupled to glass or ceramic beads, more incubation, then separation from liquid medium]

FULL TEXT: 1183 lines

6/6/181 (Item 178 from file: 654)

02427347

AMPLIFICATION OF TARGET NUCLEIC ACIDS USING GAP FILLING LIGASE CHAIN REACTION

[Diagnostic assays; improved sensitivity]  
FULL TEXT: 344 lines

6/6/182 (Item 179 from file: 654)  
02421027  
BIDENTATE CONJUGATE AND METHOD OF USE THEREOF  
[Two different chemical moieties attached through an adequate spacer moiety  
capable of simultaneously binding to their respective binding partners]  
FULL TEXT: 1197 lines

6/6/183 (Item 180 from file: 654)  
02414099  
METHOD FOR ENHANCING TRANSMEMBRANE TRANSPORT OF EXOGENOUS MOLECULES  
FULL TEXT: 943 lines

6/6/184 (Item 181 from file: 654)  
02398123  
BIOLOGICALLY ACTIVE REAGENT PREPARED FROM ALDEHYDE-CONTAINING POLYMER, TEST  
KIT, ANALYTICAL ELEMENT AND METHODS OF USE  
[Immunology, label detection]  
FULL TEXT: 913 lines

6/6/185 (Item 182 from file: 654)  
02319560  
METHOD FOR DETECTION OF A NUCLEIC ACID USING PARTICULATE REAGENT HAVING  
POLYOXYALKYLENE SIDE CHAINS  
FULL TEXT: 1256 lines

6/6/186 (Item 183 from file: 654)  
02295053  
METHOD OF PREPARING BIOLOGICALLY ACTIVE REAGENTS FROM  
SUCCINIMIDE-CONTAINING POLYMERS, ANALYTICAL ELEMENT AND METHODS OF USE  
[ REACTING A WATER INSOLUBLE, NONPOROUS PARTICLE OF A NONCROSSLINKED  
COPOLYMER WITH A BIOLOGICALLY ACTIVE SUBSTANCE]  
FULL TEXT: 1150 lines

6/6/187 (Item 184 from file: 654)  
02243291  
SPECIFIC BINDING ANALYTICAL AND SEPARATION METHODS USING CARBOXY CONTAINING  
POLYMERS  
[Medical diagnosis with active materials bound to polymers]  
FULL TEXT: 2500 lines

6/6/188 (Item 185 from file: 654)  
02239026  
POLYPEPTIDE LINKERS FOR PRODUCTION OF BIOSYNTHETIC PROTEINS  
[ Targeted multifunctional proteins, immunological treatment of cancer and  
infection]  
FULL TEXT: 1585 lines

6/6/189 (Item 186 from file: 654)  
02204422  
BRAIN DERIVED NEUROTROPHIC FACTOR  
[Protein for treating Parkinson's and Alzheimer's disease]  
FULL TEXT: 4123 lines



6/6/190 (Item 187 from file: 654)

02172141

PARTICULATE BIOLOGICALLY ACTIVE REAGENT CONTAINING POLYOXYALKYLENE SIDE CHAINS, ANALYTICAL ELEMENT AND METHODS FOR USE OF THE REAGENT

[ Nonporous particle is coated with copolymer of ethylene unsaturated reacted group, acrylic group with alkylene oxide branching and oleophilic addition monomers bonded to biological active substance; water insoluble; detection]

FULL TEXT: 1434 lines

6/6/191 (Item 188 from file: 654)

02167782

BIDENTATE CONJUGATE AND METHOD OF USE THEREOF

FULL TEXT: 1159 lines

6/6/192 (Item 189 from file: 654)

02136659

TRIFUNCTIONAL CONJUGATES

[Immunoassay]

FULL TEXT: 2308 lines

6/6/193 (Item 190 from file: 654)

02114374

BIOLOGICALLY ACTIVE REAGENTS PREPARED FROM CARBOXY-CONTAINING POLYMER, ANALYTICAL ELEMENT AND METHODS OF USE

[Analysis, diagnosis]

FULL TEXT: 2496 lines

6/6/194 (Item 191 from file: 654)

02084603

VECTOR COMPRISING DNA SEQUENCE CODING FOR ENZYME-DONOR POLYPEPTIDE

FULL TEXT: 2546 lines

6/6/195 (Item 192 from file: 654)

02072008

METHOD FOR ENHANCED TRANSMEMBRANE TRANSPORT OF EXOGENOUS MOLECULES

[Contacting living cell membrane with complex of biotin and derivatives and biologically functional molecules; modifying cell function]

FULL TEXT: 890 lines

6/6/196 (Item 193 from file: 654)

02023396

METHOD OF MANUFACTURING A PLURALITY OF UNIFORM MICROFABRICATED SENSING DEVICES HAVING AN IMMOBILIZED **LIGAND** RECEPTOR

[ Multilayer; permselective layer, photoformable proteinaceous photoresist and overcoating of immobilized **ligand** receptor]

FULL TEXT: 4068 lines

6/6/197 (Item 194 from file: 654)

01967078

VECTORS ENCODING BRAIN DERIVABLE POLYPEPTIDE FACTORS

[DNA expression construct]

FULL TEXT: 1412 lines

6/6/198 (Item 195 from file: 654)

01913320

BRAIN DERIVABLE POLYPEPTIDE FACTORS AND ANTIBODIES THERETO

6/6/199 (Item 196 from file: 654)  
01898981  
PROLONGED ENHANCED CHEMILUMINESCENCE  
[DETECTION OF NUCLEIC ACID HYBRIDS, ANTIBODIES ANTIGENS]  
FULL TEXT: 2470 lines  
? t s6/3,ab/10, 154

6/3,AB/10 (Item 7 from file: 654)  
DIALOG(R)File 654:US PAT.FULL.  
(c) FORMAT ONLY 2000 THE DIALOG CORP. All rts. reserv.

03047342

Utility  
LABELLING AND SELECTION OF MOLECULES

PATENT NO.: 5,994,519  
ISSUED: November 30, 1999 (19991130)  
INVENTOR(s): Osbourn, Jane Katharine, Cambridge, GB (United Kingdom)  
Derbyshire, Elaine Joy, Royston, GB (United Kingdom)  
McCafferty, John Gerald, Babraham, GB (United Kingdom)  
Vaughan, Tristan John, Cambridge, GB (United Kingdom)  
Johnson, Kevin Stuart, Caldecote Highfields, GB (United Kingdom)  
ASSIGNEE(s): Cambridge Antibody Technology Limited, (A Non-U.S. Company or Corporation), Cambridgeshire, GB (United Kingdom)  
[Assignee Code(s): 39989]  
APPL. NO.: 8-889,291  
FILED: July 08, 1997 (19970708)  
PRIORITY: 9614292, GB (United Kingdom), July 8, 1996 (19960708)  
9624880, GB (United Kingdom), November 29, 1996 (19961129)  
9712818, GB (United Kingdom), June 18, 1997 (19970618)  
FULL TEXT: 3299 lines

ABSTRACT

A method of labelling molecules which includes providing in a common medium a label molecule, a marker **ligand** able to bind a member of a specific binding pair, such as an antigen, a sbp member, an enzyme able to catalyse binding of the label molecule to other molecules, the enzyme being associated with the marker **ligand**; causing or allowing binding of the marker **ligand** to the sbp member; and causing or allowing binding of the label molecule to other molecules in the vicinity of the marker **ligand** bound to the sbp member. The marker **ligand** may be an antibody or any specific binding molecule, such as a chemokine or cytokine. A complementary member of the specific binding pair may be included, e.g. an antibody, or a diverse population of such sbp members, e.g. antibodies, may be included within which those which bind the counterpart sbp member, e.g. antigen, may be labelled and subsequently isolated for manipulation and/or use. Suitable labels include biotin-tyramine with signal transfer being catalysed by hydrogen peroxidase. Cells, virus particles and other moieties may be labelled, for identification or obtention of proteins which interact or are in close proximity with a particular sbp member, or of cells of interest, or for enhancement of labelling, e.g. for cell sorting.

6/3,AB/154 (Item 151 from file: 654)  
DIALOG(R)File 654:US PAT.FULL.  
(c) FORMAT ONLY 2000 THE DIALOG CORP. All rts. reserv.

02624996

PATENT NO.: 5,607,691  
ISSUED: March 04, 1997 (19970304)  
INVENTOR(s): Hale, Ron L., Woodside, CA (California), US (United States of America)  
Lu, Amy, Los Altos, CA (California), US (United States of America)  
Solas, Dennis, San Francisco, CA (California), US (United States of America)  
Selick, Harold E., Belmont, CA (California), US (United States of America)  
Oldenburg, Kevin R., Fremont, CA (California), US (United States of America)  
Zaffaroni, Alejandro C., Atherton, CA (California), US (United States of America)  
ASSIGNEE(s): Affymax Technologies NV, (A Non-U.S. Company or Corporation), Middlesex, GB (United Kingdom) England  
[Assignee Code(s): 41252]  
APPL. NO.: 8-449,188  
FILED: May 24, 1995 (19950524)

This is a Continuation of application Ser. No. 08-164,293, filed Dec. 9, 1993 now abandoned, which is a continuation-in-part of application Ser. No. 08-077,296, filed Jun. 14, 1993 which is a continuation-in-part of applications Ser. Nos. 07-898,219, filed Jun. 12, 1992 now abandoned, and 08-009,463, filed Jan. 27, 1993 now abandoned. Each of the above identified applications are incorporated herein by reference for all purposes.

FULL TEXT: 5232 lines

#### ABSTRACT

The present invention relates to methods of delivering pharmaceutical agents across membranes, including the skin layer or mucosal membranes of a patient. A pharmaceutical agent is covalently bonded to a chemical modifier, via a physiologically cleavable bond, such that the membrane transport and delivery of the agent is enhanced.

? s oligonucleotide and ligand and (benzodiapenies, naproxen, butazone, oxyphenbutazone, danylsarcosine, triiodobenzoic or palimitic or salicylates or penicillin or flurbiprofen or pirprofin or oxaprozin or flufenamic)

80069	OLIGONUCLEOTIDE
202209	LIGAND
0	BENZODIAPENIES, NAPROXEN, BUTAZONE, OXYPHENBUT
7	PALIMITIC
9830	SALICYLATES
77670	PENICILLIN
4231	FLURBIPROFEN
0	PIRPROFIN
628	OXAPROZIN
2188	FLUFENAMIC
S7	1021 OLIGONUCLEOTIDE AND LIGAND AND (BENZODIAPENIES, NAPROXEN, BUTAZONE, OXYPHENBUTAZONE, DANYLSARCOSINE, TRIODOBENZOIC OR PALIMITIC OR SALICYLATES OR PENICILLIN OR FLURBIPROFEN OR PIRPROFIN OR OXAPROZIN OR FLUFENAMIC)

? t s7/6/1

7/6/1 (Item 1 from file: 155)  
06590485 90203007

The aspirin and  $\text{Ca}^{2+}$ -binding sites of ovine and murine prostaglandin  
endoperoxide synthases  
Mar 25 1990  
? t s7/6/1-10

7/6/1 (Item 1 from file: 155)  
06590485 90203007  
The aspirin and heme-binding sites of ovine and murine prostaglandin  
endoperoxide synthases.  
Mar 25 1990

7/6/2 (Item 1 from file: 357)  
0185217 DBA Accession No.: 95-12038  
A new DNA - **oligonucleotide** useful for diagnosis and gene therapy of  
X-linked hyper IgM syndrome 1995

7/6/3 (Item 1 from file: 654)  
03065296  
CALCIUM RECEPTOR-ACTIVE MOLECULES  
FULL TEXT: 8512 lines

7/6/4 (Item 2 from file: 654)  
03065240  
HUMAN CYSTATIN E  
FULL TEXT: 2543 lines

7/6/5 (Item 3 from file: 654)  
03065231  
FLT-4(FMS-LIKE TYROSINE KINASE), FLT-15, VARIANTS THEREOF USED AS GROWTH  
FACTOR INHIBITORS  
FULL TEXT: 1005 lines

7/6/6 (Item 4 from file: 654)  
03065136  
GENE THERAPY BY SMALL FRAGMENT HOMOLOGOUS REPLACEMENT  
FULL TEXT: 4201 lines

7/6/7 (Item 5 from file: 654)  
03065106  
INTERLEUKIN-1 .BETA. CONVERTING ENZYME LIKE APOPTOTIC PROTEASE-6  
FULL TEXT: 2458 lines

7/6/8 (Item 6 from file: 654)  
03062176  
ANTISENSE MODULATION OF PHOSPHOLIPASE A2 GROUP IV EXPRESSION  
FULL TEXT: 2916 lines

7/6/9 (Item 7 from file: 654)  
03062032  
IMMUNOMODULATORY OLIGONUCLEOTIDES  
FULL TEXT: 1665 lines

7/6/10 (Item 8 from file: 654)  
03062027  
ANTIMICROBIAL PEPTIDES AND METHODS OF USE

7/7/1 (Item 1 from file: 155)  
DIALOG(R)File 155:MEDLINE(R)  
(c) format only 1999 Dialog Corporation. All rts. reserv.

06590485 90203007

The aspirin and heme-binding sites of ovine and murine prostaglandin endoperoxide synthases.

DeWitt DL; el-Harith EA; Kraemer SA; Andrews MJ; Yao EF; Armstrong RL; Smith WL

Department of Biochemistry, Michigan State University, East Lansing 48824.

J Biol Chem (UNITED STATES) Mar 25 1990, 265 (9) p5192-8, ISSN 0021-9258 Journal Code: HIV

Contract/Grant No.: DK22042, DK, NIDDK; DK42509, DK, NIDDK; GM40713, GM, NIGMS

Languages: ENGLISH

Document type: JOURNAL ARTICLE

Acetylation of Ser-530 of sheep prostaglandin endoperoxide (PGG/H) synthase by aspirin causes irreversible inactivation of the cyclooxygenase activity of the enzyme. To determine the catalytic function of the hydroxyl group of Ser-530, we used site-directed mutagenesis to replace Ser-530 with an alanine. Cos-1 cells transfected with expression vectors containing the native (Ser-530) or mutant (Ala-530) cDNAs for sheep PGG/H synthase expressed comparable cyclooxygenase and hydroperoxidase activities. Km values for arachidonate (8 microM) and ID50 values for reversible inhibition by the cyclooxygenase inhibitors, **flurbiprofen** (5 microM), **flufenamate** (20 microM), and aspirin (20 mM), were also the same for both native and mutant PGG/H synthases; however, only the native enzyme was irreversibly inactivated by aspirin. Thus, the "active site" Ser-530 of PGG/H synthase is not essential for catalysis or substrate binding. Apparently, acetylation of native PGG/H synthase by aspirin introduces a bulky sidechain at position 530 which interferes with arachidonate binding. In related studies, a cDNA for mouse PGG/H synthase was cloned and sequenced. A sequence of 35 residues with Ser-530 at the midpoint was identical in the two proteins. Thus, Ser-530 does lie in a highly conserved region, probably involved in cyclooxygenase catalysis. Sequence comparisons of mouse and sheep PGG/H synthase also provided information about the heme-binding site of the enzyme. The sheep HYPR sequence (residues 274-277), which had been proposed to form a portion of the distal heme-binding site, is not conserved in the mouse PGG/H synthase, suggesting that this region is not the distal heme-binding site. One sequence, TIWLREHNRV (residues 303-312 of the sheep enzyme), is very closely related to the sequence TLW(L)LRHNRL common to thyroid peroxidase and myeloperoxidase. The histidine in this latter sequence is the putative axial heme **ligand** of these peroxidases. We suggest that the histidine (His-309) of sheep PGG/H synthase sequence is the axial heme **ligand** of this enzyme.

7/7/2 (Item 1 from file: 357)  
DIALOG(R)File 357:DERWENT BIOTECHNOLOGY ABS  
(c) 1999 DERWENT PUBL LTD. All rts. reserv.

0185217 DBA Accession No.: 95-12038 PATENT

A new DNA - **oligonucleotide** useful for diagnosis and gene therapy of X-linked hyper IgM syndrome

PATENT ASSIGNEE: Mitsubishi-Petrochem. 1995

PATENT NUMBER: JP 7163362 PATENT DATE: 950627 WPI ACCESSION NO.: 95-260044 (9534)

PRIORITY APPLIC. NO.: JP 93295102 APPLIC. DATE: 931125

NATIONAL APPLIC. NO.: JP 93295102 APPLIC. DATE: 931125

LANGUAGE: JA

ABSTRACT: A new DNA fragment contains a chromosomal CD40 ligand gene of disclosed DNA sequence. Also claimed is an oligonucleotide complementary to the new ds DNA fragment and being capable of analyzing the sequence of the DNA fragment containing the chromosomal CD40 ligand gene. The DNA fragment and oligonucleotide can be used for gene analysis and for diagnosis and gene therapy of X-linked hyper IgM syndrome. In an example, peripheral blood (10 ml) was mixed with phosphate buffer (20 ml) and a 7.5 ml aliquot of the mixture was layered on 3 ml of lymphosepal and subjected to specific gravity centrifugation. A buffy coat leukocyte fraction was recovered and suspended in RPMI-1640 medium containing 100 ug/ml streptomycin and 100 U/ml penicillin. PHA (1 ml) was added to the mixture, which was incubated at 37 deg for 70 hr. The medium was renewed and the mixture was incubated a further 4 hr at 37 deg. The culture was centrifuged to recover the lymphocyte fraction. RNA was extracted from the fraction and used to prepare cDNA for chromosomal CD40 ligand gene cloning. (14pp)

? s oligonucleotide and ligand and (bilirubin or hydantoin or valproic or tolmetin or quinalbaritone or barbiturate or cephalosporin or sulfa or tollbutamide or antidiabetic or antibacterial or quinolones or nalidixic or cinoxacin or antibiotic)

>>>Command is too long.

? s oligonucleotide and ligand and (bilirubin or hydantoin or valproic or tolmetin or quinalbaritone or barbiturate or cephalosporin or sulfa or tollbutamide or antidiabetic)

80069	OLIGONUCLEOTIDE
202209	LIGAND
41973	BILIRUBIN
12791	HYDANTOIN
9488	VALPROIC
2552	TOLMETIN
1	QUINALBARITONE
12897	BARBITURATE
20628	CEPHALOSPORIN
6740	SULFA
1	TOLLBUTAMIDE
19313	ANTIDIABETIC
S8	215 OLIGONUCLEOTIDE AND LIGAND AND (BILIRUBIN OR HYDANTOIN OR VALPROIC OR TOLMETIN OR QUINALBARITONE OR BARBITURATE OR CEPHALOSPORIN OR SULFA OR TOLLBUTAMIDE OR ANTIDIABETIC)

? rd

>>>Duplicate detection is not supported for File 654.

>>>Records from unsupported files will be retained in the RD set.

...examined 50 records (50)  
...examined 50 records (100)  
...examined 50 records (150)  
...examined 50 records (200)  
...completed examining records  
S9 214 RD (unique items)  
? t /s9/6/1-10

>>>'9' valid only in keyword format  
? t s9/6/1-10

9/6/1 (Item 1 from file: 155)  
09044509 97166429

Chimeric GABAA/glycine receptors: expression and barbiturate pharmacology.  
1996

9/6/2 (Item 2 from file: 155)  
05768931 89308559

Mutations affecting the catalytic activity of *Bacillus cereus* 5/B/6  
beta-lactamase II.  
Jul 15 1989

9/6/3 (Item 1 from file: 399)  
DIALOG(R)File 399:(c) 2000 AMERICAN CHEMICAL SOCIETY. All rts. reserv.

Genetic therapy of hyperlipidemia by mutation of apolipoprotein genes

9/6/4 (Item 1 from file: 654)  
03061879  
DRUG AND PESTICIDE SCREENING  
FULL TEXT: 2847 lines

9/6/5 (Item 2 from file: 654)  
03058289  
PROMISCUOUS G-PROTEIN COMPOSITIONS AND THEIR USE  
FULL TEXT: 1938 lines

9/6/6 (Item 3 from file: 654)  
03058036  
METHODS FOR THE SPECIFIC COAGULATION OF VASCULATURE  
FULL TEXT: 7675 lines

9/6/7 (Item 4 from file: 654)  
03055295  
CHEMILUMINESCENT COMPOUNDS AND METHODS OF USE  
FULL TEXT: 1802 lines

9/6/8 (Item 5 from file: 654)  
03054875  
SUPPORTS AND COMBINATORIAL CHEMICAL LIBRARIES THEREOF ENCODED BY  
NON-SEQUENCABLE TAGS  
FULL TEXT: 2832 lines

9/6/9 (Item 6 from file: 654)  
03051475  
N-(AMINOALKYL)- AND/OR N-(AMIDOALKYL)-DINITROGEN HETEROCYCLES  
FULL TEXT: 1233 lines

9/6/10 (Item 7 from file: 654)  
03051434  
COMPOSITIONS FOR THE INHIBITION OF TNF HORMONE FORMATION AND USES THEREOF  
FULL TEXT: 2361 lines  
? t s9/7/1-3

9/7/1 (Item 1 from file: 155)  
DIALOG(R)File 155:MEDLINE(R)  
(c) format only 1999 Dialog Corporation. All rts. reserv.

09044509 97166429  
Chimeric GABAA/glycine receptors: expression and **barbiturate**

pharmacology.

Koltchine VV; Ye Q; Han SE; Harrison NL

Department of Pharmacological and Physiological Sciences, University of Chicago, IL 60637, USA.

Neuropharmacology (ENGLAND) 1996, 35 (9-10) p1445-56, ISSN 0028-3908  
Journal Code: NZB

Contract/Grant No.: GM 45129, GM, NIGMS; GM 00623, GM, NIGMS; DA 07255, DA, NIDA

Languages: ENGLISH

Document type: JOURNAL ARTICLE

GABAA and glycine receptors are close relatives in the "gene superfamily" of **ligand** -gated ion channels, but have distinctly different pharmacology. For example, barbiturates have two effects on GABAA receptors (GABAA-R): at low micromolar concentrations (2-5 microM), the anesthetic **barbiturate** methohexital potentiates submaximal chloride current responses to GABA; at higher concentrations (20-50 microM), the **barbiturate** causes direct gating of the channel in the absence of agonist. Neither of these **barbiturate** effects is seen on the glycine receptor (Gly-R). In order to study the structural parts of the GABAA-R involved in this **barbiturate** pharmacology, two unique restriction sites were introduced into the cDNAs encoding the alpha 2 and beta 1 subunits of the human GABAA-R and the alpha 1 subunit of the human gly-R. The first site ('X') corresponded to the C-terminal end of the third transmembrane domain (M3) in each subunit and enabled exchange of C-terminal fragment of approximately 100 amino acids (which includes the large 'cytoplasmic loop' and M4 segment) between GABAA-R and Gly-R subunits. The second site ('S') was approximately 30 amino acids 3' from the N-terminal end of each subunit and enabled exchange of a small N-terminal fragment between GABAA-R and Gly-R subunits. Several chimeric receptor subunit cDNAs were constructed and the resulting receptors tested for their ability to respond to GABA and glycine and for sensitivity to the **barbiturate** methohexital (MTX). The results show that neither the large C-terminal fragment nor the smaller N-terminal fragment is associated with the enhancement or direct activation of the GABAA-R by MTX. These results demonstrate the viability of chimeric GABAA/Gly-R and suggest that the method will be suitable for further investigation of the molecular basis of the **barbiturate** pharmacology of the GABA-R.

9/7/2 (Item 2 from file: 155)

DIALOG(R) File 155:MEDLINE(R)

(c) format only 1999 Dialog Corporation. All rts. reserv.

05768931 89308559

Mutations affecting the catalytic activity of Bacillus cereus 5/B/6 beta-lactamase II.

Lim HM; Pene JJ

School of Life and Health Sciences, University of Delaware, Newark 19716.

J Biol Chem (UNITED STATES) Jul 15 1989, 264 (20) p11682-7, ISSN 0021-9258 Journal Code: HIV

Languages: ENGLISH

Document type: JOURNAL ARTICLE

Random in vitro mutagenesis of a cloned Bacillus cereus 5/B/6 beta-lactamase II gene was used to select defective genes unable to confer ampicillin or **cephalosporin** C resistance to Escherichia coli. DNA sequencing of mutant genes identified histidine at position 28 as important to beta-lactamase II function. In addition, the isolation of six identical frameshift mutants established that the carboxyl-terminal end of beta-lactamase II is critical for enzyme function. Random mutagenesis also revealed that His88 (implicated previously as one of 4 residues acting as a zinc **ligand**) is crucial to enzymatic activity and that a glycine to glutamic acid substitution at position 148 produced a defective beta-lactamase. **Oligonucleotide** mutagenesis directed at Glu37 and Glu212 suggests that these residues are inconsequential to enzyme function but that histidine at position 28 may be involved in substrate binding or



recognition.

9/7/3 (Item 1 from file: 399)  
DIALOG(R) File 399:CA SEARCH(R)  
(c) 2000 AMERICAN CHEMICAL SOCIETY. All rts. reserv.

131153753 CA: 131(12)153753w PATENT  
Genetic therapy of hyperlipidemia by mutation of apolipoprotein genes  
INVENTOR(AUTHOR): Steer, Clifford J.; Kren, Betsy T.; Bandyopadhyay,  
Paramita T.; Roy-Chowdhury, Jayanta  
LOCATION: USA  
ASSIGNEE: Regents of the University of Minnesota; Albert Einstein College  
of Medicine of Yeshiva University  
PATENT: PCT International ; WO 9940789 A1 DATE: 19990819  
APPLICATION: WO 98US17908 (19980828) \*US PV74497 (19980212) \*US 108006  
(19980630)  
PAGES: 106 pp. CODEN: PIXXD2 LANGUAGE: English CLASS: A01N-043/04A;  
C07H-021/04B; C12N-015/09B; C12N-015/11B; C12N-015/85B  
DESIGNATED COUNTRIES: AL; AM; AU; BA; BB; BG; BR; CA; CN; CU; CZ; EE; GE;  
HU; IL; IS; JP; KP; KR; LC; LK; LR; LT; LV; MG; MK; MN; MX; NO; NZ; PL; RO;  
SG; SI; SK; SL; TR; TT; UA; US; UZ; VN; YU; AM; AZ; BY; KG; KZ; MD; RU; TJ;  
TM DESIGNATED REGIONAL: GH; GM; KE; LS; MW; SD; SZ; UG; ZW; AT; BE; CH; CY  
; DE; DK; ES; FI; FR; GB; GR; IE; IT; LU; MC; NL; PT; SE; BF; BJ; CF; CG;  
CI; CM; GA; GN; GW; ML; MR; NE; SN; TD; TG  
SECTION:  
CA201012 Pharmacology  
CA203XXX Biochemical Genetics  
IDENTIFIERS: apolipoprotein gene mutagenesis gene therapy hyperlipidemia  
DESCRIPTORS:  
Jaundice...  
Crigler-Najjar syndrome, treatment of; genetic therapy of  
hyperlipidemia by mutation of apolipoprotein genes  
Antiatherosclerotics... Apolipoprotein A-I... Apolipoprotein B-100...  
Apolipoprotein E4... Gene therapy... Hepatocyte... High-density  
lipoproteins... Hyperlipidemia... Liposomes(drug delivery systems)...  
Low-density lipoproteins... Protein F...  
genetic therapy of hyperlipidemia by mutation of apolipoprotein genes  
Transferrins...  
ligand for asialoglycoprotein receptor; genetic therapy of  
hyperlipidemia by mutation of apolipoprotein genes  
Asialoglycoprotein receptors...  
ligands for; genetic therapy of hyperlipidemia by mutation of  
apolipoprotein genes  
Spheres...  
nanospheres, lipid; genetic therapy of hyperlipidemia by mutation of  
apolipoprotein genes  
Hyperlipoproteinemia...  
type III; genetic therapy of hyperlipidemia by mutation of  
apolipoprotein genes  
CAS REGISTRY NUMBERS:  
236111-78-7 amino acid sequence; genetic therapy of hyperlipidemia by  
mutation of apolipoprotein genes  
59-67-6 9004-10-8 biological studies, ligand for asialoglycoprotein  
receptor; genetic therapy of hyperlipidemia by mutation of  
apolipoprotein genes  
236732-60-8 236740-48-0 chimeric mutational vector for apolipoprotein B;  
genetic therapy of hyperlipidemia by mutation of apolipoprotein genes  
236732-56-2 chimeric mutational vector for apolipoprotein E4; genetic  
therapy of hyperlipidemia by mutation of apolipoprotein genes  
237418-60-9 chimeric mutational vector for bilirubin-UDP-glucuronate  
glucuronosyltransferase gene; genetic therapy of hyperlipidemia by  
mutation of apolipoprotein genes  
236732-61-9 236732-62-0 236740-49-1 236740-50-4 chimeric mutational  
vector for blood coagulation factor IX in dog; genetic therapy of

hyperlipidemia by mutation of apolipoprotein genes  
 236732-57-3 236732-58-3 236732-59-5 chimeric mutational vector for  
 blood-coagulation factor IX; genetic therapy of hyperlipidemia by  
 mutation of apolipoprotein genes  
 4682-48-8 9001-28-9 9002-98-6 14268-17-8 61969-98-0 68737-67-7  
 85305-88-0 124050-77-7 144189-73-1 genetic therapy of hyperlipidemia  
 by mutation of apolipoprotein genes  
 9002-98-6D lactosylated, genetic therapy of hyperlipidemia by mutation of  
 apolipoprotein genes  
 541-15-1 67763-96-6 ligand for asialoglycoprotein receptor; genetic  
 therapy of hyperlipidemia by mutation of apolipoprotein genes  
 140738-87-0 140738-93-8 140957-09-1 nucleotide sequence; genetic therapy  
 of hyperlipidemia by mutation of apolipoprotein genes  
 236112-13-3D 236112-14-4D 236112-15-5D 236112-16-6D 236112-17-7D  
 RNA-DNA hybrid oligonucleotide contg., chimeric mutational vector for  
 apolipoprotein A-I; genetic therapy of hyperlipidemia by mutation of  
 apolipoprotein genes  
 236111-79-8D 236111-80-1D 236111-83-4D 236111-84-5D 236111-86-7D  
 236111-87-8D 236111-88-9D 236111-89-0D 236111-90-3D 236111-91-4D  
 236111-92-5D 236111-93-6D 236111-94-7D 236111-95-8D 236111-96-9D  
 236111-97-0D 236111-99-2D 236112-00-8D RNA-DNA hybrid  
 oligonucleotide contg., chimeric mutational vector for apolipoprotein  
 B; genetic therapy of hyperlipidemia by mutation of apolipoprotein  
 genes  
 236112-01-9D 236112-02-0D 236112-03-1D 236112-04-2D RNA-DNA hybrid  
 oligonucleotide contg., chimeric mutational vector for apolipoprotein  
 E4; genetic therapy of hyperlipidemia by mutation of apolipoprotein  
 genes

? ds

Set	Items	Description
S1	71	OLIGONUCLEOTIDE AND LIGAND AND (COUMARINS OR ISOCOUMARINS - OR ANILINOCOUMARIN OR KETOPROFEN OR CARPROFEN OR ETODOLAC)
S2	71	OLIGONUCLEOTIDE AND LIGAND AND (COUMARINS OR ISOCOUMARINS - OR ANILINOCOUMARIN OR KETOPROFEN OR CARPROFEN OR ETODOLAC OR - SUPROFEN OR INDOPROFEN OR FENBUFEN)
S3	71	RD (unique items)
S4	217	OLIGONUCLEOTIDE AND LIGAND AND (ARYLPROPRIONIC OR ARYLALKO- NIC OR FLUOROPROPIONIC OR GLIBENCLAMID OR ACETOHEXAMIDE OR A- RYLALKANOIC OR TOBUTAMIDE OR GLICLAZIDE OR METFORMIN OR CURCU- MIN OR DIGITOXIN OR DIGOXIN OR DIAZEPAM)
S5	216	RD (unique items)
S6	199	S4 NOT S3
S7	1021	OLIGONUCLEOTIDE AND LIGAND AND (BENZODIAPENIES, NAPROXEN, - BUTAZONE, OXYPHENBUTAZONE, DANYLSARCOSINE, TRIODOBENZOIC OR - PALIMITIC OR SALICYLATES OR PENICILLIN OR FLURBIPROFEN OR PIR- PROFIN OR OXAPROZIN OR FLUFENAMIC)
S8	215	OLIGONUCLEOTIDE AND LIGAND AND (BILIRUBIN OR HYDANTOIN OR - VALPROIC OR TOLMETIN OR QUINALBARITONE OR BARBITURATE OR CEPH- ALOSPORIN OR SULFA OR TOLLBUTAMIDE OR ANTIDIABETIC)
S9	214	RD (unique items)
? s oligonucleotide and ligand and (antibacterial or quinolones or nalidixic or cinoxacin or antibiotic)		

80069	OLIGONUCLEOTIDE
202209	LIGAND
158947	ANTIBACTERIAL
10389	QUINOLONES
8280	NALIDIXIC
597	CINOXACIN
210810	ANTIBIOTIC
S10 1537	OLIGONUCLEOTIDE AND LIGAND AND (ANTIBACTERIAL OR QUINOLONES OR NALIDIXIC OR CINOXACIN OR ANTIBIOTIC)

? t s10/6/1-10

10/6/1 (Item 1 from file: 155)

09427048 98149665

Slipped loop structure of DNA: a specific nucleotide sequence forms only one unique conformer.

Jan 30 1998

10/6/2 (Item 2 from file: 155)

08985166 97199355

Differential interactions of the Mg<sup>2+</sup> complexes of chromomycin A3 and mithramycin with poly(dG-dC) x poly(dC-dG) and poly(dG) x poly(dC).

Feb 25 1997

10/6/3 (Item 3 from file: 155)

07280863 92338157

A <sup>1</sup>H-NMR study of the DNA binding characteristics of thioformyl-distamycin, an amide isosteric lexitropsin.

Jul 21 1992

10/6/4 (Item 1 from file: 5)

11349042 BIOSIS NO.: 199800130374

Slipped loop structure of DNA: A specific nucleotide sequence forms only one unique conformer.

1998

10/6/5 (Item 2 from file: 5)

10853836 BIOSIS NO.: 199799474981

Differential interactions of the Mg<sup>2+</sup> complexes of chromomycin A-3 and mithramycin with poly(dG-dC) cntdot poly(dC-dG) and poly(dG) cntdot poly(dC).

1997

10/6/6 (Item 3 from file: 5)

10703185 BIOSIS NO.: 199799324330

Solution structure studies of the cobalt complex of a bleomycin functional model bound to d(CGCAATTGGC)-2 by two-dimensional nuclear magnetic resonance methods and restrained molecular dynamics simulation.

1996

10/6/7 (Item 4 from file: 5)

08921724 BIOSIS NO.: 199396073225

NMR characterization of a heterocomplex formed by distamycin and its analog 2-ImD with d(CGCAAGTTGGC):d(GCCAACCTGGC): Preference for the 1:1:1 2-ImD:Dst:DNA complex over the 2:1 2-ImD: DNA and the 2:1 Dst: DNA complexes.

1993

10/6/8 (Item 5 from file: 5)

08335965 BIOSIS NO.: 000094087213

A PROTON NMR STUDY OF THE DNA BINDING CHARACTERISTICS OF THIOFORMYLDISTAMYCIN AN AMIDE ISOSTERIC LEXITROPSIN

1992

10/6/9 (Item 1 from file: 357)

0194821 DBA Accession No.: 96-05592

Oligoribonucleotide analog for identifying new antibiotics - drug screening

system by DNA footprinting with a ribosome RNA oligonucleotide  
template, and DNA probe hybridization or reverse transcription using a  
DNA primer 1996

10/6/10 (Item 2 from file: 357)  
0193031 DBA Accession No.: 96-03802  
**Oligonucleotide** encoding ribosome inactivating protein bryodin-1 from  
Bryonia dioica - immunotoxin or chimeric toxin fusion protein  
production 1995  
? t sl0/6/11-20

10/6/11 (Item 3 from file: 357)  
0185184 DBA Accession No.: 95-12005  
Helix-stabilizing agent, CC-1065, enhances suppression of translation by an  
antisense oligodeoxynucleotide - horse-infectious-anemia virus enhanced  
translation inhibition using vector plasmid pSP585 harboring antisense  
**oligonucleotide, antibiotic CC-1065 ligand, for**  
application in gene therapy 1995

10/6/12 (Item 1 from file: 654)  
03065296  
CALCIUM RECEPTOR-ACTIVE MOLECULES  
FULL TEXT: 8512 lines

10/6/13 (Item 2 from file: 654)  
03065246  
REGULATED TRANSCRIPTION OF TARGETED GENES AND OTHER BIOLOGICAL EVENTS  
FULL TEXT: 4885 lines

10/6/14 (Item 3 from file: 654)  
03065240  
HUMAN CYSTATIN E  
FULL TEXT: 2543 lines

10/6/15 (Item 4 from file: 654)  
03065136  
GENE THERAPY BY SMALL FRAGMENT HOMOLOGOUS REPLACEMENT  
FULL TEXT: 4201 lines

10/6/16 (Item 5 from file: 654)  
03065135  
EUKARYOTIC USE OF NON-CHIMERIC MUTATIONAL VECTORS  
FULL TEXT: 955 lines

10/6/17 (Item 6 from file: 654)  
03065114  
RECEPTOR FOR ONCOSTATIN M  
FULL TEXT: 2554 lines

10/6/18 (Item 7 from file: 654)  
03065113  
EXPRESSION OF HETEROLOGOUS POLYPEPTIDES IN HALOBACTERIA  
FULL TEXT: 2420 lines

10/6/19 (Item 8 from file: 654)

03065109  
RIBG  
FULL TEXT:

1460 lines

10/6/20 (Item 9 from file: 654)  
03065089  
TARGET SPECIFIC SCREENS AND THEIR USE FOR DISCOVERING SMALL ORGANIC  
MOLECULAR PHARMACOPHORES  
FULL TEXT: 4776 lines  
? t s10/7/11

10/7/11 (Item 3 from file: 357)  
DIALOG(R)File 357:DERWENT BIOTECHNOLOGY ABS  
(c) 1999 DERWENT PUBL LTD. All rts. reserv.

0185184 DBA Accession No.: 95-12005  
Helix-stabilizing agent, CC-1065, enhances suppression of translation by an  
antisense oligodeoxynucleotide - horse-infectious-anemia virus enhanced  
translation inhibition using vector plasmid pSP585 harboring antisense  
**oligonucleotide, antibiotic CC-1065 ligand**, for  
application in gene therapy

AUTHOR: Kim D Y; +Swenson D H; Cho D Y; Taylor H W; Shih D S  
CORPORATE AFFILIATE: Univ.Louisiana-State  
CORPORATE SOURCE: Department of Veterinary Physiology, Pharmacology and  
Toxicology, School of Veterinary Medicine, Louisiana State University,  
Baton Rouge, LA 70803, USA.

JOURNAL: Antisense Res.Dev. (5, 2, 149-54) 1995  
ISSN: 1050-5261 CODEN: 1282R  
LANGUAGE: English

ABSTRACT: CC-1065 (an antitumor **antibiotic**) may enhance translation  
inhibition by antisense oligonucleotides (ON) directed against a  
specific mRNA. The antisense ON used was a 20 base DNA sequence  
complementary to part of the overlapping region of the  
horse-infectious-anemia virus (EIAV) S2 and env genes. Plasmid pSP585  
(a transcription plasmid, constructed by inserting a 585 bp DNA segment  
into the SmaI site of plasmid pSP65) was linearized and the DNA was  
used as the template for RNA synthesis. The pSP585 in vitro transcript  
was incubated with 1.2 nmol, 0.6 nmol or 0.17 nmol antisense ON alone  
or in the presence of 4.8, 2.4 and 0.67 nmol CC-1065, respectively. The  
center of the target sequence had an expected CC-1065 recognition  
sequence. Translation in the presence of CC-1065 and antisense was  
markedly suppressed compared with that of antisense alone. Addition of  
a 20 mer sense strand, with or without CC-1065, had little effect or no  
effect on translation. Therefore CC-1065, and related compounds, may be  
useful as ligands for enhancing the stability of sense-antisense  
duplexes and for promoting the inhibition of translation by antisense  
oligonucleotides. (26 ref)

?

PLEASE ENTER A COMMAND OR BE LOGGED OFF IN 5 MINUTES

? ds

Set	Items	Description
S1	71	OLIGONUCLEOTIDE AND LIGAND AND (COUMARINS OR ISOCOUMARINS - OR ANILINOCOUMARIN OR KETOPROFEN OR CARPROFEN OR ETODOLAC)
S2	71	OLIGONUCLEOTIDE AND LIGAND AND (COUMARINS OR ISOCOUMARINS - OR ANILINOCOUMARIN OR KETOPROFEN OR CARPROFEN OR ETODOLAC OR - SUPROFEN OR INDOPROFEN OR FENBUFEN)
S3	71	RD (unique items)
S4	217	OLIGONUCLEOTIDE AND LIGAND AND (ARYLPROPRIONIC OR ARYLALKO- NIC OR FLUOROPROPIONIC OR GLIBENCLAMID OR ACETOHEXAMIDE OR A- RYLALKANOIC OR TOBUTAMIDE OR GLICLAZIDE OR METFORMIN OR CURCU- MIN OR DIGITOXIN OR DIGOXIN OR DIAZEPAM)

S5 216 RD (unique items)  
 S6 199 S4 NOV 83  
 S7 1021 OLIGONUCLEOTIDE AND LIGAND AND (BENZODIAPENIES, NAPROXEN, -  
 BUTAZONE, OXYPHENBUTAZONE, DANYLSARCOSINE, TRIODOBENZOIC OR -  
 PALMITIC OR SALICYLATES OR PENICILLIN OR FLURBIPROFEN OR PIR-  
 PROFIN OR OXAPROZIN OR FLUFENAMIC)  
 S8 215 OLIGONUCLEOTIDE AND LIGAND AND (BILIRUBIN OR HYDANTOIN OR -  
 VALPROIC OR TOLMETIN OR QUINALBARITONE OR BARBITURATE OR CEPH-  
 ALOSPORIN OR SULFA OR TOLLBUTAMIDE OR ANTIDIABETIC)  
 S9 214 RD (unique items)  
 S10 1537 OLIGONUCLEOTIDE AND LIGAND AND (ANTIBACTERIAL OR QUINOLONES  
 OR NALIDIXIC OR CINOXACIN OR ANTIBIOTIC)  
 ? s s7 and s10

1021 S7  
 1537 S10  
 S11 424 S7 AND S10  
 ? s s11 and (conjugate or conjugating or moiety)  
 424 S11  
 72923 CONJUGATE  
 6183 CONJUGATING  
 98854 MOIETY  
 S12 279 S11 AND (CONJUGATE OR CONJUGATING OR MOIETY)  
 ? s s12 and serum  
 279 S12  
 1074673 SERUM  
 S13 263 S12 AND SERUM  
 ? t s13/6/1-133

13/6/1 (Item 1 from file: 654)  
 03065296  
 CALCIUM RECEPTOR-ACTIVE MOLECULES  
 FULL TEXT: 8512 lines

13/6/2 (Item 2 from file: 654)  
 03065136  
 GENE THERAPY BY SMALL FRAGMENT HOMOLOGOUS REPLACEMENT  
 FULL TEXT: 4201 lines

13/6/3 (Item 3 from file: 654)  
 03061855  
 HUMAN CYTOKINE POLYPEPTIDE  
 FULL TEXT: 2157 lines

13/6/4 (Item 4 from file: 654)  
 03061853  
 BRAIN-ASSOCIATED INHIBITOR OF TISSUE-TYPE PLASMINOGEN ACTIVATOR  
 FULL TEXT: 3466 lines

13/6/5 (Item 5 from file: 654)  
 03058412  
 METHOD FOR INHIBITING GROWTH HORMONE ACTION  
 FULL TEXT: 4203 lines

13/6/6 (Item 6 from file: 654)  
 03058036  
 METHODS FOR THE SPECIFIC COAGULATION OF VASCULATURE

FULL TEXT: 767 lines

13/6/7 (Item 7 from file: 654)

03055118

TREATMENT OR PROPHYLAXIS OF DISEASES CAUSED BY PILUS-FORMING BACTERIA

FULL TEXT: 5203 lines

13/6/8 (Item 8 from file: 654)

03054916

PROTEIN TYROSINE KINASES

FULL TEXT: 4621 lines

13/6/9 (Item 9 from file: 654)

03054894

TWO NEW HUMAN DNAJ-LIKE PROTEINS

FULL TEXT: 2509 lines

13/6/10 (Item 10 from file: 654)

03054880

ONCOPROTEIN PROTEIN KINASE

FULL TEXT: 2009 lines

13/6/11 (Item 11 from file: 654)

03054662

IN VITRO ACTIVATION OF CYTOTOXIC T CELLS

FULL TEXT: 3941 lines

13/6/12 (Item 12 from file: 654)

03051654

IMMUNOADHESINS AND METHODS OF PRODUCTION AND USE THEREOF

FULL TEXT: 2452 lines

13/6/13 (Item 13 from file: 654)

03051227

POLYNUCLEOTIDES ENCODING HUMAN ENDOKINE ALPHA

FULL TEXT: 2468 lines

13/6/14 (Item 14 from file: 654)

03047336

ONCOPROTEIN PROTEIN KINASE

FULL TEXT: 1990 lines

13/6/15 (Item 15 from file: 654)

03047334

ANTI-IGE ANTIBODIES AND METHODS OF IMPROVING POLYPEPTIDES

FULL TEXT: 5666 lines

13/6/16 (Item 16 from file: 654)

03042630

HUMAN ENA/VASP-LIKE PROTEIN SPLICE VARIANT

FULL TEXT: 2354 lines

13/6/17 (Item 17 from file: 654)

03042622

AGENTS AFFECTING THROMBOSIS AND HEMOSTASIS  
FULL TEXT: 179 lines

13/6/18 (Item 18 from file: 654)  
03042389  
ASSAYS TO IDENTIFY INDUCERS OF PLANT DEFENSE RESISTANCE  
FULL TEXT: 2597 lines

13/6/19 (Item 19 from file: 654)  
03042357  
SCREENING METHODS IN EUKARYOTIC CELLS  
FULL TEXT: 1956 lines

13/6/20 (Item 20 from file: 654)  
03038200  
PHOSPHORYLATED FUSION PROTEINS  
FULL TEXT: 2403 lines

13/6/21 (Item 21 from file: 654)  
03038198  
T-CELL SELECTIVE INTERLEUKIN-4 AGONISTS  
FULL TEXT: 2889 lines

13/6/22 (Item 22 from file: 654)  
03038188  
PURIFIED THROMBOPOIETIN AND METHOD OF MAKING IT  
FULL TEXT: 2624 lines

13/6/23 (Item 23 from file: 654)  
03037402  
METHOD OF TREATMENT WITH EPITHELIUM DERIVED T-CELL FACTOR  
FULL TEXT: 2263 lines

13/6/24 (Item 24 from file: 654)  
03033571  
DNA ENCODING CD40 LIGAND, A CYTOKINE THAT BINDS CD40  
FULL TEXT: 3829 lines

13/6/25 (Item 25 from file: 654)  
03033314  
AMINIMIDE-CONTAINING MOLECULES AND MATERIALS AS MOLECULAR RECOGNITION  
AGENTS  
FULL TEXT: 2577 lines

13/6/26 (Item 26 from file: 654)  
03033078  
POLYNUCLEOTIDES ENCODING CHEMOKINE .BETA.-15  
FULL TEXT: 2408 lines

13/6/27 (Item 27 from file: 654)  
03033041  
USE OF P97 AND IRON BINDING PROTEINS AS DIAGNOSTIC AND THERAPEUTIC AGENTS  
FULL TEXT: 5227 lines



13/6/28 (Item 28 from file: 654)  
03028925  
LACTOFERRIN RECEPTOR GENES OF MORAXELLA  
FULL TEXT: 4955 lines

13/6/29 (Item 29 from file: 654)  
03028899  
53BP2 COMPLEXES  
FULL TEXT: 5262 lines

13/6/30 (Item 30 from file: 654)  
03028896  
PLATELET-ACTIVATING FACTOR ACETYLHYDROLASE  
FULL TEXT: 4709 lines

13/6/31 (Item 31 from file: 654)  
03028125  
PRETARGETING PROTOCOLS FOR THE ENHANCED LOCALIZATION OF CYTOTOXINS TO  
TARGET SITES AND CYTOTOXIC COMBINATIONS USEFUL THEREFORE  
FULL TEXT: 4010 lines

13/6/32 (Item 32 from file: 654)  
03020166  
ANTIBODIES THAT BIND HEK LIGANDS  
FULL TEXT: 1688 lines

13/6/33 (Item 33 from file: 654)  
03019953  
AGENTS AFFECTING THROMBOSIS AND HEMOSTASIS  
FULL TEXT: 1717 lines

13/6/34 (Item 34 from file: 654)  
03019836  
DENDRITIC CELL-DERIVED GROWTH FACTOR  
FULL TEXT: 3297 lines

13/6/35 (Item 35 from file: 654)  
03019570  
ERBB3 ANTIBODIES  
FULL TEXT: 2068 lines

13/6/36 (Item 36 from file: 654)  
03016182  
RECOMBINANT DNAS ENCODING THREE-PART HYBRID PROTEINS  
FULL TEXT: 1065 lines

13/6/37 (Item 37 from file: 654)  
03016142  
METHODS OF IDENTIFYING PATIENTS HAVING AN ALTERED IMMUNE STATUS  
FULL TEXT: 1711 lines

13/6/38 (Item 38 from file: 654)  
03012819  
SCREENING METHODS FOR CYTOKINE INHIBITORS  
FULL TEXT: 4604 lines

13/6/39 (Item 39 from file: 654)  
03012766  
METHODS AND COMPOSITIONS FOR TARGETING SELECTINS  
FULL TEXT: 3130 lines

13/6/40 (Item 40 from file: 654)  
03012748  
RECOMBINANT SOLUBLE CD40 **LIGAND** POLYPEPTIDE AND PHARMACEUTICAL  
COMPOSITION CONTAINING THE SAME  
FULL TEXT: 3795 lines

13/6/41 (Item 41 from file: 654)  
03012656  
CALCIUM RECEPTOR-ACTIVE MOLECULES  
FULL TEXT: 8162 lines

13/6/42 (Item 42 from file: 654)  
03012318  
MONOCLONAL ANTIBODIES TO CD40 **LIGAND** , PHARMACEUTICAL COMPOSITION  
COMPRISING THE SAME AND HYBRIDOMAS PRODUCING THE SAME  
FULL TEXT: 3343 lines

13/6/43 (Item 43 from file: 654)  
03012267  
MATRICES WITH MEMORIES AND USES THEREOF  
FULL TEXT: 8111 lines

13/6/44 (Item 44 from file: 654)  
03005329  
SUBSTRATES FOR .BETA.-LACTAMASE AND USES THEREOF  
FULL TEXT: 2318 lines

13/6/45 (Item 45 from file: 654)  
03005170  
ANTISENSE MODULATION OF PECAM-1  
FULL TEXT: 4433 lines

13/6/46 (Item 46 from file: 654)  
03001627  
DNA ENCODING THE CHEMOTACTIC CYTOKINE III  
FULL TEXT: 2170 lines

13/6/47 (Item 47 from file: 654)  
02998016  
STREPTOCOCCUS PNEUMONIAE CAPSULAR POLYSACCHARIDE GENES AND FLANKING REGIONS  
FULL TEXT: 4978 lines

13/6/48 (Item 48 from file: 654)  
02994356  
PALLADIUM CATALYZED NUCLEOSIDE MODIFICATION METHODS USING NUCLEOPHILES AND  
CARBON MONOXIDE  
FULL TEXT: 1467 lines

13/6/49 (Item 49 from file: 654)  
02994138  
CYTOSTATIN III NUCLEIC ACIDS ENCODING  
FULL TEXT: 2611 lines

13/6/50 (Item 50 from file: 654)  
02994132  
HUMAN HEMATOPOIETIC-SPECIFIC PROTEIN  
FULL TEXT: 2117 lines

13/6/51 (Item 51 from file: 654)  
02991005  
CD44-LIKE PROTEIN AND NUCLEIC ACIDS  
FULL TEXT: 3059 lines

13/6/52 (Item 52 from file: 654)  
02987674  
ALLERGENIC PROTEINS AND PEPTIDES FROM DOG DANDER AND USES THEREFOR  
FULL TEXT: 3663 lines

13/6/53 (Item 53 from file: 654)  
02983962  
METHOD FOR DETECTING EUBACTERIA IN BIOLOGICAL SAMPLES WITH CATALYTICALLY  
INACTIVE MUREIN BINDING ENZYMES  
FULL TEXT: 3411 lines

13/6/54 (Item 54 from file: 654)  
02980717  
RIBA  
FULL TEXT: 1706 lines

13/6/55 (Item 55 from file: 654)  
02976434  
METHOD OF USING CD2-BINDING DOMAIN OF LYMPHOCYTE FUNCTION ASSOCIATED  
ANTIGEN 3 TO INITIATE T CELL ACTIVATION  
FULL TEXT: 2936 lines

13/6/56 (Item 56 from file: 654)  
02973365  
ISOLATED EPSTEIN-BARR VIRUS BZLF2 PROTEINS THAT BIND MHC CLASS II  
.BETA.CHAINS  
FULL TEXT: 1740 lines

13/6/57 (Item 57 from file: 654)  
02972965  
METHODS FOR MODULATION OF LIPID UPTAKE  
FULL TEXT: 1967 lines

13/6/58 (Item 58 from file: 654)  
02970290  
THERAPEUTIC MULTISPECIFIC COMPOUNDS COMPRISED OF ANTI-FC.ALPHA. RECEPTOR  
ANTIBODIES  
FULL TEXT: 1990 lines

13/6/59 (Item 59 from file: 654)

02970012  
TWO NEW HUMAN DNAJ-LIKE PROTEINS  
FULL TEXT: 2445 lines

13/6/60 (Item 60 from file: 654)  
02969988  
METHOD FOR DETECTION OF PF4A RECEPTOR NUCLEIC ACID  
FULL TEXT: 2686 lines

13/6/61 (Item 61 from file: 654)  
02967200  
COMPOUNDS  
FULL TEXT: 1637 lines

13/6/62 (Item 62 from file: 654)  
02967192  
PF4A RECEPTOR  
FULL TEXT: 2672 lines

13/6/63 (Item 63 from file: 654)  
02966957  
HUMAN REQUIEM  
FULL TEXT: 2178 lines

13/6/64 (Item 64 from file: 654)  
02966955  
HUMAN CYSTATIN F  
FULL TEXT: 2366 lines

13/6/65 (Item 65 from file: 654)  
02963899  
HUMAN MARCO SCAVENGER RECEPTOR  
FULL TEXT: 2752 lines

13/6/66 (Item 66 from file: 654)  
02961083  
EXPRESSION OF FUSION POLYPEPTIDES TRANSPORTED OUT OF THE CYTOPLASM WITHOUT  
LEADER SEQUENCES  
FULL TEXT: 3039 lines

13/6/67 (Item 67 from file: 654)  
02961066  
KINASE RECEPTOR ACTIVATION ASSAY  
FULL TEXT: 3452 lines

13/6/68 (Item 68 from file: 654)  
02960941  
CD2-BINDING DOMAIN OF LYMPHOCYTE FUNCTION ASSOCIATED ANTIGEN-3  
FULL TEXT: 2944 lines

13/6/69 (Item 69 from file: 654)  
02958618  
ARGINASE II  
FULL TEXT: 2601 lines

13/6/70 (Item 70 from file: 654)  
02958587  
HUMAN ENA/VASP-LIKE PROTEIN SPLICE VARIANT  
FULL TEXT: 2341 lines

13/6/71 (Item 71 from file: 654)  
02956768  
COMPOUNDS  
FULL TEXT: 1889 lines

13/6/72 (Item 72 from file: 654)  
02956631  
METHOD FOR OBTAINING RETROVIRAL PACKAGING CELL LINES PRODUCING HIGH  
TRANSDUCING EFFICIENCY RETROVIRAL SUPERNATANT  
FULL TEXT: 2205 lines

13/6/73 (Item 73 from file: 654)  
02956628  
POLYNUCLEOTIDES ENCODING CHEMOKINE .ALPHA.-2  
FULL TEXT: 2347 lines

13/6/74 (Item 74 from file: 654)  
02935197  
NUCLEIC ACID ENCODING PF4A RECEPTOR  
FULL TEXT: 2686 lines

13/6/75 (Item 75 from file: 654)  
02935183  
EPITHELIUM-DERIVED T-CELL FACTOR ANTIBODIES  
FULL TEXT: 2222 lines

13/6/76 (Item 76 from file: 654)  
02934905  
METHODS AND COMPOSITIONS FOR INHIBITING HEXOKINASE  
[Genetic engineered cell]  
FULL TEXT: 5632 lines

13/6/77 (Item 77 from file: 654)  
02934860  
POLYNUCLEOTIDES ENCODING GTP CYCLOHYDROLASE II (RIBA)  
FULL TEXT: 1670 lines

13/6/78 (Item 78 from file: 654)  
02934856  
MAMMALIAN TUMOR SUSCEPTIBILITY GENES AND THEIR USES  
FULL TEXT: 1668 lines

13/6/79 (Item 79 from file: 654)  
02934852  
VECTORS AND METHODS FOR RECOMBINANT PRODUCTION OF UPA-BINDING FRAGMENTS OF  
THE HUMAN UROKINASE-TYPE PLASMINOGEN RECEPTOR (UPAR)  
FULL TEXT: 6107 lines

13/6/80 (Item 80 from file: 654)

02934838  
KINASE RECEPTOR ACTIVATION ASSAY  
FULL TEXT: 3461 lines

13/6/81 (Item 81 from file: 654)  
02932020  
RECOMBINANT NEOSPORA ANTIGENS AND THEIR USES  
FULL TEXT: 1980 lines

13/6/82 (Item 82 from file: 654)  
02932010  
TNF DELETION MUTEINS  
FULL TEXT: 2419 lines

13/6/83 (Item 83 from file: 654)  
02932004  
PURIFIED PDGF AB ISOFORM AND METHOD OF MAKING IT  
FULL TEXT: 2102 lines

13/6/84 (Item 84 from file: 654)  
02931998  
EVALUATION AND TREATMENT OF PATIENTS WITH PROGRESSIVE IMMUNOSUPPRESSION  
FULL TEXT: 2330 lines

13/6/85 (Item 85 from file: 654)  
02931674  
RECOMBINANT HOST CELLS ENCODING TNF PROTEINS  
FULL TEXT: 2660 lines

13/6/86 (Item 86 from file: 654)  
02928360  
POLYNUCLEOTIDE SEQUENCES ENCODING PROTEINS INVOLVED IN MYOGENESIS  
FULL TEXT: 3377 lines

13/6/87 (Item 87 from file: 654)  
02925424  
ISOLATION OF NOVEL HIV-2 PROVIRUSES  
[ Rev gene hybridizes to second exon; activating deletion; high basal activity; vaccines; packaging cells, transduction vectors, gene therapy; diagnosing]  
FULL TEXT: 4303 lines

13/6/88 (Item 88 from file: 654)  
02925213  
BIOMARKERS AND TARGETS FOR DIAGNOSIS, PROGNOSIS AND MANAGEMENT OF PROSTATE DISEASE  
FULL TEXT: 4963 lines

13/6/89 (Item 89 from file: 654)  
02922382  
COMPOUNDS  
FULL TEXT: 2073 lines

13/6/90 (Item 90 from file: 654)  
02922035

HEPATOCYTE GROWTH FACTOR PROTEASE DOMAIN VARIANTS  
FULL TEXT: 199 lines

13/6/91 (Item 91 from file: 654)  
02919186  
TISSUE FACTOR COMPOSITIONS AND LIGANDS FOR THE SPECIFIC COAGULATION OF  
VASCULATURE  
FULL TEXT: 7350 lines

13/6/92 (Item 92 from file: 654)  
02918911  
THYMIDINE KINASE MUTANTS  
FULL TEXT: 4265 lines

13/6/93 (Item 93 from file: 654)  
02916200  
ANTIBODIES TO PF4A RECEPTOR  
[Platelet factor 4; antiinflammatory agent]  
FULL TEXT: 2690 lines

13/6/94 (Item 94 from file: 654)  
02915905  
HUMAN 4-1BB RECEPTOR SPLICING VARIANT  
[Polypeptides, polynucleotides for gene expression and medical diagnosis]  
FULL TEXT: 2175 lines

13/6/95 (Item 95 from file: 654)  
02915743  
HUMAN TIL CELLS EXPRESSING RECOMBINANT TNF PROHORMONE  
[Tumor Infiltrating Lymphocyte (TIL) cells transformed with exogenous DNA  
encoding tumor necrosis factor (TNF) prohormone variants are disclosed.]  
FULL TEXT: 2737 lines

13/6/96 (Item 96 from file: 654)  
02913639  
ANTIBODIES TO INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN IGFBP-6  
[Useful in various diagnostic applications]  
FULL TEXT: 1611 lines

13/6/97 (Item 97 from file: 654)  
02910549  
METHODS FOR ELICITING OR ENHANCING REACTIVITY TO HER-2/NEU PROTEIN  
[Administering a polypeptide encoded by a specific DNA sequence]  
FULL TEXT: 1800 lines

13/6/98 (Item 98 from file: 654)  
02907484  
DNA ENCODING HUMAN MAD PROTEINS  
[Detecting mutations in the polynucleotides encoding the MADr3 or MADr4 and  
for detecting altered levels of the polypeptide in a host.]  
FULL TEXT: 2382 lines

13/6/99 (Item 99 from file: 654)  
02907186  
LEUCYL TRNA SYNTHETASE POLYNUCLEOTIDES OF STREPTOCOCCUS  
[Polypeptides; screening for **antibacterial** compounds]

FULL TEXT: 1577 lines

13/6/100 (Item 100 from file: 654)  
02904347  
HUMAN LIM PROTEINS  
[Diagnosis, treatment of disorders related to abnormal cell growth]  
FULL TEXT: 2317 lines

13/6/101 (Item 101 from file: 654)  
02904247  
GENE FUSION ENCODING A HYPERSECRETOR PROTEIN  
[ virion expression system for a desired protein packaged in an envelope  
derived from a retrovirus useful in administering proteins]  
FULL TEXT: 2310 lines

13/6/102 (Item 102 from file: 654)  
02898484  
METHOD OF SCREENING CALCIUM RECEPTOR-ACTIVE MOLECULES  
[ Contacting recombinant cell with test compound which is not verapamil or  
gallopamil, determining ability of compound to affect activities of  
inorganic ion receptor; determination of agonist and antagonist drugs]  
FULL TEXT: 7663 lines

13/6/103 (Item 103 from file: 654)  
02895764  
DNA ENCODING INTERLEUKIN-4 RECEPTORS  
[Suppressing an IL-4-dependent immune or inflammatory response in a mammal,  
including a human, by administering an effective amount of soluble IL-4]  
FULL TEXT: 2340 lines

13/6/104 (Item 104 from file: 654)  
02893525  
KAPOSI'S SARCOMA-ASSOCIATED HERPESVIRUS (KSHV) INTERLEUKIN 6 (IL-6) AND  
USES THEREOF  
FULL TEXT: 4609 lines

13/6/105 (Item 105 from file: 654)  
02893207  
HEXOKINASE INHIBITORS  
FULL TEXT: 5547 lines

13/6/106 (Item 106 from file: 654)  
02888076  
METHOD FOR MAKING A PRECONJUGATE  
FULL TEXT: 1158 lines

13/6/107 (Item 107 from file: 654)  
02888063  
INFECTIVE PROTEIN DELIVERY SYSTEM  
FULL TEXT: 2507 lines

13/6/108 (Item 108 from file: 654)  
02888043  
POLYPEPTIDES FROM KAPOSI'S SARCOMA-ASSOCIATED HERPESVIRUS, DNA ENCODING  
SAME AND USES THEREOF  
FULL TEXT: 5870 lines



13/6/109 (Item 109 from file: 654)  
02888017  
HUMAN GROWTH HORMONE VARIANTS  
FULL TEXT: 4305 lines

13/6/110 (Item 110 from file: 654)  
02885289  
PRODUCTION OF NITRO-BENZYL-DOTA VIA DIRECT PEPTIDE CYCLIZATION  
FULL TEXT: 4206 lines

13/6/111 (Item 111 from file: 654)  
02884931  
POLYPHOSHOINOSITIDE BINDING PEPTIDES FOR INTRACELLULAR DRUG DELIVERY  
FULL TEXT: 2083 lines

13/6/112 (Item 112 from file: 654)  
02881948  
VERTEBRATE EMBRYONIC PATTERN-INDUCING PROTEINS, AND USES RELATED THERETO  
FULL TEXT: 7761 lines

13/6/113 (Item 113 from file: 654)  
02881655  
HUMAN DORSAL TISSUE AFFECTING FACTOR (NOGGIN) AND NUCLEIC ACIDS ENCODING  
SAME  
FULL TEXT: 2535 lines

13/6/114 (Item 114 from file: 654)  
02881593  
NUCLEIC ACID ENCODING A NOVEL P-SELECTIN **LIGAND** PROTEIN  
FULL TEXT: 2948 lines

13/6/115 (Item 115 from file: 654)  
02881317  
METHODS OF STIMULATING HEMATOPOIETIC CELLS WITH FLT3-**LIGAND**  
FULL TEXT: 1988 lines

13/6/116 (Item 116 from file: 654)  
02878450  
DNA ENCODING INTERLEUKIN-4 RECEPTORS  
[ DNA sequences; suppressing an interleukin-4 dependent immune or  
inflammatory response in a mammal]  
FULL TEXT: 2308 lines

13/6/117 (Item 117 from file: 654)  
02878439  
ANTIBODIES TO A HUMAN PF4 SUPERFAMILY RECEPTOR  
[Antiinflammatory]  
FULL TEXT: 2574 lines

13/6/118 (Item 118 from file: 654)  
02878267  
METHOD OF INHIBITING P-SELECTIN **LIGAND** ACTIVITY  
[Administering isolated glycoprotein having P-selectin **ligand**  
activity as antiinflammatory agent]

13/6/119 (Item 119 from file: 654)  
02878102  
PROTEASE AND RELATED NUCLEIC ACID COMPOUNDS  
[Identifying inhibitors of apoptosis by incubating interleukin-1beta  
converting enzyme related protease with protein/peptide substrate in  
presence of potential inhibitor and quantifying amount of cleavage]  
FULL TEXT: 1749 lines

13/6/120 (Item 120 from file: 654)  
02874949  
AGENTS AFFECTING THROMBOSIS AND HEMOSTASIS  
[Blood coagulation factor for hemophilia]  
FULL TEXT: 1889 lines

13/6/121 (Item 121 from file: 654)  
02874765  
POLYNUCLEOTIDES ENCODING GELONIN SEQUENCES  
[Treatment of autoimmune diseases, cancer, graft-versus-host disease]  
FULL TEXT: 7510 lines

13/6/122 (Item 122 from file: 654)  
02874753  
METHOD OF IDENTIFYING MODULATORS OF BINDING BETWEEN AND VCAM-1  
[Cellular adhesion molecules]  
FULL TEXT: 9188 lines

13/6/123 (Item 123 from file: 654)  
02874525  
ONCOPROTEIN PROTEIN KINASE  
[Treating a cell proliferative disorder]  
FULL TEXT: 1931 lines

13/6/124 (Item 124 from file: 654)  
02867375  
POLYPEPTIDE FUSIONS TO POLYPEPTIDES OF THE BETA-TREFOIL FOLD STRUCTURAL  
FAMILY  
[Fusion polypeptides]  
FULL TEXT: 1892 lines

13/6/125 (Item 125 from file: 654)  
02867321  
HYBRIDIZATION AND AMPLIFICATION OF NUCLEIC ACIDS ENCODING MPL LIGAND  
FULL TEXT: 3143 lines

13/6/126 (Item 126 from file: 654)  
02864204  
P-SELECTIN LIGAND PROTEIN  
[Comprises sialyl Lewis carbohydrate and a protein comprising specific  
amino acid sequence]  
FULL TEXT: 2925 lines

13/6/127 (Item 127 from file: 654)  
02864127  
IN VITRO ACTIVATION OF CYTOTOXIC T CELLS

[Stable Drosophila cell line]  
FULL TEXT: 386 lines

13/6/128 (Item 128 from file: 654)  
02863932  
ORAL DOSAGE COMPOSITION COMPRISING ZONNULA OCCLUDENS TOXIN AND A  
THERAPEUTIC AGENT FOR INTESTINAL DELIVERY  
[Therapeutic agent, intestinal absorption enhancing amount of vibrio  
cholera zonula occludens toxin]  
FULL TEXT: 1482 lines

13/6/129 (Item 129 from file: 654)  
02856970  
HYBRIDOMA CELL LINES AND ANTIBODIES THAT BIND NOGGIN  
FULL TEXT: 2514 lines

13/6/130 (Item 130 from file: 654)  
02856699  
METHOD FOR TARGETING A DIAGNOSTIC AGENT TO CELLS  
[Administering a diagnostic agent complexed with a targeting **ligand**  
of folates or receptor-binding derivatives; for transporting exogenous  
molecules into cells with folate receptors; drug delivery]  
FULL TEXT: 901 lines

13/6/131 (Item 131 from file: 654)  
02842937  
MAMMALIAN TUMOR SUSCEPTIBILITY GENES AND THEIR USES  
[Diagnosis and treatment of cancer]  
FULL TEXT: 1695 lines

13/6/132 (Item 132 from file: 654)  
02842689  
MONOCLONAL ANTIBODIES AND FV SPECIFIC FOR CD2 ANTIGEN  
[Polypeptide]  
FULL TEXT: 1685 lines

13/6/133 (Item 133 from file: 654)  
02839143  
HUMAN NEUTRALIZING MONOCLONAL ANTIBODIES TO HUMAN IMMUNODEFICIENCY VIRUS  
[A deoxypolynucleotide encoding heavy chain immunoglobulin variable  
region amino acid residue sequence portion of humans monoclonal antibody  
which is used in immunotherapy and diagnosis]  
FULL TEXT: 8564 lines  
?  
PLEASE ENTER A COMMAND OR BE LOGGED OFF IN 5 MINUTES  
? t s13/6/133-163

13/6/133 (Item 133 from file: 654)  
02839143  
HUMAN NEUTRALIZING MONOCLONAL ANTIBODIES TO HUMAN IMMUNODEFICIENCY VIRUS  
[A deoxypolynucleotide encoding heavy chain immunoglobulin variable  
region amino acid residue sequence portion of humans monoclonal antibody  
which is used in immunotherapy and diagnosis]  
FULL TEXT: 8564 lines

13/6/134 (Item 134 from file: 654)  
02839103

ONCOPROTEIN PROTEIN KINASE  
[ Incubation; measure effect of composition on kinase or polynucleotide  
encoding the kinase]  
FULL TEXT: 1952 lines

13/6/135 (Item 135 from file: 654)  
02829472  
MONOCLONAL ANTIBODIES AND FV SPECIFIC FOR CD2 ANTIGEN  
FULL TEXT: 1793 lines

13/6/136 (Item 136 from file: 654)  
02826264  
CELL PROLIFERATION-BASED AMPLIFIED DETECTION OF ANALYTES  
[BCR (bacterial chain reaction) based]  
FULL TEXT: 954 lines

13/6/137 (Item 137 from file: 654)  
02822701  
HUMAN ETS FAMILY MEMBER, ELF3  
[ Polypeptides and DNA[RNA] codes by genetic engineering for diagnosis and  
treatment of cancer, prostate, breast, lung or epithelial tumors]  
FULL TEXT: 2033 lines

13/6/138 (Item 138 from file: 654)  
02819342  
ANTIBODIES IMMUNOREACTIVE WITH LEUKEMIA INHIBITORY FACTOR RECEPTORS  
[Proteins, DNA and expression vector codes]  
FULL TEXT: 2935 lines

13/6/139 (Item 139 from file: 654)  
02816901  
POLYPHOSPHOINOSITIDE BINDING PEPTIDES FOR INTRACELLULAR DRUG DELIVERY  
FULL TEXT: 1845 lines

13/6/140 (Item 140 from file: 654)  
02816811  
METHOD FOR INCREASING OR DECREASING TRANSFECTION EFFICIENCY  
[Adjustment concentration of membrane proteoglycans]  
FULL TEXT: 1518 lines

13/6/141 (Item 141 from file: 654)  
02813454  
ARGINASE II  
FULL TEXT: 2502 lines

13/6/142 (Item 142 from file: 654)  
02809831  
METHODS AND MATERIALS FOR THE DETECTION OF STAPHYLOCOCCUS AUREUS  
FULL TEXT: 879 lines

13/6/143 (Item 143 from file: 654)  
02809584  
ANTIBODIES TO HUMAN PF4A RECEPTOR AND COMPOSITIONS THEREOF  
[Genetic engineering, DNA codes of human tissues and diagnosis]  
FULL TEXT: 2593 lines

13/6/144 (Item 144 from file: 654)  
02808518  
PHOTODYNAMIC THERAPY OF PIGMENT-RELATED LESIONS  
[Antitumor]  
FULL TEXT: 1382 lines

13/6/145 (Item 145 from file: 654)  
02806440  
TREATMENT OF TOXOPLASMOSIS  
[Parasiticide]  
FULL TEXT: 1927 lines

13/6/146 (Item 146 from file: 654)  
02806270  
POLYNUCLEOTIDES ENCODING A TRANSCRIPTIONAL RESPONSE REGULATOR OF  
STREPTOCOCCUS PNEUMONIAE  
FULL TEXT: 2025 lines

13/6/147 (Item 147 from file: 654)  
02799858  
USE OF INTERLEUKIN-4 RECEPTORS TO INHIBIT BIOLOGICAL RESPONSES MEDIATED BY  
INTERLEUKIN-4  
[Suppressing immune or inflammatory response]  
FULL TEXT: 2438 lines

13/6/148 (Item 148 from file: 654)  
02799857  
SOLUBLE TYPE II INTERLEUKIN-1 RECEPTORS AND METHODS  
[Regulating an Interleukin-1 immune or inflammatory response in mammals]  
FULL TEXT: 2218 lines

13/6/149 (Item 149 from file: 654)  
02799694  
TARGETED NUCLEIC ACID DELIVERY INTO LIVER CELLS  
[Complex comprising circumsporozoite region II-containing polypeptide,  
nucleic acid binding agent]  
FULL TEXT: 1735 lines

13/6/150 (Item 150 from file: 654)  
02799673  
POLYNUCLEOTIDES ENCODING A TRANSCRIPTIONAL RESPONSE REGULATOR OF  
STREPTOCOCCUS PNEUMONIAE  
[Screening for bactericides; vaccines; meningitis; pneumonia]  
FULL TEXT: 2257 lines

13/6/151 (Item 151 from file: 654)  
02799658  
KINASE RECEPTOR ACTIVATION ASSAY  
[Measuring autophosphorylation of tyrosine kinase receptor]  
FULL TEXT: 3482 lines

13/6/152 (Item 152 from file: 654)  
02796218  
CALCIUM RECEPTOR-ACTIVE MOLECULES  
[Polypeptides as calcium receptors to generate antibodies]  
FULL TEXT: 7576 lines

13/6/153 (Item 153 from file: 654)  
02795882  
DNA ENCODING A CYTOKINE THAT INDUCES APOPTOSIS  
FULL TEXT: 2202 lines

13/6/154 (Item 154 from file: 654)  
02795851  
METHODS FOR THE IDENTIFICATION OF COMPOUNDS CAPABLE OF INDUCING THE NUCLEAR  
TRANSLOCATION OF A RECEPTOR COMPLEX COMPRISING THE GLUCOCORTICOID RECEPTOR  
TYPE II AND VIRAL PROTEIN R INTERACTING PROTEIN  
[Detecting the human immunodeficiency virus type I protein]  
FULL TEXT: 1638 lines

13/6/155 (Item 155 from file: 654)  
02788989  
IMMUNOTOXINS COMPRISING RIBOSOME-INACTIVATING PROTEINS  
[Have a cysteine available for disulfide bonding to targeting molecules]  
FULL TEXT: 7272 lines

13/6/156 (Item 156 from file: 654)  
02785615  
VIRAL VECTOR COMPLEXES HAVING ADAPTERS OF PREDEFINED VALENCE  
[Retroviral particle having gene linked to promoter active in target cell,  
envelope protein with affixed bifunctional adaptor comprising binding site  
for acceptor of target cell and linking molecule noncovalently bonded to  
protein]  
FULL TEXT: 1047 lines

13/6/157 (Item 157 from file: 654)  
02779076  
POLYNUCLEOTIDES ENCODING A TRANSCRIPTIONAL RESPONSE REGULATOR OF  
STREPTOCOCCUS PNEUMONIAE  
[Screening for antibiotics; genetic engineering]  
FULL TEXT: 1677 lines

13/6/158 (Item 158 from file: 654)  
02776184  
IMMUNOTOXINS COMPRISING RIBOSOME-INACTIVATING PROTEINS  
[Fusion protein]  
FULL TEXT: 7109 lines

13/6/159 (Item 159 from file: 654)  
02770111  
CYTOKINES THAT BIND THE CELL SURFACE RECEPTOR HEK  
[Polypeptides]  
FULL TEXT: 1675 lines

13/6/160 (Item 160 from file: 654)  
02764911  
MHC CLASS II .BETA. CHAIN/PEPTIDE COMPLEXES USEFUL IN AMELIORATING  
DELETERIOUS IMMUNE RESPONSES  
[Contacting isolated major histocompatibility complex chain component with  
an autoantigenic peptide such that the peptide is coupled to the antigen  
binding site to form a complex]  
FULL TEXT: 2026 lines

13/6/161 (Item 161 from file: 654)

02764658

COMPLEXES OF NUCLEIC ACID AND POLYMER, THEIR PROCESS OF PREPARATION AND  
THEIR USE FOR THE TRANSFECTION OF CELLS

[Conjugated glycoproteins for drug delivery]

FULL TEXT: 2412 lines

13/6/162 (Item 162 from file: 654)

02759060

ANTIBODIES DIRECTED AGAINST ELK **LIGAND**

[Polypeptides and DNA sequences, vectors and host cells]

FULL TEXT: 1625 lines

13/6/163 (Item 163 from file: 654)

02758928

METHODS OF INHIBITING T-CELL DEPENDENT PROLIFERATION OF PERIPHERAL BLOOD  
LYMPHOCYTES USING THE CD2-BINDING DOMAIN OF LYMPHOCYTE FUNCTION ASSOCIATED  
ANTIGEN 3

[Administering a specified polypeptide to a mammal]

FULL TEXT: 2918 lines

? s oligonucleotide and ligand and integrin

80069 OLIGONUCLEOTIDE

202209 LIGAND

29307 INTEGRIN

S14 299 OLIGONUCLEOTIDE AND LIGAND AND INTEGRIN

? rd

>>>Duplicate detection is not supported for File 654.

>>>Records from unsupported files will be retained in the RD set.

...examined 50 records (50)

...examined 50 records (100)

...examined 50 records (150)

...examined 50 records (200)

...examined 50 records (250)

...completed examining records

S15 296 RD (unique items)

? t s15/6/1-10

15/6/1 (Item 1 from file: 155)

09899560 99173885

Cloning of a beta **integrin** subunit cDNA from an embryonic cell line  
derived from the freshwater mollusc, *Biomphalaria glabrata*.

Mar 4 1999

15/6/2 (Item 2 from file: 155)

08452516 96086497

Induction of carcinoma cell migration on vitronectin by NF-kappa  
B-dependent gene expression.

Jul 1995

15/6/3 (Item 3 from file: 155)

08421177 95314788

Adhesion co-receptor expression and intracellular signalling in HIV  
disease: implications for immunotherapy.

Apr 1995

15/6/4 (Item 4 from file: 155)  
07339538 90153958

NPXY, a sequence often found in cytoplasmic tails, is required for coated pit-mediated internalization of the low density lipoprotein receptor.  
Feb 25 1990

15/6/5 (Item 5 from file: 155)  
06443091 90364410

A beta 3 **integrin** mutation abolishes **ligand** binding and alters divalent cation-dependent conformation.  
Aug 24 1990

15/6/6 (Item 6 from file: 155)  
06431896 90338125

Molecular cloning of the rat **integrin** alpha 1-subunit: a receptor for laminin and collagen.  
Aug 1990

15/6/7 (Item 7 from file: 155)  
06406069 90277633

Human platelets and megakaryocytes contain alternately spliced glycoprotein IIb mRNAs.  
Jun 15 1990

15/6/8 (Item 1 from file: 5)  
08177390 BIOSIS NO.: 000094001163

EXPRESSION OF THE ADHESION MOLECULES ICAM-1 AND ICAM-2 ON TUMOR CELL LINES DOES NOT CORRELATE WITH THEIR SUSCEPTIBILITY TO NATURAL KILLER CELL-MEDIATED CYTOLYSIS EVIDENCE FOR ADDITIONAL LIGANDS FOR EFFECTOR CELL BETA-2 INTEGRINS  
1992

15/6/9 (Item 1 from file: 399)  
DIALOG(R)File 399:(c) 2000 AMERICAN CHEMICAL SOCIETY. All rts. reserv.

Hybrid proteins containing receptor binding sites in a repressor protein scaffold

15/6/10 (Item 1 from file: 357)  
0235371 DBA Accession No.: 99-05472

Preventing and treating acute lung injury and pulmonary fibrosis - using fibronectin receptor-antagonist and tenascin receptor **integrin** -alpha-v-beta-6-antagonist monoclonal antibody or antisense **oligonucleotide** with antimetastatic activity 1999  
? t s15/6/11-20

15/6/11 (Item 2 from file: 357)  
0186267 DBA Accession No.: 95-13088

New isolated **integrin**-alpha subunit - peptide library screening and therapeutic antisense **oligonucleotide** expression in cell culture  
1995

15/6/12 (Item 1 from file: 654)  
03065246

REGULATED TRANSCRIPTION OF TARGETED GENES AND OTHER BIOLOGICAL EVENTS  
FULL TEXT: 4885 lines



15/6/13 (Item 2 from file: 654)

03062176

ANTISENSE MODULATION OF PHOSPHOLIPASE A2 GROUP IV EXPRESSION

FULL TEXT: 2916 lines

15/6/14 (Item 3 from file: 654)

03062167

METHODS OF SCREENING FOR ULCERATIVE COLITIS AND CROHN'S DISEASE

FULL TEXT: 1476 lines

15/6/15 (Item 4 from file: 654)

03058412

METHOD FOR INHIBITING GROWTH HORMONE ACTION

FULL TEXT: 4203 lines

15/6/16 (Item 5 from file: 654)

03058036

METHODS FOR THE SPECIFIC COAGULATION OF VASCULATURE

FULL TEXT: 7675 lines

15/6/17 (Item 6 from file: 654)

03054917

INTEGRIN-LINKED KINASE AND ITS USE

FULL TEXT: 2947 lines

15/6/18 (Item 7 from file: 654)

03051228

ANTI-CD6 LIGAND ANTIBODIES

FULL TEXT: 2383 lines

15/6/19 (Item 8 from file: 654)

03051208

HIGH-THROUGHPUT SCREENING ASSAYS FOR MODULATORS OF NUCLEIC ACID

TOPOISOMERASES

FULL TEXT: 1448 lines

15/6/20 (Item 9 from file: 654)

03050922

AGONIST ANTIBODIES AGAINST THE FLK2/FLT3 RECEPTOR AND USES THEREOF

FULL TEXT: 2161 lines

? antisense and ligand and insulin

>>>Unrecognizable Command

? s antisense and ligand and insulin

42038 ANTISENSE

202209 LIGAND

405941 INSULIN

S16 941 ANTISENSE AND LIGAND AND INSULIN

? t s16/6/1-10

16/6/1 (Item 1 from file: 155)

09612449 98305499

Synthesis and accumulation of a receptor regulatory protein associated with lipid droplet accumulation in 3T3-L1 cells.

Jun 1998

16/6/2 (Item 2 from file: 155)  
09602922 98363229

Regulation of the Mr 72,000 type IV collagenase by the type I **insulin**-like growth factor receptor.  
Aug 1 1998

16/6/3 (Item 3 from file: 155)  
09459627 98187981

The role of **insulin** (INS) and **insulin**-like growth factor-I (IGF-I) in regulating human erythropoiesis. Studies in vitro under serum-free conditions--comparison to other cytokines and growth factors.  
Mar 1998

16/6/4 (Item 4 from file: 155)  
09325061 98037801

Notch-1 controls the expression of fatty acid-activated transcription factors and is required for adipogenesis.  
Nov 21 1997

16/6/5 (Item 5 from file: 155)  
09196753 97428292

**Insulin**-like growth factor-1 receptor and its **ligand** regulate the reentry of adult ventricular myocytes into the cell cycle.  
Aug 25 1997

16/6/6 (Item 6 from file: 155)  
09076016 97256226

Evidence for role of transforming growth factor-beta in RRR-alpha-tocopheryl succinate-induced apoptosis of human MDA-MB-435 breast cancer cells.  
1997

16/6/7 (Item 7 from file: 155)  
09046954 97287832

**Insulin**-like growth factors in breast cancer.  
1996

16/6/8 (Item 8 from file: 155)  
08737289 96321041

C-myc expression affects proliferation but not terminal differentiation or survival of explanted erythroid progenitor cells.  
Aug 1996

16/6/9 (Item 9 from file: 155)  
08659137 96132803

The transmembrane protein-tyrosine phosphatase LAR modulates signaling by multiple receptor tyrosine kinases.  
Jan 12 1996

16/6/10 (Item 10 from file: 155)  
08657670 96133526

G-protein coupled and tyrosine kinase receptors: evidence that activation of the **insulin**-like growth factor I receptor is required for thrombin-induced mitogenesis of rat aortic smooth muscle cells.  
Jan 1 1996

16/6/11 (Item 11 from file: 155)  
08469160 96082466

Regulation of **insulin**-like growth factor (IGF)-binding protein-6 and mannose 6-phosphate/IGF-II receptor expression in IGF-IL-overexpressing NIH 3T3 cells.  
Jul 1995

16/6/12 (Item 12 from file: 155)  
08404605 95393879

Growth inhibition of MCF-7 breast cancer cells by stable expression of an **insulin**-like growth factor I receptor **antisense** ribonucleic acid.  
Oct 1995

16/6/13 (Item 13 from file: 155)  
08321679 95277910

Inhibition of vascular smooth muscle cell growth through **antisense** transcription of a rat **insulin**-like growth factor I receptor cDNA.  
Jun 1995

16/6/14 (Item 14 from file: 155)  
08296206 95237168

Coordinate regulation by diethylstilbestrol of the platelet-derived growth factor-A (PDGF-A) and -B chains and the PDGF receptor alpha- and beta-subunits in the mouse uterus and vagina: potential mediators of estrogen action.  
May 1995

16/6/15 (Item 15 from file: 155)  
08195241 95079441

Episomal expression of sense and **antisense insulin**-like growth factor (IGF)-binding protein-4 complementary DNA alters the mitogenic response of a human colon cancer cell line (HT-29) by mechanisms that are independent of and dependent upon IGF-I.  
Dec 15 1994

16/6/16 (Item 16 from file: 155)  
08063265 95073496

The IGF-1-IGF-1 receptor system modulates myocyte proliferation but not myocyte cellular hypertrophy in vitro.  
Dec 1994

16/6/17 (Item 17 from file: 155)  
07768892 94358057

Expression of **insulin**-like growth factor-I (IGF-I) and IGF-II and the IGF-I, IGF-II, and **insulin** receptor genes and localization of the gene products in the human ovary.  
Nov 1993

16/6/18 (Item 18 from file: 155)  
07731374 94133531

Distribution and relevance of **insulin**-like growth factor-I receptor in metanephric development.  
Dec 1993

16/6/19 (Item 19 from file: 155)  
07577698 93307161

**Insulin** receptor-related receptor messenger ribonucleic acid is focally expressed in sympathetic and sensory neurons and renal distal tubule cells [see comments]  
Jul 1993

16/6/20 (Item 20 from file: 155)  
07400393 91153224

The interaction of signal transduction pathways in FRTL5 thyroid follicular cells: studies with stable expression of beta 2-adrenergic receptors.

Mar 1991  
? t s16/6/21-30

16/6/21 (Item 21 from file: 155)  
07295882 94028466

Inhibition of cell cycle progression by **antisense** oligodeoxynucleotides.  
Oct 28 1992

16/6/22 (Item 22 from file: 155)  
07277345 92275358

**Insulin** -like growth factor II acts through an endogenous growth pathway regulated by imprinting in early mouse embryos.  
Jun 1992

16/6/23 (Item 23 from file: 155)  
07136961 92385813

**Insulin**-like growth factor-I regulates pro-B cell differentiation.  
Sep 1 1992

16/6/24 (Item 24 from file: 155)  
06954761 92097477

**Insulin** -like growth factor-I expression is not increased in the retina of diabetic BB/W-rats.  
Nov 1991

16/6/25 (Item 25 from file: 155)  
05880161 88246433

Tissue localization of *Drosophila melanogaster* **insulin** receptor transcripts during development.  
Apr 1988

16/6/26 (Item 1 from file: 5)  
11612212 BIOSIS NO.: 199800393979

Regulation of the Mr 72,000 type IV collagenase by the type I **insulin** -like growth factor receptor.  
1998

16/6/27 (Item 2 from file: 5)  
11127993 BIOSIS NO.: 199799749138

**Insulin**-like growth factor-1 receptor and its **ligand** regulate the reentry of adult ventricular myocytes into the cell cycle.  
1997

16/6/28 (Item 3 from file: 5)

10508401 BIOSIS NO.: 199699129546

C-myc Expression affects proliferation but not terminal differentiation or survival of explanted erythroid progenitor cells.  
1996

16/6/29 (Item 4 from file: 5)

10223242 BIOSIS NO.: 199698678160

The transmembrane protein-tyrosine phosphatase LAR modulates signaling by multiple receptor tyrosine kinases.  
1996

16/6/30 (Item 5 from file: 5)

10190002 BIOSIS NO.: 199698644920

G-Protein coupled and tyrosine kinase receptors: Evidence that activation of the **insulin**-like growth factor I receptor is required for thrombin-induced mitogenesis of rat aortic smooth muscle cells.  
1996

? t s16/7/21, 25

16/7/21 (Item 21 from file: 155)

DIALOG(R)File 155:MEDLINE(R)

(c) format only 1999 Dialog Corporation. All rts. reserv.

07295882 94028466

Inhibition of cell cycle progression by **antisense** oligodeoxynucleotides.

Baserga R; Reiss K; Alder H; Pietrzkowski Z; Surmacz E  
Jefferson Cancer Institute, Jefferson Medical College, Philadelphia, Pennsylvania 19107-5541.

Ann N Y Acad Sci (UNITED STATES) Oct 28 1992, 660 p64-9, ISSN 0077-8923 Journal Code: 5NM

Contract/Grant No.: GM33694, GM, NIGMS; CA53484, CA, NCI; AG00378, AG, NIA

Languages: ENGLISH

Document type: JOURNAL ARTICLE

We have used the **antisense** strategy to study the role of certain genes in cell cycle progression. In particular, we used **antisense** oligodeoxynucleotides to study: (1) the role of the IGF-1 receptor in the control of cell proliferation; and (2) the sequence of gene expression during the cell cycle. Our results can be summarized as follows: (1) the activation of the IGF-1 receptor by its **ligand**, IGF-1, is an obligatory step in the proliferation of fibroblasts and hemopoietic cells; and (2) the expression of DNA synthesis genes, such as PCNA, DNA polymerase alpha, and cdc2, is dependent on the expression of previous genes. A tentative temporal order is: c-myc > c-myb > IGF-1 receptor > DNA synthesis genes.

16/7/25 (Item 25 from file: 155)

DIALOG(R)File 155:MEDLINE(R)

(c) format only 1999 Dialog Corporation. All rts. reserv.

05880161 88246433

Tissue localization of Drosophila melanogaster **insulin** receptor transcripts during development.

Garofalo RS; Rosen OM

Program in Molecular Biology, Memorial Sloan-Kettering Cancer Research Center, New York, New York.

Mol Cell Biol (UNITED STATES) Apr 1988, 8 (4) p1638-47, ISSN 0270-7306 Journal Code: NGY

The *Drosophila melanogaster* **insulin** receptor (*Drosophila* **insulin** receptor homolog [dIRH]) is similar to its mammalian counterpart in deduced amino acid sequence, subunit structure, and **ligand**-stimulated protein tyrosine kinase activity. The function of this receptor in *D. melanogaster* is not yet known. However, a role in development is suggested by the observations that levels of **insulin**-stimulated kinase activity and expression of dIRH mRNA are maximal during *Drosophila* midembryogenesis. In this study, a 2.9-kilobase (kb) cDNA clone corresponding to both the dIRH tyrosine kinase domain and some of the 3' untranslated sequence was used to determine the tissue distribution of dIRH mRNA during development. Two principal mRNAs of 11 and 8.6 kb hybridized with the dIRH cDNA in Northern (RNA) blot analysis. The abundance of the 8.6-kb mRNA increased transiently in early embryos, whereas the 11-kb species was most abundant during midembryogenesis. A similar pattern of expression was previously determined by Northern analysis, using a dIRH genomic clone (L. Petruzzelli, R. Herrera, R. Arenas-Garcia, R. Fernandez, M. J. Birnbaum, and O. M. Rosen, Proc. Natl. Acad. Sci. USA 83:4710-4714, 1986). In situ hybridization revealed dIRH transcripts in the ovaries of adult flies, in which the transcripts appeared to be synthesized by nurse cells for eventual storage as maternal RNA in the mature oocyte. Throughout embryogenesis, dIRH transcripts were ubiquitously expressed, although after midembryogenesis, higher levels were detected in the developing nervous system. Nervous system expression remained elevated throughout the larval stages and persisted in the adult, in which the cortex of the brain and ganglion cells were among the most prominently labeled tissues. In larvae, the imaginal disk cells exhibited comparatively high levels of dIRH mRNA expression. The broad distribution of dIRH mRNA in embryos and imaginal disks is compatible with a role for dIRH in anabolic processes required for cell growth. The apparently elevated expression of dIRH mRNA in nervous tissue during mid- and late embryogenesis coincides with a period of active neurite outgrowth and suggests that dIRH may be involved in this process.

? t sl6/6/31-40

16/6/31 (Item 6 from file: 5)  
10059187 BIOSIS NO.: 199598514105  
Growth Inhibition of MCF-7 Breast Cancer Cells by Stable Expression of an **Insulin**-Like Growth Factor I Receptor **Antisense** Ribonucleic Acid.  
1995

16/6/32 (Item 7 from file: 5)  
09966795 BIOSIS NO.: 199598421713  
Regulation of **insulin**-like growth factor (IGF)-binding protein-6 and mannose 6-phosphate/IGF-II receptor expression in IGF-II-overexpressing NIH 3T3 cells.  
1995

16/6/33 (Item 8 from file: 5)  
09901027 BIOSIS NO.: 199598355945  
Inhibition of vascular smooth muscle cell growth through **antisense** transcription of a rat **insulin**-like growth factor I receptor cDNA.  
1995

16/6/34 (Item 9 from file: 5)  
09639640 BIOSIS NO.: 199598094558  
Episomal expression of sense and **antisense** **insulin**-like growth factor (IGF)-binding protein-4 complementary DNA alters the mitogenic response of a human colon cancer cell line (HT-29) by mechanisms that are

16/6/35 (Item 10 from file: 5)  
09624869 BIOSIS NO.: 199598079787  
The IGF-1-IGF-1 receptor system modulates myocyte proliferation but not  
myocyte cellular hypertrophy in vitro.  
1994

16/6/36 (Item 11 from file: 5)  
09035807 BIOSIS NO.: 199497044177  
Expression of **insulin**-like growth factor-I (IGF-I) and IGF-II and the  
IGF-I, IGF-II, and **insulin** receptor genes and localization of the  
gene products in the human ovary.  
1993

16/6/37 (Item 12 from file: 5)  
09035000 BIOSIS NO.: 199497043370  
Distribution and relevance of **insulin**-like growth factor-I receptor  
in metanephric development.  
1993

16/6/38 (Item 13 from file: 5)  
08420910 BIOSIS NO.: 000094128114  
**INSULIN**-LIKE GROWTH FACTOR-I REGULATES PRO-B CELL DIFFERENTIATION  
1992

16/6/39 (Item 14 from file: 5)  
08269312 BIOSIS NO.: 000094050485  
**INSULIN**-LIKE GROWTH FACTOR II ACTS THROUGH AN ENDOGENOUS GROWTH  
PATHWAY REGULATED BY IMPRINTING IN EARLY MOUSE EMBRYOS  
1992

16/6/40 (Item 15 from file: 5)  
07948127 BIOSIS NO.: 000093027225  
**INSULIN**-LIKE GROWTH FACTOR-I EXPRESSION IS NOT INCREASED IN THE  
RETINA OF DIABETIC BB-W-RATS  
1991  
? logoff

12jan00 11:31:48 User233835 Session D357.4  
\$2.01 0.628 DialUnits File155  
\$0.00 44 Type(s) in Format 6  
\$1.40 7 Type(s) in Format 7  
\$1.40 51 Types  
\$3.41 Estimated cost File155  
\$3.61 0.644 DialUnits File5  
\$0.00 22 Type(s) in Format 6  
\$0.00 22 Types  
\$3.61 Estimated cost File5  
\$8.04 0.640 DialUnits File399  
\$1.00 2 Type(s) in Format 6  
\$2.60 1 Type(s) in Format 7  
\$3.60 3 Types  
\$11.64 Estimated cost File399  
\$3.35 0.283 DialUnits File357  
\$0.00 6 Type(s) in Format 6  
\$4.40 2 Type(s) in Format 7  
\$4.40 8 Types

\$7.75 Estimated cost File357  
\$19.55 14 DialUnits File654  
\$0.00 474 Type(s) in Format 6  
\$8.55 9 Type(s) in Format 4 (UDF)  
\$8.55 483 Types  
\$28.10 Estimated cost File654  
OneSearch, 5 files, 5.510 DialUnits FileOS  
\$3.80 TYMNET  
\$58.31 Estimated cost this search  
\$59.29 Estimated total session cost 5.720 DialUnits  
Logoff: level 99.12.23 D 11:31:48